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Chapter 1: Introduction to heart failure
Defining heart failure
Heart failure has often been described as acute or chronic in terms of its clinical 
presentation, systolic or diastolic in relation to the timing of the cardiac 
dysfunction, right or left sided depending on whether the pulmonary or the 
systemic veins are congested etc. Heart failure is pathophysiologically defined 
as the inability of the heart to maintain an adequate cardiac output 
commensurate with the metabolic needs of the body while maintaining normal 
left ventricular filling (atrial) pressures. The Task Force for the diagnosis and 
treatment of chronic heart failure (CHF) of the European Society of Cardiology 
has defined CHF in clinical terms, as a syndrome where the patient has 
breathlessness and/or fatigue at rest and/or during exertion or ankle swelling 
and objective evidence of cardiac dysfunction at rest and, where doubt exists, 
some improvement in the symptoms and/or signs in response to treatment. (1)
Epidemiology of heart failure 
Incidence
During the 1980s, the annual age-adjusted incidence of CHF among persons 
enrolled into Framingham Heart Study aged ^45 years was 7.2 cases/1000 in 
men and 4.7 cases/1000 in women. The overall incidence for all ages was 
2.3/1000 for men and 1.4/1000 for women. (2) The Rochester Study reported a 
lower incidence rate. (3) In Europe, the crude incidence of CHF (unadjusted for 
age) is 1-5/1000 population per annum. (4) A Finnish population-based 
surveillance study reported the age-adjusted annual incidence of 4/1000 for 
men and 1/1000 for women in the age group 45-75 years. (5) In general 
practice, the reported unadjusted annual incidence for all ages and both sexes 
was 3.3/1000 in Netherlands 1 and 2.3/1000 in the UK2 . The Hillingdon study 
reported an annual crude incidence of 1.3/1000 for those aged >25 years. (6) 
The annual incidence increases with age. It increased from 0.02/1000 in those 
aged 25-34 years to 11.6 in those >85 years in the Hillingdon study (6) and from
1 Van de Lisdonk EH, Van den Bosch WJHM, Huygen FJA, Lagro-Jansen ALM. Diseases in general 
practice. Utrecht, the Netherlands: Bunge, 1990
2 Royal College of General Practitioners, Office of Population Census and Survey, and Department of 
Health and Social Security. Morbidity statistics from general practice: fourth national study. 1991-92. 
London: HMSO, 1995.
2.8/1000 in those aged 45-64 years to 43.5/1000 in those >75 years in a Dutch 
study. 1
Prevalence
The prevalence of CHF was 24-25/1000 in subjects aged > 45 years in the 
Framingham Heart Study (2) and 7.4-21.2/1000 in other US studies depending 
on the population studied, being higher in the elderly. (3;7-9) The Dutch 
studies1 ' 3 reported a prevalence of about 11/1000 while Swedish, (10) Italian 
(11) and Danish2 studies have quoted much higher prevalence mainly because 
of the higher age of the patients studied. A survey of European secondary care 
reported that of the patients with a death or discharge diagnosis of heart failure, 
about 31% had left ventricular systolic dysfunction (LVSD) alone, 14% valve 
disease alone, 23% LVSD with valve disease (predominantly mitral 
regurgitation) and 32% heart failure with normal ejection fraction (HFNEF), 
although the diagnosis was questionable in a substantial proportion of the last 
group. (12) A survey of European primary care came to similar conclusions. (13) 
The prevalence in general practice in UK is 3.8-13/1000 across all ages.(14) 
The prevalence of CHF and LVSD in a heart failure clinic taking referrals from 
the general population was 23/1000 amongst patients aged > 45 years. 19 The 
prevalence of CHF increases rapidly with age with 15% of over 85s suffering 
with it. (15) About 15% of non-institutionalised patients (aged >70 years) 
developed CHF over six years before they died and 24% of all deaths were 
preceded by CHF. (16) Extrapolating data from several studies, it is likely that 
the true prevalence of CHF and LVSD in Western Europe is about 1-2% of the 
whole population (i.e. about 1-5% of the population aged 25-75 years). In 
addition, about 1-2% has asymptomatic LVSD, 1% has HFNEF and about 2% 
has suspected CHF that is not confirmed by investigation. Thus the total burden, 
of heart failure and/or ventricular dysfunction in the community is about 5%. (15) 
The prevalence in men and women is roughly equal. Men are more likely to 
develop CHF at a younger age and due to ischaemic heart disease (IHD) and 
suffer with asymptomatic LVSD while women suffer more with HFNEF. (15)
1 Lamberts H, Brouwer HJ, Mohrs J. Reason for encounter   and episode and process oriented standard 
output from the Transition Project. Part 1 & 2. Amsterdam: Dept. of General Practice, 1993
2 Wendelboe O, Hansen JF. Prevalence of mild and severe congestive heart failure in the community. 
Heart Failure '95. International Meeting of the Working Group on Heart Failure of the European Society of 
Cardiology, 1995, Amsterdam
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Epidemiology of LVSD
About half of patients with important LVSD are symptomatic but a substantial 
proportion of these develop HF symptoms subsequently. Men are more likely to 
be asymptomatic than women. Asymptomatic patients have a better prognosis 
than symptomatic ones. (17; 18) The commonest presentation of asymptomatic 
LVSD is sudden death. (19)
LVSD is usually due to IHD most commonly myocardial infarction. About a third 
will have extensive coronary disease but no classical evidence of myocardial 
infarction. Less than 10% of LVSD is due to dilated cardiomyopathy, 
constituting a relatively high proportion of LVSD in people aged <50 years. 
(13;20)
The Epidemiology of HFNEF
The epidemiology of HFNEF is more complex. It is more common in older 
women and results from multiple pathologies. (13;20) It appears that 
conventional echocardiography is unreliable in the diagnosis of HFNEF as the 
Doppler criteria are controversial at best. NT-proBNP appears to be useful in 
identifying patients who are at increased risk of cardiovascular events and 
death and who respond to treatment. (21)
Epidemiological studies, mainly of hospital discharge populations, suggest that 
the prognosis of HFNEF is similar to or only slightly better than HF due to LVSD. 
(22;23) However, clinical trials suggest dramatically lower rates of 
hospitalisation with heart failure and death, compared to patients with LVSD. 
(21;24) This may reflect the effects of non-cardiac co-morbidity and mortality, as 
this constitute a higher proportion of events in these patients than for patients 
with LVSD. The prognosis of HFNEF patients included in clinical trials seems 
better than that suggested by epidemiology due to exclusion of patients with 
serious non-cardiac co-morbidity from clinical trial. It also suggests that many of 
the deaths observed in the epidemiological studies would not be prevented by 
trial interventions.
Morbidity and mortality
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Heart failure remains an important cause of morbidity and mortality. A survey of 
heart failure in European primary care suggests that half of patients remained 
moderately or severely symptomatic on therapy with gross impairment of the 
quality of life after discharge, perhaps due to suboptimal treatment in most 
patients. (13) The mortality amongst newly diagnosed patients with heart failure 
may be as high as 20% during index admission. (25;26) The Bromley, (27) 
Hillingdon, (28) Framingham, (2) Rochester, (3) and Olmsted County (29) 
studies all suggest a 1-month survival of 80-85%, dropping to 57-68% at 18 
months. The three-year mortality of patients with new onset heart failure is 
about 60%, with evidence of a small improvement over the last 15 years. (30;31) 
Mortality is biphasic, with a six month mortality of 35-40% presumably reflecting 
a rapid decline in cardiac dysfunction, a high-risk of cardiac arrhythmias and 
sudden death and serious co-morbidities. The mortality is subsequently about 
7% per annum or, if rebased to those still alive at 6 months, 10-15% per annum. 
The calculated median survival of incident heart failure is 2-3 years and of those 
who survive the first year, about 5 years and few patients surviving >10 years. 
(30)
Most deaths in patients with LVSD are cardiovascular. Sudden death occurs in 
about 3% per year due to arrhythmias, acute vascular events or other causes. 
The lifetime risk of sudden death in an asymptomatic LVSD patient may be 
higher than that of symptomatic patients. (32)
Problem in interpreting epidemiology
Epidemiological studies often exclude young patients (e.g. <25 years) and have 
an upper age limit (e.g.75 years). The elderly populations with highest 
prevalence rates may thus be under-represented leading to an underestimation 
of prevalence. The incidence and prevalence averaged over all ages reported in 
a study population cannot be directly applied to the general population as the 
prevalence varies widely across age groups. (4) Prevalence of heart failure is 
often determined using data collected from medical records supplemented by 
direct questioning and/or examination of individuals within the general 
population, drug prescription data analysis, and general practitioner monitoring. 
Hospital discharge codes substantially underestimate hospital events related to 
HF (33)
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Diagnosis of CHF is often difficult. Despite the definition, (1) there are 
considerable uncertainties in its diagnosis. Only about a third to half of the 
patients suspected of having CHF in primary care has the diagnosis confirmed 
in secondary care, (6;34;35) Uncertainties persist even after assessment of 
these patients in secondary care. A survey of US cardiologists indicated that 
they felt that they could diagnose only advanced heart failure with certainty by 
clinical means alone. (36) In the EuroHeart Failure survey programme, a 
diagnosis of heart failure could not made or excluded in 46% of patients seen in 
the hospital. (20) Whether heart failure was the cause of dyspnoea could be 
determined in only 50% of the patients with normal left ventricular ejection 
fraction (LVEF) who were assessed in a heart failure clinic in the UK.(37)
This uncertainty stems from several factors. First, the symptoms and signs of 
heart failure are non-specific. The positive predictive value of these symptoms 
is poor and the inter-observer agreement on the presence of symptoms and 
signs is low, especially amongst the non-specialists and in routine clinic setting. 
(38-42) Many patients with LVSD are asymptomatic. (15) The signs may 
disappear in well treated heart failure even when severe. The relationship 
between symptoms and cardiac dysfunction is poor (43) and symptoms are 
often similar across the different levels of ejection fraction. (44) The relation 
between heart size on chest x-ray and left ventricular function is poor (45) and 
upper lobe venous dilatation is a poor guide to the simultaneous pulmonary 
capillary wedge pressure. (46) Inter-observer agreement on the interpretation of 
pulmonary congestion on chest x-rays is only modest. (47)
Second, cardiac dysfunction is often inadequately quantified. The use of 
transthoracic echocardiography for the documentation of cardiac dysfunction 
and measurement of LVEF for diagnosis of heart failure is far from universal. 
The IMPROVEMENT of Heart Failure Programme reported large variations in 
the likelihood that a physician would request echocardiography for diagnosis of 
heart failure in primary care in Europe. On the whole only 45% of the family 
physicians surveyed would request an echocardiogram in a patient with 
suspected heart failure and almost 20% of patients enrolled did not have an 
echocardiogram. (13) This variation persists even in secondary care. The
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EuroHeart Failure Survey reported that one third of the patients with known or 
suspected heart failure never had an echocardiogram. (20) The suggested 
assessment of cardiac function includes global and regional systolic and 
diastolic and valvular function. In clinical practice, however, the quantification of 
systolic LV function is often restricted to a single estimation of LVEF at rest. 
LVEF was reported in only 39% of the patients who had an echocardiogram in 
the IMPROVEMENT of Heart Failure Programme (13) and less than 213rd of the 
patients in the EuroHeart Failure Survey. (20)
Third, the modality by which LVEF is quantified is not standardised. Though 
echocardiography is the commonest and the recommended modality, contrast 
ventriculography, radionuclide ventriculography (RNVG) and cine magnetic 
resonance imaging (CMRI) are all used. The LVEF measured by these 
different modalities are not interchangeable or comparable. (48) Most (but not 
all) large clinical trials in heart failure and LVSD entered patients on the basis 
of LVEF measured by RNVG. However, LVEF in clinical practice is measured 
on echocardiography. Echocardiography tends to be overestimate LVEF 
compared to RNVG. (48) A proportion of patients whose LVEF is "normal" as 
measured by echocardiography would be diagnosed with LVSD using RNVG. 
Epidemiological studies also have commonly used echocardiography as the 
main method for estimating LVEF. (6;27;34;35;37) Prevalence of LVSD may be 
an underestimate compared to that measured on RVNG, a modality used to test 
benefits of treatments in clinical trials.
Fourth, the method used for estimating LVEF on echocardiography is often not 
robust. Most epidemiological studies measured LVEF from M-mode images. 
(6;27;34;35;37) M-mode echocardiography is acoustic window and operator 
dependent. It assumes an ellipsoid geometry of the LV that does not hold true 
when the LV undergoes progressive dilatation and becomes spherical and/or is 
dyssynchronous. (48) It also assumes that a single segment is representative of 
the entire LV and this is erroneous in patients with wall motion abnormalities. 
Inadequately defined endocardial borders, gain-dependent edge identification 
and variations in transducer position during imaging limit even the Simpson's 
method for measurement of LVEF. These methodological limitations introduce 
errors in estimates of the prevalence of LVSD. CMRI provides the most
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accurate and reproducible measurements of LV volumes and thence the LVEF. 
LVEF by M-mode echocardiography is significantly different from that by CMRI 
with unacceptably wide Bland-Altman range of agreement. (48) Though the 
mean LVEF measured by CMRI and 2D echo using Simpson's rule were similar 
suggesting that 2D echo provides estimates of EF comparable to CMRI, the 
Bland-Altman range for these two modalities reveal wide limits of agreement. 
(48) Estimating LVEF in the presence of atrial fibrillation and bundle branch 
blocks is difficult by any method. Measurement of LVEF by Simpson's rule may 
be impossible in an about half of the acute myocardial infarction patients (49) 
and one third of elderly patients (50) due to poor image quality.
Fifth, heart failure may occur in the absence of significant abnormality of 
conventionally measured LVEF. A number of epidemiological studies have 
suggested that 30-50% of cases of HF have normal ejection fractions. 
(6;13;20;29;51-54) Amongst the patients enrolled in the Euroheart Failure 
Survey whose LVEF was recorded, an LVEF>40% was reported in 49% of the 
males and 72% of the females. But diastolic measurements were seldom 
reported. (20) Thus in these patients with suspected heart failure, normal 
ejection fractions either excluded the diagnosis of heart failure or generated 
significant uncertainty in this diagnosis. This reflects clinical practice where 
diastolic evaluation of ventricles in patients with suspected heart failure is 
seldom undertaken. This reluctance in diastolic evaluation arises from several 
factors. There is a general lack of appreciation of this condition. The 
IMPROVEMENT of Heart Failure Programme reported that almost a quarter of 
the primary care physicians in Europe are unaware of the concept of HFNEF 
and only a third of them differentiated heart failure with from without normal 
ejection fraction. (13) There are doubts surrounding the very existence of 
HFNEF. HF was deemed to be more often a misdiagnosis than a true entity in 
patients with normal ejection fraction as most of these patients have an 
alternative; often non-cardiological cause for their symptoms.(55) The lack of 
observed LVSD in these patients was deemed only to be "apparent" due to the 
transient and thus elusive nature of the LVSD resulting from ischaemia or 
arrhythmia induced regional wall motion abnormalities (56) or the remoteness of 
the measured LVEF from the episode of HF. (52) Studies have confirmed that 
though conventionally measured LVEF is normal in these patients, LV "systolic"
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function is not. Selective impairment of long-axis systolic and diastolic 
dysfunction at rest that do not manifest as a major impairment of global LV 
systolic function occurs in the absence of depressed LVEF. (57-62) Despite 
these studies, the presence of "pure" diastolic dysfunction has been strongly 
argued for by some authors. Gandhi et al demonstrated a low prevalence of 
LVSD during an acute episode of heart failure and on subsequent follow-up in 
patients with hypertension and acute cardiogenic pulmonary oedema, 
suggesting that transient LV systolic dysfunction is not a common entity and 
transient new or exacerbation of pre-existing diastolic dysfunction may occur. 
(63) Zile et al suggested that diastolic LV dysfunction was so common amongst 
patients with normal LVEF that there was no need to measure diastolic function 
in these patients. (64) Other authors have suggested that stress-induced left 
ventricular outflow tract (LVOT) obstruction may result in symptoms of heart 
failure in these patients. (65) There is lack of universally accepted robust 
diagnostic criteria for diastolic heart failure (DHF). The diagnostic criteria for 
DHF published by The European Study Group on Diastolic Heart Failure in 
1998 (66) was found to be of limited use (67) and thus did not gain widespread 
acceptance. Numerous studies using mitral valve blood flow Doppler showed a 
variable outcome in terms of predictive value for HFNEF. The criteria proposed 
by the European Study Group were fulfilled in only 43% of patients hospitalised 
for HFNEF.(68) The concordance between diagnosis of HFNEF based on 
conventional echocardiographic measure of LV diastolic dysfunction and that 
based on other diagnostic criteria is poor. (69;70) Both E/A ratio and IVRT 
poorly correlate to serum NT-proBNP in patients with HFNEF. (71;72) The 
assessment of LV diastolic function is technically challenging. The conventional 
echocardiographic parameters of diastolic dysfunction are dependent on left 
ventricular pre- and after- load, heart rate, PR interval and QRSd. The E/A is 
often "pseudonormalised" and thus underestimate the condition. About 50% of 
normal E/A are pseudonormal. Valsalva manoeuvre, that unmasks abnormal 
diastolic filling in patients with pseudonormalisation, is rarely undertaken. 
Valsalva is unobtainable in about 40% patients with pseudonormalisation due to 
inability to comprehend instructions or strain adequately. Deep inspiration may 
degrade image quality and limit E and A assessment at peak Valsalva. The 
change in the E/A with Valsalva, decrease with age. There are no cut-offs for 
the decrease in E or E/A ratio to reach a diagnostic threshold. The threshold
16
depends upon baseline values for E and A, the quality of Valsalva, degree of 
patient effort etc. The changes with Valsalva manoeuvre is less predictive of 
elevated LV filling pressure when EF is normal. Other measurements of 
diastolic dysfunction like pulmonary venous flow are difficult to obtain and 
accuracy of recordings is highly dependent on skill of the operator and body 
size of the patient. Artifacts from LA motion also affect these measurements.
Rationale for the thesis
The current guidelines recommend assessment of the LV function at rest for the 
diagnosis of heart failure (1) though symptoms of heart failure are often present 
only during exercise and are almost universally induced by it. Conventionally 
assessed resting LVEF may be normal or abnormal in patients with symptoms 
suggestive of heart failure. Resting echocardiography may be adequate in 
confirming the diagnosis if the LVEF is abnormal at rest. But this strategy 
would fail to explain the genesis of the exercise-induced symptoms of heart 
failure in patients with normal resting LVEF. Stress echocardiography may 
potentially unmask global, regional and long-axis systolic LV dysfunction that 
are absent at rest and are likely to be responsible for exercise-induced 
symptoms. It may also demonstrate changes in the severity of abnormalities 
present at rest and provide prognostic information.
Coronary artery disease (CAD) is widely prevalent amongst patients with 
heart failure and normal LVEF (52) and is thus expected to be so amongst 
patients with suspected heart failure. Patients with CAD with and without past 
myocardial infarctions have considerable volumes of myocardium served by 
stenotic coronary arteries. The resting LVEF is often normal in these patients. 
Severe brief ischaemia may cause prolonged but transient LVSD that 
persists after the ischaemic insult itself has resolved, a process termed 
exercise-induced "stunning". (73) Inducible ischaemia per se may present as 
breathlessness that could be misconstrued as a heart failure symptom. 
Exercise may also precipitate isolated diastolic dysfunction by inducing 
ischaemia, (74-81) systolic hypertension, (82-84) and tachycardia. (85) 
Exercise-induced increases in the LVOT gradient may also give rise to heart 
failure symptoms. (86;87) Even though exercise induced ischaemia could 
potentially provoke LV systolic and diastolic dysfunction extensive enough to
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give rise to symptoms of heart failure in patients with normal ejection fraction, 
search for myocardial ischaemia has rarely been undertaken in these patients. 
Ischaemia was systematically evaluated in only 1(n=20) (88) of the 11 studies 
(n=763) reviewed by Choudhury et al (89) and was found to be absent. Studies 
that have reported low prevalence or even the absence of systolic dysfunction 
with or without diastolic impairment have not systematically excluded ischaemia 
as a cause for their symptoms. (63;90;91) Stress echocardiography could 
potentially identify ischaemia and clarify its possible role in the genesis of 
symptoms in these patients.
CAD with and without associated myocardial infarction is common in patients 
with heart failure with reduced LVEF. (92) Stress echocardiography is also 
likely to be helpful in the assessment of the burden of myocardium that is 
dysfunctional but viable (hibernating) and/or is reversibly ischaemic in 
patients with LVSD.
Another potential mechanism for the exercise induced deterioration of LV 
systolic function in patients with heart failure and LVSD is intra-ventricular 
dyssynchrony that is induced or exacerbated with stress. LV dyssynchrony at 
rest is seen in patients with heart failure and LVSD irrespective of the QRSd. 
(93-96) Studies investigating the effects of exercise or pharmacological 
stress on ventricular dyssynchrony have yielded conflicting results. (97-100) 
Indices of dyssynchrony did not change in subjects without heart disease in 
these studies whether the stressor was exercise or dobutamine. In patients 
with heart failure, changes in the dyssynchrony indices in response to stress 
were either absent (97;99) or unreported.(98;100) Stress echocardiography 
could identify these changes
The heart could be stressed during echocardiography using exercise (treadmill 
and upright or supine bicycle ergometry), pharmacology (inotropes like 
dobutamine, arbutamine or enoximone and vasodilators like dipyridamole or 
adenosine) or electricity (pacing). Dobutamine stress echocardiography was 
used for this thesis. Though most physiological, exercise stress 
echocardiography has several disadvantages. Imaging the heart during any 
form of exercise is difficult. Movement and increased rate and depth of
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respiration may render the image quality suboptimal. It is well recognised that 
only 40% of patients tested for CAD, can perform a truly diagnostic exercise test 
(101; 102) This proportion is likely to be even lower in the elderly patients, with 
musculoskeletal or neuromotor problems, general frailty and breathlessness. 
Treadmill exercise, the available form of exercise stress in our setting, has 
additional limitations. The heart cannot be continuously imaged. Thus the time 
of onset of ischaemia and changes in the cardiac function at each level of 
exercise cannot be precisely identified. Myocardial viability, a prognostically 
important component of left ventricular evaluation in patients with heart failure, 
cannot be assessed with exercise stress echocardiography (ESE). British 
Society of Echocardiography Policy Committee does not recommend exercise 
echocardiography for assessment of viability in dysfunctional myocardial 
segments. (103) The end-points of the test are non-echocardiographic i.e. 
attainment of target heart rate, ST-segment changes, development of 
symptoms etc. These changes with exercise occur later in the ischaemic 
cascade than the wall motion changes. (104) Thus ischaemia is detected later. 
And lastly, because ischaemia induced wall motion abnormalities may resolve 
quickly, imaging needs to be completed quickly after the completion of exercise. 
It is recommended that post-exercise imaging be accomplished within 60-90 
seconds of termination of exercise. But even under "study" conditions, this was 
barely achievable and information gained at peak exercise was lost in 
significant proportion of patients with post-exercise imaging. About 34% of new 
RWMA that develop at peak exercise resolve by the time images were acquired 
after exercise and 29% patients would have been missed had imaging been 
performed after exercise alone. (105) More precisely, new RWMA at peak 
exercise resolved at post-exercise imaging obtained within 80 seconds of 
exercise termination in 31% of patients with positive exercise echocardiography. 
There was a significant decrease in heart rate between peak exercise and the 
image acquisition. (106) No new RWMA was however missed when images 
where acquired within the recommended time in another study. (107) These 
problems could be overcome with supine bicycle stress testing. This was not 
available in our setting. Both exercise and dobutamine have a similar accuracy 
for the detection of coronary disease. (107-109)
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As an adjunct to 2-D grey-scale stress echocardiography, colour tissue 
Doppler imaging (cTDI) was used to quantitatively assess global, especially 
long-axis, and regional myocardial function. cTDI is a useful technique that 
provides an objective and reproducible measure of global, regional and 
longitudinal systolic and diastolic function at rest and different levels of stress 
This technique has been extensively used in cardiovascular research and its 
usefulness in the assessment of the LV function has been confirmed both at 
rest and during stress. The application of this technique is discussed in detail 
later.
Aims of the thesis
The principle aim of this thesis is to assess the application of conventional DSE 
supplemented by cTDI in the evaluation of patients with suspected heart failure. 
The reasons for patients declining or being excluded from DSE would be 
recorded to assess the applicability of this imaging technique to a general 
population of patients with heart failure. In particular, the prevalence, both at 
rest and during pharmacological stress, of the global and regional systolic and 
diastolic abnormalities of cardiac function that could cause or contribute to the 
symptoms of CHF in an unselected population of subjects suspected of having 
heart failure would be determined.
Hypotheses
  DSE supplemented with cTDI is likely to be applicable only to a highly 
selected group of patients with suspected heart failure.
  Quantitative echocardiography using cTDI would supplement 
conventional DSE in further unmasking abnormalities not otherwise 
detected.
  In subjects who undergo DSE, it would clarify the prevalence of stress 
induced changes in global, regional or long axis systolic or diastolic 
function in patients with symptoms of heart failure with reduced or normal 
ejection fraction.
  In patients with HFNEF, DSE would detect changes in global, regional or 
long axis systolic or diastolic function that would explain the genesis of 
symptoms in these patients.
  In patients with heart failure and LVSD, DSE would detect changes in 
intraventricular dyssynchrony.
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Chapter 2: Stress echocardiography
Introduction
Wann et al first introduced echocardiography during stress in 1979. (110) It is
based on the principle proposed by Gallagher et al (111) and then by Ross et al 
(112) that during stress-induced ischaemia, the decrement in myocardial 
contractile function is directly related to the decrease in regional subendocardial 
blood flow. 2-dimensional echocardiography, by virtue of its ability to assess 
regional and global contractile function, is an excellent tool for obtaining 
valuable information on cardiac function when combined with any stress- 
producing modality. It is widely available, rapidly performed, and safe without 
radiation and highly versatile test that can be used in variety of environments 
and for a variety of indications.
Methodology
Modalities of stress
The heart can be stressed during echocardiography using exercise (treadmill 
and upright or supine bicycle ergometry), pharmacological agents (vasodilators 
like dipyridamole or adenosine and inotropes like dobutamine, arbutamine or 
enoximone) or electricity (pacing). Exercise and dobutamine are the commonest 
stressors used in clinical practice. Both exercise and dobutamine have a similar 
accuracy for the detection of coronary disease. (107-109) Although both 
exercise and dobutamine induce ischaemia through increasing cardiac work, 
the haemodynamic responses to the two are different. Despite increasing 
contractility, systolic blood pressure does not increase to a major degree 
because dobutamine reduces peripheral vascular resistance. Although both 
stressors can achieve the same heart rate, both systolic blood pressure and the 
rate-pressure product at peak stress are significantly greater with exercise than 
with dobutamine. Dobutamine stress was used for this study.
Vasodilator stress work by the induction of coronary steal with minimal 
haemodynamic effects in the setting of severe or extensive coronary disease. 
British Society of Echocardiography Policy Committee recommends that 
vasodilator stress echocardiography should only be considered when physical 
stress is not possible and there are contraindications to dobutamine (103) 
because its sensitivity to assess mild to moderate CAD is low, it is unable to
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assess myocardial viability and it is contraindicated in asthma and untreated 
conduction abnormalities.
Imaging techniques
Native 2-dimensional transthoracic echocardiography with harmonic imaging is 
routinely used. Parasternal long and short axis and apical 4-chamber, 2- 
chamber and 3-chamber views, optimised for image quality, are recorded. The 
images are acquired in suspended respiration (at end-expiration if possible to 
avoid Valsalva manoeuvre, which can degrade image quality) to minimize 
translational motion. Minimizing depth and using the narrowest sector angle 
attain maximum frame rates. The recommended frame rates are at least 25 
frames per second to be increased to 30 when heart rates >140 beats is 
reached. Gains are adjusted and highest possible transducer frequency is used 
to maximise image resolution. Steep lateral decubitus position minimises apical 
foreshortening. Acquisition and storage of digital loops is standard. Digital 
imaging allows split or "quad-screen" side-by-side displays for comparison of 
regional function at rest and stress and real-time reviews of changes in 
contractility on a frame-by-frame basis. Simultaneous side-by-side display of 
previously acquired loops facilitates acquisition of new images in a comparable 
plane. At least two cardiac cycles is acquired when the patient is in sinus 
rhythm and five in atrial fibrillation. Loops are edited to exclude atrial or 
ventricular premature complexes.
If resting native images are sub-optimal in quality, echocardiographic contrast 
may be used. Left ventricular contrast is used for enhancement of the 
endocardial border. Myocardial contrast is used to directly assess myocardial 
motion, thickening and perfusion. When ultrasound contrast agents are used 
contrast specific imaging modalities is employed (reducing the mechanical 
index to minimise bubble destruction). The best images are recorded several 
cardiac cycles after the appearance of contrast in the LV. When less than 80% 
of the endocardial border is adequately visualised, the use of contrast agents 
for endocardial border delineation is strongly recommended. (113)
Study protocol
During echocardiography dobutamine is injected intravenously via a syringe
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pump using standardised protocol depending on the indication of the test. (103) 
For assessment myocardial ischaemia, dobutamine is infused starting at 10 
mcg/kg/min, with increment of 10 mcg/kg/min every three minutes to a 
maximum of 40 mcg/kg/min. Some studies have used a maximum dose of 50 
mcg/kg/min. If the heart rate response is "inadequate", atropine is administered 
in 0.3 mg increments every 60 seconds until the target heart rate or a maximum 
dose of 1.2 mg is reached. Atropine may also be administered early if heart rate 
has not increased after the 20 mcg/kg/min of dobutamine. Atropine should be 
used to increase the sensitivity of the test in patients whose beta-blocker cannot 
be stopped. It is contraindicated in patients with glaucoma and history of urinary 
retention. For assessment of myocardial viability, dobutamine is infused starting 
at 5 mcg/kg/min followed every five minutes by 10 mcg/kg/min and 20 
mcg/kg/min stages. Further stages at 30 and 40 mcg/kg/min may be used to 
assess a "biphasic" response. The sensitivity of the test for detection of 
ischaemia is reduced in patients on blockers due to its negative inotropic effect. 
(114) Thus, as recommended, beta-blockers were stopped 48 hours before the 
test.
Images are recorded at rest and in the final 60 seconds of every stage of the 
protocol and sometimes during recovery. The British Society of 
Echocardiography Policy Committee recommends acquisition, for detection of 
ischaemia, at baseline, low stress (10% increase in heart rate), intermediate 
stress (70% of the age predicted heart rate), peak stress (85% of the age 
predicted heart rate) and sometimes during recovery. Continuous 
echocardiographic monitoring of ventricular function and out flow tract gradient 
is informative.
Blood pressure and 12-lead ECG monitoring is continued throughout the test. 
Heart rate and rhythm, blood pressure, symptoms and wall motion 
abnormalities are recorded at the end of each stage, during any symptoms and 
at test termination. The persons present at the test include one skilled in 
acquisition and interpretation of the echocardiographic images and one trained 
in haemodynamic and ECG monitoring. All personnel should be trained in basic 
life support. Someone with training in advanced life support should be 
immediately available if needed even if not present during the test. If contrast
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agents are used, patient should be monitored for hypersensitivity reactions.
The end-points for test termination include attainment of target heart rate (THR) 
{85% of (220-age in years)}, decrease in systolic blood pressure >20 mmHg 
below the level recorded at the previous level of test, increase in the systolic 
blood pressure to >240/120 mmHg, new or worsening wall motion or thickening 
abnormalities in at least two adjacent segments, new or worsening wall motion 
or thickening abnormalities with or without ventricular dilatation, intolerable 
symptoms of chest pain or severe breathlessness, >2mm flat or down-sloping 
ST depression or >1mm ST elevation in any lead, recurrent ventricular couplets 
or triplets, single run of non-sustained ventricular tachycardia (defined at >5 
consecutive ventricular ectopics), sustained ventricular tachycardia or new atrial 
fibrillation and finally global reduction in the systolic function
Study analysis and interpretation.
Normal myocardium contracts at rest and increases its contractility and 
thickening during stress. Detection of myocardial ischaemia by DSE is based on 
the principle that motion and thickening of the left ventricular wall decreases 
with stress-induced relative reduction in myocardial blood flow. Myocardial 
viability is diagnosed on the basis that dobutamine at low-dose increases 
contractility in dysfunctional and viable myocardium by activating contractile 
reserve but not in dysfunctional and non-viable myocardium. (115)
During DSE, changes in regional wall motion and thickening and global left 
ventricular volumes, shape and ejection fraction are visually estimated at each 
level of stress by comparing acquired loops side-by-side. Analysis of thickening 
is better than analysis of motion in estimating contractile function as the later 
may be influenced by translation and tethering For systematic description of 
regional contractile function the left ventricular wall has been divided into 
standardised segments. In 1989, the American Society of Echocardiography 
recommended a 16-segment model for LV segmentation. (116) This model 
consists of basal and midventricular segments of the anteroseptal, inferoseptal, 
inferior, posterior, lateral and anterior walls and 4 segments at the apex: 
inferoseptal, inferior, lateral and anterior segments. In 2002, the apical cap, a 
segment beyond the end of the LV cavity was added by the American Heart
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Association Writing Group on Myocardial Segmentation and Registration for 
Cardiac Imaging, as the 17th segment in an attempt to establish segmentation 
standards applicable to all types of imaging and not only echocardiography. 
(117) However, the ASE recommends using the 16-segment model of for 
studies assessing wall-motion abnormalities, as the tip of the normal apex 
(segment 17) does not move. (118) This model was used for this thesis. For 
analysis of regional contractile function, each of the 16 segments of the left 
ventricular wall is designated a semi-quantitative score at each level of stress: 
normal=1, hypokinesia=2, akinesia=3, dyskinesia=4, and aneurysmal 
(diastolically deformed)=5. (116) Wall motion score index (WMSI) is calculated 
by dividing the sum of the scores in each segment by the number of segments 
analysed. WMSI of 1 is normal; higher score indicates wall motion 
abnormalities. WMSI and LVEF are linearly correlated. (119; 120)
The response of the myocardium to dobutamine varies according to its 
contractile state. "Normal" myocardium contracts at rest and increases its 
contractility and thickening at peak stress. Mild hypokinesia is considered 
normal. "Ischaemic" myocardium contracts normally at rest but is hypokinetic, 
akinetic or dyskinetic at peak stress. Dysfunctional but "viable" non-ischaemic 
myocardium (stunned myocardium) is hypokinetic or akinetic at rest, improves 
with low dose of dobutamine and sustains that improvement at high dose. 
Dysfunctional and "viable" but ischaemic myocardium (hibernating myocardium) 
demonstrates a "biphasic" response to dobutamine (the hypokinetic or akinetic 
myocardium improves in contractility with low dose dobutamine stress but then 
worsens with higher dose). This indicates myocardial dysfunction due to 
ischaemia and strongly predicts its recovery following revascularisation. 
Dysfunctional and non-viable myocardium ("scar") is akinetic or dyskinetic at 
rest and does not change with dobutamine stimulation. Whether the 
development of dyskinesia in an akinetic segment represents ischaemia is still a 
matter of debate. It has been suggested that these changes result from 
increase in the wall stress rather than induced ischaemia. The absence of a 
hyperdynamic response at higher doses of dobutamine is also difficult to 
interpret.
Mvocardial substrate for ischaemia heart failure
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Ischaemia affects several aspects of LV function. Foremost of these is 
impairment of systolic contraction of the myocardium. When the balance 
between the normo-contractile and hypo-contractile myocardium is tipped 
unfavourably, the long-axis followed by the global systolic function of the LV is 
impaired. The systolic dysfunction of the myocardium due to ischaemia results 
from such pathophysiological processes as hibernation, stunning, repetitive 
stunning and varying degrees of myocardial scarring and fibrosis. All these 
processes may co-exist in the same ventricle and even within the same region 
of the ventricle. These pathophysiological states of the myocardium respond 
distinctly to dobutamine stimulation.
Myocardial hibernation
Diamond et al, in 1978, were the first to use the word "hibernation" in the 
introduction to an experimental study that demonstrated that post-extrasystolic 
potentiation markedly restored systolic shortening of acutely dysfunctional 
ischaemic myocardium suggesting a preservation of contractile reserve within it 
up to shortly after complete arterial occlusion. This responsiveness was lost 
with time as the myocardium reached a point of non-viability. (121) After 
reviewing the literature suggesting that akinetic LV segments that were 
previously assumed to be fibrotic and non-viable recovered systolic function 
after revascularisation, Rahimtoola et al (122) proposed the concept of 
"myocardial hibernation". It refers to a prolonged sub-acute or chronic stage of 
myocardial ischaemia in which myocardial contractility and metabolism and 
consequently ventricular function are reduced to match the reduced blood 
supply to achieve a new state of equilibrium whereby myocardial necrosis is 
prevented and the myocardium is capable of returning to normal or near normal 
function on restoration of adequate blood supply. (123) This is a state of 
"perfusion-contraction match" where cellular viability is maintained at the 
expense of normal contractile function in the face of chronically reduced oxygen 
supply leading to overall LV dysfunction. (124; 125) Reduced contractility 
reduces oxygen demand thus maintaining viability despite poor perfusion.
Hibernating myocardium is physiologically characterised by hypo-contractility 
with persistent inotropic reserve, reduced resting perfusion (126) (though some 
studies have claimed the contrary) (127-129) and metabolic activity and
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severely impaired vasodilatory coronary flow reserve. During recruitment of 
inotropic reserve with intravenous dobutamine oxidative metabolism and 
glucose utilisation increases as does the perfusion (129; 130) but prolonged 
stimulation may lead to myonecrosis. Restoration of blood flow to chronically 
underperfused myocardium leads to the functional recovery of hibernating 
myocardium.
Myocardial Stunning
Heyndrickx et al, in 1975, described the phenomenon where regional 
mechanical function remained impaired for prolonged periods after short 
episodes of coronary occlusion in conscious dogs. (131) Myocardial stunning, a 
term coined in 1982, (132) is a state of reversible contractile dysfunction that 
results from a short period of interruption of blood flow and persists after 
restoration of normal or near-normal perfusion despite the absence of 
irreversible damage. (133) This was subsequently noted after selective 
subendocardial (134) and exercise-induced ischaemia (135) It may result from 
single or multiple completely reversible ischaemic episode or a single, partly 
irreversible ischaemic episode and exercise, in presence or absence of 
coronary stenosis. Exercise-induced increase in myocardial oxygen demands in 
the face of limited supply (flow-limiting stenosis) is likely to be a common clinical 
scenario in patients with CAD with symptoms of heart failure. This may provoke 
myocardial ischaemia and contractile abnormalities that persist after cessation 
of exercise when demand returns to the resting state. (135; 136) Stunning has 
been demonstrated after exercise, particularly in patients with multi-vessel 
disease. (137; 138) Exercise can induce both ischaemic myocardial dysfunction 
and post-ischaemic myocardial stunning in hypertrophied ventricles in the 
absence of any coronary stenosis. (139)
Stunning is a state of "perfusion-contraction mismatch" where the contraction is 
impaired even though the perfusion is intact. Stunned myocardium has 
persistent inotropic reserve, normal resting perfusion and decreased coronary 
flow reserve. Dobutamine challenge recruits the inotropic reserve without 
deterioration of metabolism and does not produce necrosis even on prolonged 
stimulation.
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Repetitive Stunning
One of the key differences between stunning and chronic hibernation is that 
resting perfusion is intact in stunning but reduced in hibernation. However some 
studies have reported normal resting perfusion in dysfunctional myocardium 
thought to be "hibernating". (127-129;140) An inverse relationship has also 
been demonstrated between the degree of contractile dysfunction and coronary 
reserve. (140) These facts have prompted investigators to postulate that some 
patients thought to suffer with chronic hibernation are actually suffering from 
"repetitive stunning". This is a state of persistent myocardial dysfunction 
resulting from cumulative effect of repetitive brief episodes of ischaemia in 
myocardium (with normal resting perfusion but severely reduced coronary flow 
reserve) that is not capable of increasing its blood flow sufficiently to meet its 
metabolic demands leading to repetitive stunning. Repetitive bouts of 
myocardial stunning can produce a prolonged, reversible depression of 
contractility that mimics myocardial "hibernation". (141)
In ischaemic cardiomyopathy, dysfunctional segments with severely reduced 
(hibernating) and near normal (stunned) resting perfusion may co-exist in the 
same ventricle in humans.(142) Some myocardial regions that are hibernating 
at rest may develop ischaemia during exercise with a subsequent process of 
post-ischaemic stunning superimposed on the baseline hibernating state. This 
phenomenon has been shown in animals. (141) It appears that there is a 
temporal progression from stunning, characterized by (nearly) normal flow (with 
reduced flow reserve), to hibernation, with reduced resting flow. 
Revascularisation of myocardium with adequate perfusion at rest but with 
recurrent ischaemic episodes during stress may successfully reverse persistent 
contractile dysfunction caused by repetitive stunning. (143) The timing of 
functional recovery after revascularisation appears to differ between stunned 
and hibernating myocardium. Stunned myocardium recovery appears to be 
early after revascularisation and more complete, while recovery of hibernating 
myocardium is late and often incomplete.(144)
Myocardial necrosis and scarring
Myocardial necrosis and scarring occur as sequelae of single or recurrent
myocardial infarctions, with loss of functioning myocytes, development of
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fibrosis and subsequent left ventricular dysfunction and remodelling. Atkinson et 
al in 1989, described heart failure due to severe CAD without Ml in 26% of 
consecutive necropsies with ischaemic cardiomyopathy.(145) This suggested 
that LVSD is related to progression of CAD and does not require a distinct 
coronary event, such as Ml with enzymatic elevation. (92) Superimposed on the 
ventricles with irreversibly damaged myocardium is chronic hibernation. The 
balance between perfusion and tissue viability is so precarious in this state that 
this cannot be maintained indefinitely and that myocardial necrosis and 
associated fibrosis will ultimately occur if blood flow is not increased. (146-148) 
Loss of cardiomyocytes by apoptosis, de-differentiation of myocytes, loss of 
contractile components within the remaining myocytes, increased glycogen 
deposit and interstitial fibrosis characterises chronic hibernation. (149) This 
suggests that adaptive changes to chronic hypo-perfusion are incomplete. (147) 
The severity of these changes does not correlate with the degree of 
hypoperfusion and wall motion abnormality. Activation of neurohormonal 
systems in patients with heart failure and CAD lead to direct stimulation of 
interstitial fibrosis that contributes to the pathophysiology of heart failure. (150) 
The extent of fibrosis is the major determinant of postoperative functional 
recovery, (147;151) indicating that there may be a progressive diminution of the 
chance for complete structural and functional recovery after restoration of blood 
flow with time.
Pathophysioloqy of myocardial response to dobutamine
In the early 1970s, it was documented using contrast ventriculography that 
resting wall motion abnormalities may improve with use of inotropic agents 
(epinephrine, isoproterenol, and post-extrasystolic potentiation). (152) This 
improvement was predictive of subsequent improvement with coronary bypass 
surgery. (153-155) Since then several imaging techniques have been used to 
identify ventricles with dysfunctional and viable myocardium and predict 
recovery with revascularisation. Of these, DSE is widely used and has been 
used in this study.
Dysfunctional segments that are hypoperfused or normally perfused exhibit 
contractile reserve with dobutamine (142) though this improvement of 
contractile function is not sustained in the former in keeping with the reduced
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coronary flow reserve. (143) Dobutamine elicits a contractile response in 
hypoperfused dysfunctional segments without precipitating ischaemia by 
concomitant increase in myocardial blood flow. The percentage of increase in 
blood flow during dobutamine infusion in the dysfunctional myocardium 
approached that of normal myocardial regions. (129; 156) However, prolonged 
stimulation by dobutamine of a dysfunctional myocardium is known to 
precipitate ischaemia and even myocardial infarction. (157) Another potential 
mechanism whereby the contractile response may be elicited during 
dobutamine, despite reduced resting myocardial flow, is through the peripheral 
vasodilator effect of dobutamine, which causes reduction in LV size and end 
systolic wall stress by reducing afterload, thus increasing systolic wall 
thickening for the same myocardial blood flow. (158) Low-dose DSE identifies 
this contractile reserve while high-dose DSE identifies inducible myocardial 
ischaemia by direct visualisation of the consequential regional and global 
contractile dysfunction.
Possible clinical role of DSE in suspected heart failure
CAD is common in patients with heart failure. More than 70% of the patients 
with heart failure symptoms and LVSD have underlying CAD. (2;92) Most 
patients will have had a myocardial infarction but perhaps a third will have 
extensive coronary disease but no classical evidence of myocardial infarction. 
(13;20) In a review of 31 studies of HFNEF published between January 1970 
and March 1995, Vasan et al reported that the prevalence of coronary disease 
varied from 5-67%. Studies including patients with a mean age of 55-71 years 
reported a prevalence of 14-67%. (52) CAD is thus likely to be highly prevalent 
amongst patients with suspected HF and play a significant role in the genesis of 
their symptoms. Angina could present as breathlessness. Myocardium 
subtended by critically stenosed arteries is likely to suffer persistent contractile 
dysfunction due to either hibernation or repetitive stunning. (127; 140) Both 
dysfunctional and normal segments may suffer with ischaemia.
Detection and quantification of coronary artery disease 
DSE has been extensively used to diagnose CAD. After a review of 28 studies, 
Geleijnse et al reported mean sensitivity, specificity and accuracy of DSE for a 
total of 2,246 patients as 80%, 84% and 81% respectively. Mean sensitivity
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increased significantly from 74% for single-vessel disease to 86% for double- 
vessel disease and to 92% for triple-vessel disease. (159)
Several studies have shown ESE and DSE to have a similar accuracy for the 
detection of coronary disease. (107-109) Studies directly comparing ESE and 
DSE, reported a sensitivity of 76-85% and 72-86%, specificity 77-94% and 81- 
97% and accuracy of 82-87% and 80-87% for ESE and DSE respectively. 
(108; 160-162) The sensitivities of detecting patients with 3 and multi-vessel 
CAD were also similar (100% and 90% for ESE compared to 100% and 95% for 
DSE). (108) Peak exercise imaging has higher sensitivity and similar specificity 
to post-exercise imaging for detection of CAD. (106)
DSE also fares favourably when compared to single photon emission computed 
tomography (SPECT) in its ability to detect CAD. DSE had similar sensitivity 
(90% vs 96%) but higher specificity (90 vs 71%) compared to SPECT for 
detection of CAD. Diagnostic accuracy of dobutamine and exercise SPECT was 
also similar (90 vs 89%). (163)
Several factors affect sensitivity, specificity and accuracy with which DSE 
detects CAD. False negative tests result from sub-maximal stress, on-going 
beta-blocker therapy, female sex, single vessel disease, intermediate coronary 
stenosis and poor image quality. There are indications that segments visually 
reported to be non-ischaemic on DSE but are subtended by stenosed arteries 
(a false negative result) may fail to develop ischaemia because afterload 
reduction during DSE leads to lower myocardial oxygen consumption. These 
segments thus truly lack induced ischaemia, rather than having unrecognized 
wall-motion abnormalities. (164) False positive tests result from interpreter bias 
towards over interpretation, cardiomyopathies and hypertensive response to 
stress. Wall motion abnormalities in the left circumflex territory tend to be 
underestimated while those in the basal inferior wall and septum (in the 
presence of LBBB and post-cardiac surgery) are overestimated.
DSE in patients with both concentric remodelling has a lower sensitivity than 
observed in other groups. (165) There is a close inverse relation between 
systolic wall stress and systolic function at rest (166) and peak stress. (167) The
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lower metabolic requirements of myocardium exposed to lower systolic wall 
stress at rest and peak stress protects it from developing ischaemia severe 
enough to induce wall motion abnormalities. Thus, patients with low systolic wall 
stress at peak dobutamine have a hyperdynamic response during DSE. In this 
situation, the detection of a new wall motion abnormality may be difficult 
because of tethering effects from adjacent hyperdynamic segments and LV 
cavity obliteration.
Accuracy of DSE when compared to angiographically demonstrated coronary 
stenosis is often affected by the limitations of an angiographic cutoff for 
significant disease, including the variation of the physiologic effect of a stenosis 
based on site, length, and vessel size, as well as over- and under-estimation of 
coronary lesion severity. DSE is a more sensitive marker of ischaemia in lesions 
involving larger (>2.6 mm diameter) vessels than smaller vessels. The 
quantitative angiography parameters associated with ischaemia are a minimum 
lumen diameter of <1 mm diameter, per cent diameter stenosis of >52%, and 
per cent area stenosis of >75%. The minimal lumen diameter is most predictive 
of an abnormal dobutamine stress test. Although the sensitivity for identifying 
multi-vessel disease is high, it is not uncommon to understate the number of 
diseased vessels. This phenomenon occurs when the most critical lesion gives 
rise to test end-points and the test is stopped leaving the less severe lesions 
undetected. Sensitivity analysis is affected by the cut-offs used to define 
"significant" stenosis that has varied between studies. Sensitivity is greatest 
when significant stenosis is defined as a threshold of >70% diameter narrowing 
and falls when significant stenosis is defined as >50% diameter narrowing. The 
presence of cardiomyopathy, microvascular disease, an acute hypertensive 
response to stress, and significant concentric remodelling all affect accuracy 
increasing the likelihood of a false-negative result. The ability to precisely 
identify an obstruction in the LAD exceeds that for the posterior circulation due 
to 1) the greater ease with which the LAD territory is visualised compared to the 
posterior endocardium, 2) the greater amount of myocardium perfused by the 
anterior circulation and 3) because of the overlap between the right coronary 
artery and circumflex coronary artery territories, precise separation of these 
territories has been problematic. Suboptimal stress reduces the accuracy with 
which CAD is detected.
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Detection of viability of dysfunctional myocardium
It has long been observed that revascularisation improves systolic function of 
akinetic segments that were presumed to be non-viable.(123) This is only likely 
if the akinetic segments are pre-operatively viable. Improvement of the 
contractile function of a dysfunctional myocardial segment with restoration of 
perfusion is the only absolute proof of its viability. It is therapeutically useful to 
determine if and how much of a left ventricle consists of dysfunctional and 
viable (hibernating or stunned) as opposed to dysfunctional and non-viable 
(scar) myocardium. This identifies patients with LVSD that are most likely to 
benefit from revascularisation especially surgical as the risks of performing 
surgical revascularisation in patients with severe LVSD vary between 11% and 
16%. (168) Observational studies have suggested that revascularisation offers 
a prognostic advantage in patients with high volumes of hibernating 
myocardium over medical therapy whereas revascularising non-viable 
myocardium may be harmful. (169-176)
In a meta-analysis of 28 studies (925 patients) using low-dose DSE (LDDSE) to 
detect functional recovery of hypo-contractile segments after revascularisation, 
Bax et al (177) calculated a weighted mean sensitivity, specificity, positive 
predictive value (PPV) and negative predictive value (NPV) of LDDSE in 
predicting functional recovery as 82%, 79%, 78% and 83% respectively. The 
same for all 32 studies (using low-dose and high-dose DSE) taken together 
were 81%, 80%, 77% and 85% respectively. From analysis of 18 studies 
involving 563 patients that directly compared DSE with nuclear techniques, the 
sensitivity, specificity, PPV and NPV were 88%, 53%, 63% and 83% for the 
nuclear techniques compared to 76%, 81%, 79% and 79% for the DSE, 
respectively. When the analysis was restricted to 11 studies comparing LDDSE 
and nuclear techniques without stress (thus excluding studies that assessed 
viability and ischaemia) the weighted mean sensitivities of DSE and nuclear 
imaging were 74% and 90%, specificities were 57% and 80%, PPV were 84% 
and 75% and NPV were 69% and 80% respectively. Thus LDDSE has lower 
sensitivity and NPV and higher specificity and PPV compared to the nuclear 
modalities of imaging.
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The difference in the specificity and sensitivity of LDDSE compared to the 
nuclear techniques results partly from the difference in the physiological 
mechanism by which each of the modalities detect myocardial viability. LDDSE 
tests for myocardial contractility, a function that requires the integrity of multiple 
cellular processes. In contrast, nuclear techniques identify viability in the 
myocardium if there is cellular uptake of a tracer. This requires adequate 
perfusion and intact cell membrane function. Positron emission tomography 
(PET), in addition, requires integrity of the biochemical processes that generate 
the high-energy phosphates. When faced with chronic ischaemia, contractility, 
because of the complexity of the process, is likely to be in jeopardy earlier than 
cell membrane function. Thus myocardial segments with systolic dysfunction 
will manifest thallium uptake due to intact cell membrane and adequate 
perfusion but lack inotropic reserve during DSE. Studies comparing DSE and 
PET, have reported dysfunctional segments with preserved metabolic activity 
but no contractile reserve. (178) Thus nuclear modalities are likely to identify 
more myocardium with intact cell membrane as "viable" though the contractile 
apparatus within these cells are in disarray. Restoration of blood supply to this 
"viable" myocardium is unlikely to restore its contractile function. Thus these 
methods are more likely to pronounce viability in dysfunctional segments that do 
not recover with revascularisation.
Several factors contribute to the inaccuracies of DSE in detecting viability. 
Evaluation of the changes in myocardial function before and after 
revascularisation may be suboptimal due to inadequate images. False-positive 
prediction of improvement in function of the hypo- and akinetic segments with 
revascularisation result from the following: 1) The tethering effect of systolic 
contraction of normal segments on non-contractile segments may be interpreted 
falsely as inotropic reserve in these segments 2) Subendocardial infarction 
gives rise to hypokinesia as myocardial thickening occurs mainly a the 
subendocardium. Increased contraction of the normal mid and epicardial 
regions adjacent to these areas may predict functional improvement in these 
segments with revascularisation though that does not occur. 3) Reassessment 
of function after revascularisation may be undertaken too early as recovery may 
occur up to 12 to 14 months after revascularisation. 4) Ischaemia (or necrosis)
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before, during, or after revascularisation may render a segment initially deemed 
viable, non-viable thus resulting in failure of improvement. 5) The balance 
between resting perfusion and the physiological demand of the myocardium 
may be so precarious in long-hibernating segments that they may be viable at 
the time of initial assessment but may have undergone enough morphological 
changes between the initial assessment and revascularisation to render them 
non-viable. 6) Incomplete revascularisation as a result of diffuse atherosclerotic 
disease may prevent improvement. 7) A repeat angiogram is rarely undertaken 
before wall motion is assessed after revascularisation. Graft occlusion shortly 
after complete revascularisation may prevent a segment that was predicted to 
improve from improving. 8) Contractile function of stunned myocardium, like 
hibernating myocardium, improves with LDDSE thus suggesting improvement 
with revascularisation. The improvement of function after revascularisation is 
routinely tested at rest. Stunned myocardium, contrary to hibernating 
myocardium, already has near normal perfusion at rest. Revascularisation thus 
is unlikely to improve their resting function. Function of these segments, 
however, may show improvement if tested under stress. False-negative 
prediction results when a viable segment is deemed non-viable 1) due to 
inadequate inotropic stimulation 2) MBF and coronary flow reserve may have 
been reduced to such a marked degree that inotropic stimulation even a low 
dose induced ischaemia with consequent deterioration rather than improvement 
in function 3) structural changes in the hibernations myocardium is far too 
progressed to allow for an adequate immediate response that could be visually 
observed and 4) resting tachycardia will sometimes render the myocardium 
ischaemic and dobutamine stimulation will only augment ischaemia.
Other factors as different cut-offs for uptake of tracers to define viability, 
inconsistency in the modality used before revascularisation to detect viability 
and after to detect functional improvement, whether the segment in question is 
hypokinetic or akinetic and the duration after which functional recovery is tested 
also affect the sensitivity and specificity of these tests.
Predicting improvement in LVEF with revascularisation
The LVEF is a very powerful predictor of prognosis. Consequently,
improvement in global LVEF with restoration of perfusion may be prognostically
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more important than improvement in regional function. Observational studies 
have consistently showed that LVEF increases after revascularisation in 
patients with contractile reserve demonstrated on LDDSE but not in those 
without. This improvement is seen only in ventricles with significant volume of 
dysfunctional and viable myocardium with contractile reserve. (176; 179) The 
precise proportions of viable segments needed to result in improvement in the 
LVEF differ among the studies. It is currently unclear how much viability is 
needed to result in improvement in the LVEF after revascularization. The 
available evidence suggests that 20-30% of the LV needs to be dysfunctional 
but viable to allow improvement in the LVEF. Few studies have emphasised 
that the extent of viability (i.e. the number of viable segments) determines the 
degree of improvement of LVEF after revascularisation. (179; 180)
Challenges in the interpretation of systolic function with DSE 
DSE has several limitations. Though quality of the images has improved with 
harmonic imaging and contrast echocardiography, this still remains the main 
obstacle in accurate interpretation of DSE. Analysis of cardiac wall motion and 
thickening becomes inaccurate if delineation of the endocardial border is 
inadequate, the same segments are not visualised on multiple views and the 
segments are not seen in the same imaging plane at different levels of stress. 
This may not be possible due to poor acoustic windows. Digitisation and 
simultaneous display of previously acquired loops when acquiring new ones 
have partly solved some of these problems. Interpretation of RWMA is more 
difficult in small LV cavities because of the smaller endocardial circumference 
over which the abnormality can be detected. (165)
The interpretation of DSE is based on a subjective visual analysis of grey-scale 
images. There is a learning curve before an observer can independently 
interpret the images. This means that even proficient echocardiographers 
require special training in order to become expert in stress echocardiography. 
(181) Interpretation is more congruent amongst experienced observers. 
However, there is wide variability in the interpretation of the images even 
among experts in different institutions. (182) This is partly due to institutional 
standards and conventions of interpretation that are not uniform. There is 
substantial regional variation in wall thickening of the normal left ventricle in
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response to dobutamine. This heterogeneity is magnified by dobutamine 
infusion, making differentiation of this normal variation from the variation due to 
coronary artery disease difficult. Lack of uniformity in interpretation of worsening 
wall motion abnormalities in areas with resting abnormalities makes recognition 
of ischaemia in these areas difficult. Each interpreter may have a different 
threshold for identifying wall motion as abnormal, and therefore read with 
various degrees of 'aggressiveness'. Whether a segment that is mildly 
hypokinetic is considered a normal variant or abnormal is observer dependent. 
Mild hypokinesia at rest that becomes severe but not akinesia at peak stress is 
difficult to interpret. Similarly, interpretation of stress-induced dyskinesia in 
akinetic segments at rest is also not clear. These later changes are more likely 
to denote changes in wall stress rather than ischaemia. Detecting inducible wall 
motion abnormalities in some segments e.g. the inferobasal segment is 
particularly difficult. Diagnosis of triple vessel disease can be difficult if new or 
worsening wall motion is taken as an end-point for the test as the most severe 
lesion gives rise to the end-point leaving the other less severe lesions 
undetected. Difficulty in interpretation also arises when the extent of ischaemia 
is small (e.g. mild single-vessel stenosis with collaterals or mild stenosis in the 
presence of a stenosis elsewhere causing limiting symptoms).
Assessment of heart failure with normal ejection fraction 
The cause of exercise intolerance in patients with HFNEF is unclear. Most 
studies on HFNEF have focused LV function at rest though the symptoms are 
often absent at rest and almost universally induced with exercise. Very little is 
known on the effect of stress on LV function in HFNEF. Exercise may induce 
myocardial ischaemia, transient but extensive enough to impair global EF, long- 
axis systolic and/or diastolic function. One other mechanism suggested is an 
impairment of LV diastolic relaxation during exercise. Kitzman et al 
demonstrated a smaller LV end-diastolic volume, a higher LV end-diastolic 
pressure and a rise in the left atrial pressure with exercise in 7 patients with 
HFNEF. The lack of increase in the end-diastolic LV volume with a marked 
increase in LV filling pressures during exercise in these patients suggested 
impaired diastolic relaxation. (183) Similar changes have been reported in 
normotensive patients with normal LVEF without inducible myocardial
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ischaemia and exaggerated SBP response to exercise (83) and in about a third 
of patients with conventional indications for cardiac catheterisation. (184)
Impairment of myocardial relaxation during exercise may result form stress 
induced ischaemia, tachycardia and hypertension superimposed on primary 
myocardial defect of diastolic relaxation. Myocardial ischaemia impairs both 
regional (185;186) and global left ventricular diastolic relaxation (74-81) and this 
occurs earlier than the impairment of systolic contraction. (187) In patients with 
coronary artery disease, ischaemia induced by dobutamine (76;80) and 
exercise,(75) results in a transmitral flow pattern consistent with delayed 
relaxation. Even transient, reversible episodes of ischaemia can impair LV 
relaxation and elevate LV filling pressures.(74) Regional impairment of 
myocardial relaxation of ischaemic segments even when systolic contraction is 
preserved has been seen at rest,(79) after dobutamine stress (188) and 
coronary occlusion. (81) The lengthening rate in LV segments associated with a 
stenosed artery is reduced with stress. (185) Despite the foregoing data, studies 
evaluating the effect of ischaemia in patients with HFNEF are lacking.
Stress-induced tachycardia may worsen ischaemic diastolic relaxation by 
increasing myocardial oxygen demand and decreasing coronary perfusion time 
so that ischaemic diastolic dysfunction might occur even in the absence of 
coronary disease, especially in hypertrophic hearts. This also shortens diastole 
allowing less time for relaxation. This is exaggerated in hypertrophied and 
fibrosed myocardium that is unable to generate a higher rate of diastolic 
relaxation. This prevents relaxation from being complete between beats causing 
the diastolic pressures to increase.(85; 189) This may occur at lower heart rates 
in failing hearts, which contrary to normal hearts, may exhibit a flat or even 
negative relaxation velocity versus heart rate relationship. So, as heart rate 
increases, relaxation rate does not increase or even decreases. (189)
Slower LV relaxation during exercise results from increased LV after-load due 
exaggerated systolic blood pressure response and increased circulating 
angiotensin II that impairs LV relaxation. (82) In hypertensives, a rapid increase 
in SBP at rest (63) or following exercise (183) results in deterioration of LV
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diastolic function without worsening systolic function. Similar changes in 
response to stress have been demonstrated in patients with HFNEF. (84)
DSE has the potential to explore the mechanisms of diastolic dysfunction. 
Though not in routine use, assessment of diastolic echocardiographic indices 
during stress is feasible. (190-194) The mitral inflow indices are often difficult to 
assess and interpret at high heart rates during stress. The fusion of the E and 
the A waves is a major limitation. (191) In addition, factors that change during 
stress e.g. heart rate, preload, after load, QRS duration and PR interval affect 
these parameters considerably making interpretation difficult. As a result, direct 
measurement of myocardial relaxation velocity and the non-invasive measure of 
left atrial pressure using tissue Doppler imaging has largely superseded the 
conventional assessment of the LV diastolic function. These later parameters 
are relatively independent of loading conditions are now in routine use.
Assessment of patients with dyssynchrony
Application of DSE or ESE in the assessment of LV dyssynchrony has been 
tested in a small number of studies. In heart failure patients, exercise can alter 
the magnitude of ventricular dyssynchrony. Assessment of LV dyssynchrony 
under exercise (97; 195) or dobutamine stress (99; 100) is feasible. Lafitte et al 
demonstrated that the mean LV dyssynchrony in patients with normal LVEF 
was not modified with stress. Exercise variably affected LV dyssynchrony. It 
increased, remained stable and decreased in about 34%, 37% and 29% 
patients respectively. These changes varied considerably from patient to 
patient. Patients manifesting changes with exercise most commonly had 
ischaemic cardiomyopathy. (97) Valzania et al tested the effect of dobutamine 
stress on CRT responders with QRSd > 130 ms. The dyssynchrony indices did 
not change from rest to stress irrespective of whether the CRT was "on" or "off1 . 
The measured timings were not corrected for heart rate and the heart rates 
achieved at stress were low. (99)
The other role of DSE in patients with dyssynchrony may its ability to assess the 
burden of dysfunctional but viable myocardium. This may determine response 
to CRT. Hummel et al demonstrated that in patients with ischaemic 
cardiomyopathy the extent of myocardial viability, assessed by myocardial
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contrast echocardiography, predicts acute and long-term improvement in LV 
performance, exercise tolerance, and reduction in LV end-diastolic dimension 
with CRT. (98) Da Costa et al showed that presence of contractile reserve 
independently predicted long-term haemodynamic prognosis and recovery of 
mechanical function in patients who benefit from CRT.(100)
Conclusion
DSE is a versatile tool that has been extensively used for the assessment of left 
ventricular global, regional and long-axis systolic and diastolic function. It would 
potentially be a useful tool in the assessment of patients with suspected heart 
failure.
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Chapter 3: Tissue Doppler imaging
introduction
Since it was first described by McDicken et al in 1992, tissue Doppler imaging 
(TDI) or tissue velocity imaging (TVI) has developed as an echocardiographic 
technique to quantitatively assess the motion of cardiac structures, mainly the 
myocardium. In this thesis this technique was applied at rest and as adjunct to 
DSE to interrogate the myocardium of patients with suspected heart failure. 
What follows is a comprehensive review of literature on the use of TDI in 
patients with heart failure.
Physical principles and Technical considerations
TDI is based on the principle of Doppler shift or Doppler effect. Christian 
Doppler first described this phenomenon in 1842 in relation to light waves as a 
change in frequency and wavelength of the wave for an observer moving 
relative to a source of the wave. In 1845, the Dutch scientist CHDB Ballot tested 
this hypothesis for sound waves. He confirmed that the observed frequency of 
sound waves is higher than the emitted frequency when the source and the 
observer approach and lower when the two recede relative to each other. For 
waves that propagate in a medium, such as sound waves, the velocities of the 
observer and of the source are relative to the medium in which the waves are 
transmitted. The total Doppler effect may therefore result from motion of the 
source, motion of the observer, or motion of the medium.
In Doppler echocardiography the velocities of structures of or within the heart 
are derived from the Doppler shift observed when they (the source of reflected 
ultrasound) move towards or away from a static transducer (the observer). In 
conventional blood pool Doppler echocardiography, the moving objects are 
erythrocytes that reflect low amplitude and high frequency ultrasound. In 
contrast, the ultrasound reflected from the moving cardiac structures (valve 
leaflets, valve annuli, papillary muscles, ventricular and atrial walls etc) is of 
high amplitude (about 40dB higher than that from the erythrocytes) and low 
frequency. For conventional Doppler echocardiography, a high-pass filter 
eliminates the later signals leaving those from the erythrocytes for display. For 
tissue Doppler echocardiography the signals derived from cardiac tissue motion 
are input directly into the autocorrelator without passing through the high-pass
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filter. In addition, lower gain amplification is used to improve the ability to 
measure low velocities. Velocities of 0.1 to 0.2 cm/s (a level associated with 
cardiac tissue motion) can then be detected. This technique is used to measure 
velocity and timing of motion of cardiac structures, their displacement in relation 
to the transducer and their deformation.
The cardiac structures can be interrogated using spectral pulsed Doppler (pTDI) 
or colour-coded Doppler mapping (cTDI). Pulsed Doppler measures velocities in 
one sample volume at a time by spectral analysis. The pTDI is simple to acquire, 
provides high quality records of Doppler profiles and the analysis of velocities, 
acceleration and deceleration of structures is straightforward. However, 
analysis can only be done on-line and only one structure can be interrogated at 
a time. This takes considerable time limiting its use in evaluating regional 
myocardial function during stress echocardiography. Moreover, the inability to 
interrogate all the cardiac structures in the same cardiac cycle makes 
comparison of the measurements difficult. Use of pTDI in differentiating 
subepicardial and subendocardial myocardial velocities is constrained by its low 
spatial resolution. In cTDI each pixel of the Doppler spectrum is colour coded 
according to the velocity of the structure and the direction of its motion. Brighter 
hues correspond to higher velocities (up to the Nyquist limit). Any motion 
towards the transducer is coded red and that away from the transducer is coded 
blue. cTDI samples the velocities of all the pixels in a sector nearly 
simultaneously and display the average velocity by autocorrelation. cTDI offers 
rapid visual estimation of movement of structures, good spatial resolution and 
the ability to measure velocity of multiple structures in the same cardiac cycle. 
Off-line analysis of receded loops is possible allowing sufficient time for regional 
assessment. Velocities measured by pTDI is about 20-25% higher than that 
with cTDI as pTDI measures peak velocities while the cTDI measures modal 
velocities of all pixels within the sector. cTDI and pTDI correlate well at rest and 
stress, but pTDI are greater than cTDI velocities at rest and stress. (196) 
Temporal resolution of the images can be enhanced by increasing the frame 
rates. Frame rates well over 150 Hz can be obtained by minimizing the depth 
and sector angle and increasing the pulse repetition frequency during 
acquisition. cTDI acquired at high frame rates is thus particularly suited for use 
with stress echocardiography.
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The basic data obtained by TDI is velocity. Displacement of the interrogated 
tissue can be derived by temporal integration of velocities. Strain represents the 
degree of relative deformation of the interrogated myocardium and strain rate, 
the rate of that deformation. Strain rate reflects how fast regional myocardial 
shortening or lengthening occurs. It is calculated from myocardial Doppler 
velocities measured at two locations separated by a given distance. Strain rate 
equals the instantaneous spatial velocity gradient and has units of second"1 . 
When the two velocities being measured are different, there is deformation of 
the tissue in-between. Strain is calculated as the time integral of strain rate and 
is a dimensionless quantity. In the long axis it represents shortening fraction, 
and in the short axis, thickening fraction. Deformation imaging is sensitive to 
misalignment between the cardiac axis and the ultrasound beam. 
Measurements also become inaccurate at low frame rates due to inadequate 
resolution of the different peaks of the velocity profile. Thus, the smallest 
possible sector should be used at minimum depth to attain highest possible 
frame rates. This may be best achieved by interrogating a single wall at a time. 
Strain and strain rate are relatively homogeneous throughout the myocardium 
and, compared to tissue velocity imaging, are less influenced by cardiac motion. 
However, the strain and strain rate signals generally show more background 
noise. Myocardial function can be more accurately assessed with strain and 
strain rate imaging. As only velocity imaging was used for this thesis, 
deformation imaging will not be discussed further.
TDI effectively complements conventional echocardiography. The 
measurements are quantitative, relatively independent of perfect image quality, 
are obtainable with minimal disruption/incremental time to standard imaging and 
can be interpreted quickly and objectively. The normal ranges have been 
defined for most groups of patients. Good reproducibility has been reported for 
off-line measurements even by inexperienced observers. (197) The integration 
of simple TDI data improves the accuracy of DSE interpretation by novice 
readers and experienced echocardiographers not formally trained in stress 
echocardiography but not that of expert stress echocardiographers.(198)
Physiological considerations
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LVEF is the most frequently used index of cardiac function. Stroke output 
results from systolic reduction in the LV volumes due to myocardial contraction 
both in the long and short axes. Long axis contraction of the of the ventricle is 
made possible by the orientation of the myocardial fibre bundles that are 
arranged in three layers. The mid-wall myocardial fibres that predominate are 
arranged circumferentially while the subendocardial and subepicardial muscle 
bundles are aligned longitudinally with slight spiral arrangement. The later 
connect the cardiac apex, which is fixed in relation to the chest wall, to the base 
(i.e. atrio-ventricular annulus) that moves towards and away from the apex in 
systole and diastole respectively. The reduction of the systolic volume in the 
minor axis is mediated by radial contraction of the mid-wall myocardial fibres 
(bellow action). The reduction of the systolic volume in the major axis is 
mediated by shortening of the longitudinal fibres (piston action). This systolic 
shortening is associated with a concomitant transverse thickening which then 
also contributes to the reduction in the minor axis volume. The long axis 
normally shortens by 10% to 12% with ejection at the same time as the minor 
axis falls by 25%. (199)
The mitral annular velocity (MAV) and myocardial Doppler velocity (MDV) in the 
long-axis are best measured when scanning from the apical approach as the 
atrio-ventricular ring and the myocardial segments move towards and away 
from the relatively fixed apex in systole and diastole respectively parallel or 
almost parallel to the ultrasound beam. Longitudinal motion has higher 
amplitude and is less affected by rotational and translational cardiac activity. 
These two factors make the measurements at the annulus and the non-apical 
segments from the apical approach, less prone to error and more reproducible. 
(200) Velocities of radial contraction can also be obtained if myocardial 
segments are interrogated in the short-axis views. But these are more difficult to 
interpret as they are more affected by rotational and translational movements of 
the heart. Radial velocities have not measured in this thesis and thus this will 
not be discussed further.
The velocity profile obtained with TDI consists two positive systolic peaks (S-i 
during isovolumic contraction and S2 during ejection phase), a negative early 
diastolic (E) and a negative late diastolic wave (A). The E wave corresponds to
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the early rapid filling phase and the A wave to the late rapid filling phase or the 
atrial contraction. The suffix "m" is used to denote MDV and "a" for MAV. A 
post-systolic velocity in early diastole (PS) is often seen in ischaemic heart 
disease and chronic heart failure. Though the genesis of this wave is uncertain, 
it may reflect the presence of dysfunctional but viable (stunned or hibernating) 
myocardium. The diastolic MAV can be measured almost universally, easily and 
quickly and has lowest interobserver variability compared to other diastolic 
indices. (201) Ea is an index of LV relaxation. Tau, the time constant of 
isovolumic LV pressure decline correlates inversely with peak Ea velocity. (202) 
This correlation is stronger in patients with abnormal versus normal systolic 
function. (192) Aa reflects annular motion away from the apex secondary to 
atrial contraction. There is no correlation between E and A velocities from the 
mitral inflow and the Ea and Aa velocities from the mitral annulus in normal 
subjects. However, the E/A ratio correlates well with Ea/Aa ratio. (203) Another 
index of diastolic function that is routinely derived is the E/Ea ratio (ratio of the 
early diastolic velocity from the mitral inflow and the early diastolic MAV) that 
estimates the LV filling pressure. The correlation between E/Ea and PCWP has 
been well established in various cardiac conditions in sinus rhythm, sinus 
tachycardia and cardiac transplant .(192;193;204;205)
As opposed to the blood flow velocities during diastole as measured from the 
mitral inflow Doppler, the diastolic MAV are relatively independent of left 
ventricular loading conditions. Garcia et al showed a lack of correlation between 
the peak Ea and peak E velocity, suggesting the relative preload independence 
of peak Ea. (206) Sohn et al confirmed the independence of the septal Ea 
(Easep) from the loading conditions in patients with relaxation abnormalities. 
Saline loading and nitroglycerine infusion did not affect Easep velocity and 
EaSep/AaSep ratio in contrast to the E velocity. The Easep and EaSep/Aase p ratio 
inversely correlated with tau. (202) Ea partially corrects the influence of 
relaxation on the transmitral E velocity. (204) Firstenberg et al tested the 
dependence of diastolic MAV on loading conditions in normal subjects. Preload 
altering manoeuvres (lower body negative pressure and saline loading) had no 
significant effect on lateral Ea (Eaiat), whereas Easep was affected in parallel to 
the E wave. The E/A, E/Eaiat or E/Easep did not change. The PCWP correlated 
strongly with E and Easep but weakly with Eaiat and not with E/Easep or E/Eaiat
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ratio suggesting that Easep is preload dependent when relaxation is normal. 
However, this preload dependence decreases with worsening tau. This 
suggests that while Easep is preload dependent when relaxation normal, but 
minimally so when it is impaired. (207) Agmon et al came to similar conclusion 
in patients undergoing haemodialysis. The Easep and Eatat decreased with 
volume depletion in parallel to that in the E velocity. However, the percent 
change in E velocities was higher than the percent change in Eaiat but not Easep . 
The E/Eaiat decreased but not the E/Easep . The Aa at either site remained 
unchanged. (208) In patients with chronic stable angina and LVSD maneuvers 
like Trendelenberg, reverse Trendelenberg and amyl nitrate did not affect the 
Ea. (209)
The Sa, Ea and Aa are positively and non-linearly correlated across a wide 
range of LVEFs. (61;62;210) This relation results from the inter-dependence of 
the systole and diastole. The normal LV contracts to a volume less than its 
equilibrium volume during systole due to the longitudinal shortening and 
"twisting" motion of the LV. This compresses the elastic cardiac elements 
generating potential energy that is stored within the coiled fibres of the 
myocardium. This creates early diastole-restorative forces that produce a 
"suction1 effect that lowers LV pressure and increases early filling. Thus the 
strength and coordination of the previous systole determines early diastolic 
filling velocity. As myocyte contractile function decline, recoil declines as well 
resulting in parallel decrease in the Sa and Ea. Other mechanisms e.g. 
uncoordinated systolic contraction, changes in the extracellular matrix also act 
to impair diastolic function. The Aa is also dependent on ventricular systole. 
(210) The excursion of the mitral annular ring towards the apex during 
ventricular systole stretches the pectinate muscles of the atria. This creates a 
stored potential energy within these muscles and increases the atrial volume, 
creating a suction effect, which draws blood from the pulmonary veins. The 
potential energy generated by this stretch, the amount of movement of the 
annulus away from the apex during early diastole and finally the effect of atrial 
systole to draw the mitral valve ring away from the apex all determine the late 
diastolic velocity.
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There is a considerable degree of heterogeneity of velocities within the 
myocardium. There is a graded reduction in all MDVs from the annulus to the 
apex. This does not represent a graded reduction in contractility from apex to 
base as this gradient is not seen when strain rate is measured. (211) The 
longitudinal motion of the apex relative to the transducer is small resulting in 
very low amplitude velocities making these measurements unreliable. Thus, like 
most investigators, these segments were excluded from the analysis. The 
MDVs measured at the free-walls of the LV (lateral, anterior and posterior) are 
greater than that of the para-septal walls (septum, inferior or anteroseptal) due 
to the predominance of longitudinal myocardial fibres in these walls. (212;213) 
Consequently, in the absence of prominent RWMA the most suitable site for the 
assessment of longitudinal LV systolic function are the free LV wall and the 
lateral end of the mitral annulus. The MDVs at the interventricular septum are 
also affected by the activity of the right ventricle and rotational movements 
probably due to the predominance of circular myocardial fibers in this wall. In 
the parasternal view, velocities are lower in the anteroseptal wall than in the 
posterior wall. The translational motion of the heart within the chest during the 
cardiac cycle is anteriorly directed in systole and posteriorly directed in diastole. 
Velocities related to these motions are superimposed on the intrinsic wall 
velocities, increasing them at the posterior wall, and decreasing them in the 
septum during systole and vice-versa during diastole. These variations of 
regional velocity in the normal heart mandate the use of site-specific normal 
ranges for diagnostic purposes. (214)
Myocardial velocities are age dependent, with higher Sa, Ea and Aa in younger 
patients. (212;215) Mitral annular motion decreases by up to 20% whereas the 
short axis increases by up to 18%, with increasing age in normal adults 
independent of systolic blood pressure, LV wall thickness, heart rate or sex. 
(216) Yip et al reported 18% and 30% decrease in systolic mitral annular 
displacement and Sa respectively with age (210) though this inverse correlation 
may be weak. (217) This relation persists at peak dose dobutamine, in both 
men and women. (218) Studies have consistently reported an inverse relation 
between age and Ea and a direct one between age and Aa both in health and 
cardiac disease. (210;217;219-222) In healthy subjects, age is the most 
important variable affecting Ea, Aa and the E/Ea. (221) Yip et al reported 49%
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and 56% decrease in early diastolic mitral annular displacement and Ea 
respectively, with advancing age. The Aa increased by 25-30%. (210) The 
correlation between age and Ea is stronger than that between age and Sa. (217) 
E/Ea is directly correlated to age. (221) Similar changes are seen in 
hypertensives with LVH though the E/Ea values are slightly higher for each age 
category compared with normal patients. (222) Heart rate affects regional MDV 
(218) but not the MAV. (210)
Global LV function in HFNEF
Sa is reduced in patients with HFNEF compared to healthy controls. (57-62) 
There is a decremental continuum of Sa from normal to HFNEF to HF with 
reduced ejection fraction (HFREF) so that Sa in patients with HFNEF is lower 
than normal but higher than in HFREF. (58;59;61;223;224) However, Kasner et 
al reported similar values of Sasep and Saiat amongst patients with invasively 
confirmed diastolic dysfunction compared to controls. (225) Subnormal Sa and 
reduced AV plane displacement are reported in 38% and 21-33% of patients 
with HFNEF respectively in two separate studies. (58;60) Using pTDI, Sa <7.95 
cm/s separated the HFNEF patients from control subjects with a sensitivity of 
83% and a specificity of 83% in one study. (61) Using pTDI, Sa <5.8 cm/s 
identified HFNEF with a sensitivity of 82%, specificity of 73% and a negative 
predictive value of 98.7%. (223)
Ea velocity in the HFNEF patients is lower than controls. (57;58;61;223) The 
site at which the velocities are measured may influence whether it is reduced in 
HFNEF patients. Kasner et al reported lower Eaiat but not Easep in HFNEF 
compared to controls. (225) Patients with pseudonormal filling, defined as the 
combination of normal mitral inflow variables and prolonged tau (>50 ms), could 
be separated from patients with normal filling patterns by an Ea velocity <8.5 
cm/s and a Ea/Aa ratio <1 with a sensitivity of 88% and specificity of 67%. (202) 
In comparison to controls, the Ea is reduced to a greater extent than Sa in the 
HFNEF patients. (58;61)
In a large cohort of patients with HFREF, conventionally diagnosed DHF, 
asymptomatic diastolic dysfunction (DD) and normal subjects, Yu et al reported 
lower regional systolic and diastolic velocities in DHF patients than in controls.
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The systolic velocity (both regional and the average of the 6 basal segments) in 
the 4 groups was related as follows: HFREF<DHF<DD<controls. The Em (both 
regional and the average of the 6 basal segments) was related as follows: 
HFREF=DHF<DD<controls.(59)
Nikitin et al reported higher E/Ea ratio and similar Ea/Aa ratio in patients with 
HFNEF compared to controls. (57) Kasner et al also reported higher E/Eaiat in 
HFNEF compared to control subjects. An E/Ea ratio >8 was found in 86% of 
HFNEF patients, who showed a significant increase in all diastolic indexes 
compared with control subjects. The EIEa\a{ correlated best with LVEDP. (225)
Assessment of LV filling pressure
E/Ea and invasively determined LVEDP are positively and linearly correlated. In 
patients undergoing cardiac catheterisation for angina or HF, the correlation 
between mean LVDP and Easep is consistently equivalent or better than the Eaiat 
or the two together. The correlation is better in patients with impaired than in 
those with normal LVEF. The E/Easep had the highest predictive accuracy for 
the mean LVDP when all patients were considered. E/Ea (pTDI) >15 had 86% 
specificity (64% positive predictive value) for mean LVDP >15 mm Hg (97% 
negative predictive value for E/Ea <8). (191) In patients who have had heart 
transplants, E/Eiat (pTDI) correlated strongly with the mean PCWP. An E/Ea >8 
identified a mean PCWP >15 mm Hg with a sensitivity of 87% and a specificity 
of 81%. Changes in the mean PCWP were closely reflected in the changes in 
E/Eaiat. A change in E/Ea >2.5 detected a change in PCWP >5 mm Hg, with a 
sensitivity of 77% and a specificity of 75%. There was no relation between 
changes in Ea and corresponding changes in PCWP, suggesting that the 
changes observed in Ea in the patients with transplants reflected the state of 
myocardial relaxation. (205)
Nikitin et al reported a higher 6-site averaged E/Ea (cTDI) in patients with 
HFNEF compared to controls. (57) Eaiat was lower in patients with 
asymptomatic impaired relaxation and symptomatic HF with 
pseudonormalisation, compared to the normals. E/Eaiat was elevated in the 
pseudonormal group compared with the other two groups. The mean PCWP 
correlated significantly with E/Eaiat but not with Eaiat . An E/Ea ratio >10
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predicted mean PCWP >12 mmHg with sensitivity of 91% and specificity of 81% 
and mean PCWP >15 mm Hg, with a sensitivity of 97% and a specificity of 78%. 
(204) Nagueh et al divided patients with several cardiac conditions in sinus 
tachycardia into 3 groups according to the mitral inflow patterns a) fused E and 
A (sub-grouped as A1 if velocity peaked in the first half of the diastolic filling 
period and A2 if it did so in the second half), b) E<A and c) E>A. PCWP related 
weakly to Ea and Aa and strongly with E/Eaiat irrespective of the inflow pattern 
and LVEF. PCWP >12 mmHg was predicted by E/Ealat >10 with sensitivity of 
78% and specificity of 95%, >8 with sensitivity of 87% and specificity of 70% 
and >12 sensitivity of 68% and specificity of 96%. If patients with and without 
tachycardia are taken into account, PCWP >15 mmHg was best predicted by 
E/Ea >10 (sensitivity, 92%; specificity, 80%). (193) In patients with hypertrophic 
cardiomyopathy, the preA LVEDP correlated strongly to E/Ea. The changes in 
LVEDP matched changes in E/Ea. E/Ea £10 had the best combination of 
sensitivity (92%) and specificity (85%) for preA pressure >15 mmHg. (226) 
Amongst patients with atrial fibrillation, Ea correlated with tau and the E/Ea ratio 
correlated with LVDP. The E/Ea S11 predicted LVDP >15 mmHg (sensitivity 
75%; specificity 93%). (227) In patients undergoing clinically indicated cardiac 
catheterisation E/Esep correlated best with pre-A LVDP irrespective of the LVEF 
and the mitral inflow pattern. E/Easep ^9 best discriminated pre-A LVDP >12 
mmHg from normal pre-A pressure (sensitivity, 81%; specificity, 80%). (228) In 
patients with normal or reduced LVEF undergoing right heart catheterisation, 
Rivas-Gotz et al showed that different cutoffs for E/Ea were needed to predict 
mean PCWP >15 mmHg depending on whether the LVEF was <50% or >50%. 
Best sensitivity and specificity were obtained when Ea (pTDI) was measured at 
the lateral annulus. E/Eaiat >11 had a sensitivity and specificity of 85% and 82% 
respectively in patients with LVEF<50%. In subjects with LVEF >50% E/Ea >10 
had a sensitivity and specificity of 79% and 80% respectively. In patients with 
wall motion abnormalities, a stronger correlation between the LVEDP and the 
E/Ea was obtained if the Ea was averaged over 2 or 3 periannular sites.(229) In 
patients with HFREF and HFNEF, PCWP correlated with E/Easep irrespective of 
the LVEF. LVEDP >15 mmHg was identified by E/Easep >11 in the HFNEF 
group (sensitivity, 94%; specificity, 90%; PPV, 94%; NPV, 91%) and by >14 
mmHg in patients HFREF (sensitivity, 71%; specificity,100%; PPV, 100%; NPV, 
39%). (230) Ea is reduced in comparison to normals and the E/Ea relates to
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pre-A LVDP and to LVEDP in patients with aortic stenosis. E/Ea >13 identified 
an LVEDP >15 mmHg (sensitivity, 93%; specificity, 88%) (231) Amongst 
patients with a wide range of LVEF undergoing clinically indicated cardiac 
catheterisation, Hadano et al reported a poor correlation between E/Ea and 
LVEDP and a modest one between E/Ea and PCWP irrespective of the LVEF. 
E/Ea <14 predicted mean PCWP^12 mmHg with 100% sensitivity and 85% 
specificity. (232)
The effect of exercise on E/Ea has been investigated. In healthy subjects all the 
mitral inflow velocities and the MAV increase proportionately with exercise thus 
leaving the E/A, E/Ea and Ea/Aa unchanged.(194) In patients with HFNEF, the 
E, Ea and the E/Ea increased with exercise. E/Ea <15 predicted normal PCWP 
(<20 mmHg) with a sensitivity of 89%. Conversely, in all cases where the E/Ea 
was >15, the PCWP was elevated. An E/Ea >15 during exercise was 
associated with PCWP >20 mm Hg.(233) Dyspnoeic patients with normal LVEF 
and no ischaemia underwent ESE. E/Ea increased with exercise in 35% of the 
patients with resting E/Ea <10 but did not increase in the rest of these patients 
or any patient with E/Ea >10. There was no significant difference in changes of 
mitral inflow indices (E, A, E/A, deceleration time) between groups. Exercise 
duration was significantly shorter in patients whose E/Ea increased with 
exercise and ones with resting E/Ea>10 compared to the one with E/Ea<10 
both at rest and stress.(234) Using invasive measures as standard Burgess et 
al validated exercise induced changes in the E/Ea ratio in subjects with normal 
LVEF. Patients with a normal mean LVDP both at rest and exercise had the 
lowest E/Ea at rest with no change with exercise. Patients with an elevated 
mean LVDP only during exercise had a significant increase in E/Ea from rest to 
exercise. Patients with an elevated mean LVDP at rest had a high resting E/Ea 
with no significant change with exercise. E/Ea correlated with mean LVDP at 
rest and during exercise. An exercise E/Ea >13 had a sensitivity of 73% and a 
specificity of 96% for identification of an exercise mean LVDP >15. Ea and E/Ea 
had a better correlation with exercise capacity. Exercise E/Ea >10 had a 
sensitivity of 71% and a specificity of 69% for prediction of a reduced exercise 
capacity (<8METS).(183)
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Several studies show that the E/Ea ratio is related to the exercise capacity. In 
patients with HFREF the average of Ea measured at the septal and lateral 
annuli (Eaav) and the E/Eaav correlated with peak VO2 . (235) In patients with AF, 
E/Ea is an independent predictor of exercise capacity. Patients achieving <7 
METs had higher E, higher E/Ea ratio and lower Ea than those patients showing 
a peak of >7 METs. (236) In patients with HFREF peak oxygen consumption 
correlates with Eaiat and E/Eaiat but not with conventional Doppler indexes. 
E/Eaiat >11.3 predicts severe exercise intolerance with sensitivity of 88% and 
specificity 86%.(237) In patients with CAD and normal LVEF MAV increased 
and E/Ea decreased with increasing VO2max. VO2max independently predicted 
by Sm and E/Eav . Patients in the lowest VO2 max category had higher E and 
lower Ea velocities resulting in higher E/Ea values. Patients with lower MAV 
reached lower VO2max. (238) Skaluba et al found that TDI was effective in 
predicting exercise capacity in patients irrespective of the LVEF. Resting Ea, 
Ea/Aa and E/Ea correlated with exercise tolerance. The best individual correlate 
of exercise performance was E/Easep and only E/Easep ^10 was an independent 
predictor of reduced exercise tolerance in the multivariate analysis. E/Easep 
>10.6 had a sensitivity and specificity of 85% and 88% respectively in predicting 
exercise capacity of <7 METS. Patients with E/Easep <10 performed better on 
the treadmill than the patients with E/Ea >10. Exercise capacity was similar in 
patients with a normal mitral inflow pattern and those with a slow relaxation 
pattern when E/Ea was <10. In contrast, the subjects with slow relaxation and 
E/Easep ^10 performed nearly as poorly as did the groups with 
pseudonormal/restrictive LV filling patterns. (239)
In patients assessed for suspected HF, E/Ea >15 had 83% sensitivity and 82% 
specificity for confirming the diagnosis in the overall population. E/Ea >15 
predicted presence of HF with 79% sensitivity and 93% specificity in patients 
with normal ejection fraction and 92% sensitivity and 72% specificity in patients 
with reduced ejection fraction. Overall, BNP and E/Ea have similar diagnostic 
accuracy for CHF in this patient population.(240) In patients with suspected HF 
and normal LVEF, E/Eaav of 11.5 (sensitivity, 80%; specificity, 94.3%) E/Eaiat of 
9.8 (83.3% and 88.9%) and E/Easep of 12.7 (76.7% and 91.4%) predicted HF. 
E/Ea ratios and BNP provided similar accuracy for predicting decompensated 
HF. E/Eaav yielded independent additional information to a model based on the
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clinical judgment and BMP level.(241) In patients with new onset acute 
dyspnoea, indeterminate BMP, normal LVEF and no radiological pulmonary 
oedema, average E/Ea >10 was a powerful predictor of congestive HF 
(sensitivity 100% and specificity 78.6%).(242) In chronic hypertensive patients 
with acute dyspnea and normal LVEF the E/Ea >11 precisely predicted the 
diagnosis of HF (sensitivity 77.8%, specificity 100%, and accuracy 89.5%).(243)
Some caution is to be exercised when interpreting estimates of PCWP or 
LVEDP from the TDI. cTDI and pTDI measurements are not interchangeable. 
Though the systolic and diastolic velocities quantified by the two methods 
correlate very well, those measured with cTDI are lower than pTDI. 
Consequently, E/Ea by cTDI is higher than by pTD1.(244) The site of the 
measurement (septal versus lateral) and the LVEF influence Ea and 
consequently the E/Ea ratio. E/Ea is unreliable for predicting LV diastolic 
pressures in healthy subjects and organic mitral valve disease. The Easep and 
Eaiat are lower, the E/Ea^t is higher and E/Easep is similar in patients with 
abnormal septal motion (secondary to LBBB, paced-rhythm, myocardial 
infarction and cardiac surgery) compared to patients with normal septal motion. 
The E/Easep and E/Eaiat correlated well with PCWP in patients with normal 
septal motion but not in patients with abnormal septal motion. In patients with 
abnormal septal motion, TDI methods overestimate PCWP at lower invasive 
PCWP levels and vice versa.(245)
Regional myocardial function
Diagnosis of ischaemia
CAD is characterised by resting and/or inducible regional myocardial
dysfunction. Due to their subendocardial location, the longitudinal muscle
bundles of the LV are highly susceptible to ischaemia resulting in the decrease
of longitudinal velocities very early with onset of ischaemia. TDI, by virtue of its
ability to measure this longitudinal velocity, is a very sensitive tool to detect this
ischaemia.
Regional abnormalities of MAV and MDVs at rest are often seen patients with 
myocardial infarction. Following myocardial infarction, the systolic velocity at 
each mitral peri-annular site reflects the impaired regional contractility of that
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wall. (246;247) The peak systolic amplitude of mitral annular motion is lower at 
all sites compared to the healthy controls. (247)
Gorcsan J III et al tested the potential of cTDI to quantify regional myocardial 
dysfunction in open-chest canine model of coronary occlusion using 
sonicometry as the standard of reference. The peak systolic endocardial 
velocities from cTDI and myocardial shortening velocity and fractional 
shortening from sonomicrometry decreased in the territory of coronary occlusion. 
The peak endocardial velocity was inversely correlated with end-systolic length 
by sonomicrometry during baseline and induction of ischaemia. (248) In porcine 
model, Derumeaux et al demonstrated that a reduction in myocardial blood flow 
assessed by radioactive microspheres mediated by occlusion of the left anterior 
descending artery resulted in a decrease in systolic shortening measured by 
sonicometry and systolic velocity measured by pTDI of the septum. There was a 
significant correlation between the variations of systolic velocity and systolic 
shortening. Following LAD occlusion, the systolic velocity decreased within 5 
seconds and peaked at 1 minute. One minute after reflow, the systolic velocity 
increased reaching positive values corresponding to the hyperemic phase. It 
progressively decreased within 5 minutes of reperfusion as the myocardium 
developed post-ischaemic stunning. (249) In canine model, baseline, 
endocardial velocities were higher than epicardial velocities. Ischaemia caused 
a significant and comparable reduction in endocardial and epicardial systolic 
velocities with the disappearance of the velocity gradient. Systolic velocities 
significantly correlated with segment shortening in both endocardium and 
epicardium during ischaemia and reperfusion. In the first minutes after reflow, 
endocardial velocities showed a greater improvement than epicardial velocities, 
and the velocity gradient resumed although to a limited extent, indicative of 
stunning. (81)
Coronary occlusion in humans led to similar changes in MDVs. Edvardsen et al 
demonstrated a decrease in the Sm and Em in segments supplied by the LAD 
in a response to LAD occlusion during angioplasty. Furthermore, during early 
diastole, the ischaemic segments showed a post-systolic contraction pattern. 
Reversed systolic wall motion during mid systole and marked positive velocity 
during early diastole was thought to indicate myocardial ischaemia. (250) Bach
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et al demonstrated a similar drop in Sm in segments subtended by the 
angioplasty vessels during occlusive balloon inflation. During early reperfusion, 
Sm exceeded baseline values. In regions remote from the treated artery, peak 
Sm increased in the absence of significant stenosis but remained unchanged or 
decreased in the presence of significant stenosis of the associated vessel. (251) 
In a similar study, coronary occlusion during angioplasty resulted in the 
reduction in myocardial velocity in "at risk" segments. Velocity alone had 
sensitivity and specificity of 68% and 65% respectively for identifying acute 
ischaemia in segments that were either normal or abnormal at baseline. In "at 
risk" segments that were visually abnormal at baseline, velocity parameters 
alone failed to distinguish between baseline and occlusive measurements. The 
authors concluded that quantitation of regional deformation rather than motion 
is better in detecting and quantifying acute ischaemic changes in myocardial 
function, especially in segments with pre-existing abnormal function. (252)
These observations encouraged the application of TDI in detection of inducible 
ischaemia in conjunction DSE or ESE. Gorcsan III Jr et al investigated the effect 
of positive and negative inotropy on endocardial velocities. In the canine model, 
the Sm, Em and Am increased with dobutamine infusion without changes in the 
heart rate. Esmolol infusion had an opposite effect. Increase in peak 
endocardial velocity from all sites were significantly associated with changes in 
fractional shortening and regional stroke work measured by sonicometry and in 
global LV performance measured by conductance catheters confirming the 
ability of endocardial velocity to reflect changes in regional contractility. (253) In 
normal human volunteers, MAY and MDVs were sensitive enough to detect 
changes in myocardial contractility even at very low doses of dobutamine 
stimulation. Sa increased significantly with only 1 ug/kg/min of dobutamine and 
progressively thereafter a linear dose-dependent manner suggesting an 
incremental dose-dependent alteration in global and regional LV function. 
These alterations were detected by TDI at doses of dobutamine infusion that 
was lower than where changes were detected by routine measures of wall 
thickening or ejection fraction in the same subjects. (254) Yamada et al reported 
similar progressive increase in Sm with increasing dose of dobutamine in 
normal segments averaging an increment of 148% at peak dose. The base- 
apex gradient in Sm persisted at low dose. There were no differences in the
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velocities recorded at basal or mid segments of the different walls. Ischaemic 
and scarred segments demonstrated a significantly lower Sm in all stages of the 
protocol and the lowest percentage increase in Sm when compared with the 
normal segments. Basal and mid-ventricular ischaemic segments had similar 
Sm and percent increment from rest to peak. The Sm responses of ischaemic 
and scarred segments were similar at low dose. Ischaemic segments were not 
discernible from nonischaemic segments based on Sm at rest or low dose. 
However, the ischaemic segments had a significantly lower Sm at peak dose 
with a tendency to show a lower percentage increase from rest to peak. Sm <12 
cm/s at peak dose identified ischaemic segments with a sensitivity of 86% and 
specificity of 96% for basal and a sensitivity of 81% and specificity of 89% in the 
mid segments. An increment of <90% in Sm from rest to peak, identified 
ischaemic segments from normal segments with a sensitivity and specificity of 
83% and 87%, respectively.(188) Using cTDI, Katz et al demonstrated that at 
peak dobutamine stress velocities of abnormal myocardial segments were lower 
than normal ones. Peak systolic velocity of < 5.5 cm/s had a sensitivity, 
specificity and accuracy of 96%, 81% and 86% for identifying abnormal 
segments irrespective of the segmental sites.(255) The mean peak Sm for the 
hypokinetic and akinetic posterior walls were significantly less than normal 
controls and correlated with percentage of wall thickening. (256) Using pTDI 
and quantitative coronary angiography Rambaldi et al predicted a significant 
proximal RCA stenosis (>50% diameter stenosis) with a decrease and/or <25% 
increase in segmental ejection phase velocities of the RV free wall from the 
10ug/kg/min of dobutamine to peak stress. This had sensitivity of 82%, 
specificity of 78%, positive predictive value of 69%, negative predictive value of 
88% and accuracy of 79%. (257) In addition to decrease in the Sm with 
dobutamine, MVG fails to increase in the ischaemic segments but there is a 
dose-responsive increase in the non-ischaemic segments.(258)
Using visual assessment of wall motion by an expert interpreter as standard 
reference, Pasquet et al tested the power of TDI (cTDI measured in all 
segments and pTDI in basal segments) to detect myocardial ischaemia 
following exercise treadmill testing in patients with known or suspected CAD. 
Scarred segments had lower Sm than normal segments at rest and stress. 
Ischaemic segments had a lower Sm and less increment in velocity than normal
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segments. The authors concluded that TDI with ESE is feasible and TDI is a 
useful quantitative tool for interpretation of ESE. (259) The same investigators, 
using exercise dual isotope SPECT perfusion imaging to identify abnormal 
myocardial segments, demonstrated that a) resting base-apex gradient of Sm 
persisted at peak exercise and the increment in Sm with stress was similar in 
the basal and mid-segments in normal ventricles, b) segments with rest 
perfusion defects had a lower Sm than normal segments, c) Sm in segments 
with stress-induced perfusion defect were similar to the normal segments at rest 
but lower at peak exercise d) Sm of scars were lower than ischaemic segments 
at rest but similar to them at peak and e) increments in MDV was greater in the 
normal segments than ischaemic and scarred segments but it was similar in the 
later to groups. (260) Dagianti et al, using coronary angiogram as the standard 
reference, demonstrated that Sm at infarct sites were lower than at normal sites 
at rest in patients with remote myocardial infarction. At peak exercise stress in 
patients with multivessel disease, Sm at remote regions was significantly lower 
compared with control subjects. (261) Wilkenshoff et al demonstrated that the 
Sm of the non-apical segments of all the walls increases with exercise stress in 
normal subjects. These increases were not altered with adjustment for heart 
rates. The base-apex gradient persisted in all walls throughout exercise in 
normal individuals. There was a relatively higher percentage velocity increase in 
apical and mid segments compared with basal segments.(214)
Sm responses to exercise and pharmacologic stress appear to be different. At 
least in one study, where the heart rate at peak dobutamine exceeded that after 
exercise, Sm at peak stress in both normal and abnormal segments was greater 
with dobutamine than with exercise. The increase in Sm in relation to changes 
in heart rate induced by dobutamine was greater than by exercise in normal but 
similar in abnormal segments. Sm correlated better with peak heart rate with 
exercise than with dobutamine.(262) The velocity of normal myocardial 
segments increased by 148% when measured by pTDI. (188) When measured 
by cTDI, it increased by 100% at maximum dose of dobutamine and by 107% 
with maximal exercise. (259)
In clinical practice, ischaemia is detected when the Sm at peak stress falls 
below a pre-validated level. These absolute cut-off levels have been derived
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both using velocity ranges from normal populations and using more complex 
mathematical modelling. Absolute cut-off levels are difficult to establish as there 
is an intrinsic heterogeneity of Sm, as discussed earlier and the normal Sm are 
influenced by heart rate and loading conditions at peak stress. However, most 
normal patients develop similar velocities at peak stress, and it is only at the 
extremes of age that haemodynamics and volumes exert important effects on 
normal velocities. (263) Although the velocities of basal and mid-wall segments 
are different at baseline, the relative increases in velocities for each segment 
are the same at peak stress. A less than normal increment in velocity with 
maximal stress is indicative of ischaemia. Moreover, there are some 
suggestions that changes in Sm during ejection do not appropriately reflect 
changes in myocardial contractile dysfunction when ischaemia is severe. 
Though the peak velocities during ejection decrease with moderate ischaemia, 
severe ischaemia and the resulting dyskinesia is reflected in decreased 
velocities in the isovolumic contraction phase rather than during ejection. (264)
Using cTDI, Cain et al derived normal range of velocities at peak stress of each 
non-apical segment from subjects with low probability of coronary disease, 
those with normal wall motion, and those without coronary disease seen on 
angiography. The lower 20th percentile velocity value for each segment was 
identified to establish a lowest cut-off value. The intrinsic heterogeneity of Sm 
precluded the use of a single cut-off level. At peak stress, the lower limits of 
normal in the basal and mid paraseptal segments were 7 and 5 cm/s, 
respectively, whereas in the basal and mid-free wall segments, the lower limits 
were 6 and 4 cm/s, respectively. These cut-off values, detected coronary artery 
disease with 83% sensitivity, 72% specificity and 80% accuracy compared to 
coronary angiogram. The sensitivity, specificity and accuracy were 80%, 74% 
and 77% in the LAD territory, 76%, 64% and 68% in the LCx territory and 56%, 
75% and 66% in the RCA territory. (265) The MYDISE investigators used 
logistic regression models that included systolic velocity at maximum stress, 
age, sex and peak heart rate to predict coronary artery disease with sensitivity 
and specificity of 80% and 80% for LAD territory, 91% and 80% for LCx territory 
and 93% and 82% for RCA territory. Using receiver-operator curves for peak 
Sm as the only discriminator between patients with normal and stenosed 
coronary arteries, they obtained cut-offs of 10.3 cm/s in basal anterior segment
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with sensitivities and specificities of 63% and 60% for LAD disease, 10.8 cm/s 
in basal lateral segment with sensitivities and specificities of 69% and 67% for 
Cx disease and 12.8 cm/s in basal inferior segment with sensitivities and 
specificities of 69% and 67% forRCA disease. (218) On average, peak systolic 
velocity increased >100% in healthy subjects compared with 50-75% in patients 
with coronary disease. Sm at peak stress was found to be a better discriminator 
of disease, than was its change from baseline to maximal stress with 
dobutamine.(218)
Diagnosis of viability
TDI has been used with LDDSE to detect viability in dysfunctional myocardium 
and predict its recovery after revascularisation. Using pTDI, Altinmakas et al 
demonstrated that the Sm of dysfunctional but viable segments increase more 
than the non-viable ones with 10ug/kg/min of dobutamine. An increase of more 
than 35% in segmental velocities predicts functional recovery after 
revascularization with 89% sensitivity and 86% specificity. The sensitivity, 
specificity, the positive and negative predictive value of the pTDI measurements 
was higher, though not significantly, compared to visual assessment alone. 
However, the sensitivity and the negative predictive value significantly 
increased when visual and TDI assessments were combined. (266) Larrazet et 
al reported TDI to be at least as accurate as visual assessment for viability 
detection and more sensitive than it when rest-reinjection TI-201 SPECT was 
considered as the reference. When TDI and visual assessment were combined, 
the agreement between echocardiography and TDI increased further. TDI 
tended to reveal more viable segments than visual assessment. (267) 
Ramabaldi et al compared the accuracy of pTDI with LDDSE for detection of 
myocardial viability confirmed using F18-fluorodeoxyglucose imaging. Sm 
during low-dose and peak-dose dobutamine were significantly higher in viable 
myocardium. An increase in Sm using pTDI at low-dose of 1±0-5cm/s indicated 
viability in that segment while 0±0-5cm/s predicted non-viability. The sensitivity 
and specificity of the pTDI were 87% and 52% and that of LDDSE 75% and 
51% respectively. (268)
Some studies have reported an increased diagnostic accuracy of DSE with 
application of the TDI techniques. This technique increases the accuracy of
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detection of CAD over and above the visual assessment even when used by 
less expert readers.(198) TDI detects impaired regional LV contractility not seen 
on visual analysis of images. (269) The Sm correlate to wall motion scoring 
(259) and independent markers of ischaemia such as SPECT myocardial 
perfusion imaging. (260) However, there are suggestions that the sensitivity for 
detecting the presence of CAD using TDI techniques has not been advanced 
compared with wall-motion evaluation by an expert reader. (164)
Rolejn dyssynchrony
Regional systolic and diastolic synchronicity can be evaluated by TDI 
comparing the time to peak systolic contraction and early diastolic relaxation of 
multiple segments. A number of parameters based on TDI have been proposed 
to evaluate intra-ventricular dyssynchrony. The delay between the onset of 
electrical activation (onset of the QRS complex) and the peak of mechanical 
contraction (the peak systolic velocity either during ejection (Ts) or at any time 
within the cardiac cycle) is measured in each non-apical segment of the left 
ventricular or the free wall of the right ventricular. Intra-ventricular dyssynchrony 
may be measured as the difference in Ts at the basal septal and lateral 
segments, (270) standard deviation of Ts of all non-apical segments, (271;272) 
maximum difference of Ts for 6 basal segments, maximum difference of time to 
peak systolic displacement for 4 segments and maximum difference of time to 
onset of systolic velocity for 6 basal segments. (273) The difference between 
the longest and shortest delays between the onset of the QRS complex and the 
peak systolic velocity measured in each of the 6 basal segments at any time in 
the cardiac cycle has also been measured. (274) Inter-ventricular dyssynchrony 
can be measured as the difference between the Ts at the basal segment of the 
RV free wall and the basal segment of the lateral LV wall or most delayed LV 
segment. (275) Yu et al demonstrated the presence of intra-ventricular systolic 
and diastolic dyssynchrony in patients with heart failure with and without 
prolonged QRS duration. (94)
Tissue Doppler imaging has been extensively used in an attempt to quantify 
intra- and inter-ventricular dyssynchrony and to predict the response to CRT. 
Though several small studies reported the value of mechanical dyssynchrony 
as measured by TDI parameters in predicting response to cardiac
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resynchronisation therapy, (270-272;274;276-279) a large multi-centre clinical 
trial failed to do so. (273) TDI parameters of interventricular delay have not 
been shown to predict the improvement of cardiac function. (271) In patients 
with CHF, the degree of intraventricular and interventricular asynchrony and 
their combination are the best predictive factors of LV functional recovery and 
reversed remodeling after cardiac resynchronisation therapy. (275) Severe 
dispersion of regional Ts has been shown to strongly predict responders of 
reverse remodeling. (271;272) Mechanical dyssynchrony has also been 
demonstrated in nearly half of the patients with normal QRS duration. (94) 
Prevalence of responders of reverse remodeling is lower in patients with 
narrower QRS duration (120-150 ms), possibly due to the less severe 
mechanical asynchrony as reflected by a lower Ts-SD. This has been confirmed 
in larger clinical trail. (280)
Conclusion
Tissue Doppler imaging alone and in adjunct to stress echocardiography has 
application in the assessment of the left ventricle in a wide variety of cardiac 
conditions. As these conditions are commonly prevalent in patients with 
suspected heart failure, TDI with DSE is likely to be useful in evaluating these 
patients.
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Chapter 4: Safety and Applicability of DSE with Tissue Doppler Imaging In an 
Unselected Population of Patients with Suspected Heart Failure.
ABSTRACT
Background: Symptoms suggestive of heart failure (HF) is common in the 
general population. As these symptoms are usually induced by exercise and are 
often absent at rest, cardiac function assessed at rest potentially leaves some 
patients whose cardiac dysfunction occurs only during stress, undiagnosed. The 
feasibility, safety and the applicability of DSE with cTDI in an unselected 
population of patients with suspected heart failure were studied. Method: 548 
subjects referred to a heart failure clinic with suspected heart failure were 
screened. 207 of these underwent DSE with cTDI using standard dobutamine 
atropine protocol. The segmental systolic function, long axis systolic and 
diastolic functions were visually and quantitative assessed. Results: DSE was 
applicable to 436 patients. 274 were referred for DSE that was done on 207 
patients. DSE was feasible in 183 patients. About 27% of the recruited patients 
had to be excluded due to poor image quality. Complications occurred in 6 
patients: transient ST-elevation in 2 and sustained monomorphic VT in 4. The 
reproducibility of the cTDI measurements was good. Systolic and diastolic 
myocardial velocities could be satisfactorily obtained in >90% of the segments. 
Conclusion: From among the heterogeneous population of elderly subjects with 
multiple co-morbidities with suspected heart failure expected in heart failure 
clinic, DSE with cTDI is feasible in only a highly selected group of patients. 
There may be some safety concerns in this group.
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INTRODUCTION
An estimated 5-7% of the Western European population is suspected to suffer 
from heart failure (HF). (15) Multiple cardiovascular pathologies that culminate 
in left ventricular (LV) dysfunction leading to HF are likely to be highly prevalent 
amongst these patients. However, assessment of the LV at rest as 
recommended in the current guidelines for the diagnosis of HF, (1) may not 
adequately elicit these functional abnormalities. This potentially leaves a 
proportion of patients whose cardiac dysfunction occurs only during 
physiological stress giving rise to symptoms, undiagnosed. Additionally, 
valuable diagnostic and prognostic information may be missed in patients with 
and without resting LV dysfunction. Thus evaluation of cardiac function under 
stress could potentially be useful in assessing patients with suspected heart 
failure.
Patients encountered in heart failure clinics are often elderly, infirm with 
musculoskeletal co-morbidities and breathless on exertion, all of which 
significantly limits their exercise capacity. DSE is very well suited for the 
assessment of this population. DSE is reported to be feasible in patients with 
coronary artery disease, (159;281-289) LV systolic dysfunction (290;291) and 
hypertension (292;293) and in the elderly (294-298). These reports are 
retrospective analysis of data obtained on patients who underwent DSE for 
established clinical indications, and selected in terms of their echocardiographic 
image quality, suitability to tolerate the procedure and the absence of 
contraindications. The applicability of DSE in an unselected population with 
multiple cardiovascular and non-cardiovascular co-morbidities is unknown. (159)
The limitations of DSE are its subjective interpretation (182) and dependence 
on image quality (159) and interpreter expertise. (181) Analysis of myocardial 
motion using cTDI could potentially overcome these shortcomings. (198) cTDI is 
used to quantitate the regional and long axis systolic and diastolic function of 
the LV in patients with wide variety of cardiac conditions. However, there is 
limited data on the feasibility of this technique in association with DSE. (299) 
The feasibility, safety and the applicability of DSE with cTDI in an unselected 
population of patients with suspected heart failure was studied.
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METHOD 
Patient selection
Between November 2001 and August 2003, subjects referred to a community- 
based heart failure programme, serving a mixed urban and rural population of 
600,000, with a suspected diagnosis of HF, were screened. Physicians were 
asked to refer any patient in whom the diagnosis of heart failure was being 
considered including those with breathlessness and/or evidence of fluid 
retention or receiving a loop diuretic. The diagnosis of HF was based on clinical 
evaluation by a cardiologist on the basis of the patients' previous and current 
history and physical examination. In concordance with the ESC definition of HF, 
(1) most had previous hospital admissions with acute breathlessness, clinical 
and/or radiological evidence of pulmonary congestion and clinical improvement 
with diuresis. The inclusion criteria were age above 18 years (no upper limit was 
set) and referral for assessment of suspected heart failure. The exclusion 
criteria were refusal or an inability to consent, inadequate echocardiographic 
window, contraindication to DSE (myocardial infarction, unstable angina, 
pulmonary oedema or stroke within the last 2 weeks, angina or arrhythmias 
within last 48 hours, known left main stem stenosis, severe life threatening 
tachyarrhythmias, severe valvular stenosis, implanted pacemakers, 
hypertrophic cardiomyopathy, resting systolic blood pressure >180 mm Hg, 
known sensitivity to dobutamine), advanced malignancy and immobility severe 
enough to constrain acquisition of echocardiographic images. Other 
cardiovascular conditions in which the physician would consider dobutamine 
stress unsafe were also excluded. Patients who had only temporary contra- 
indications for stress echocardiography were recalled for testing later. It was 
accepted that not all subjects would be suitable for DSE. However, rather than 
selecting subjects for the study, DSE was offered to all recruited, unless contra- 
indicated. The reason why DSE was deemed inappropriate or not performed 
was documented. Written informed consent was obtained. Medical Ethics 
Committee of the Hull and East Yorkshire NHS Trust approved the protocol.
All subjects underwent routine clinical examination, a 12 lead ECG, chest X-ray, 
pulmonary function test (hand-held spirometry) and a standardised 6-minute 
hall walk. The patient underwent full echocardiographic examination using a 
2.5-MHz phased-array transducer (GE Vingmed Vivid Five scanner, Horten,
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Norway). A standard set of images was acquired at rest. (118) cTD images of 3 
cardiac cycles in 3 apical views (4-chamber, 2-chamber and 3-chamber), were 
stored digitally and reviewed off-line (Echopac 6.3, GE.Vingmed). LV volumes 
were calculated from manually traced endocardia! borders in the apical 4 and 2 
chamber views using the modified Simpson's rule and LVEF was calculated. E 
and A velocity, EOT and IVRT were measured.
Stress echocardiographv
Subjects with adequate echocardiographic windows and without any 
contraindication underwent DSE within 6-8 weeks of referral using a standard 
dobutamine-atropine protocol, 48 hours after stopping beta-blocker.(103) A 
patient had to be free of pulmonary oedema, angina or significant arrhythmias 
for at least 48 hours before the test. The pre-specified end-points were 
attainment of target heart rate (THR) {85% of (220-age in years)} and/or 
evidence of ischaemia i.e. new or worsening regional wall motion abnormality, 
intolerable symptoms of chest pain or severe breathlessness with >2 mm flat or 
down-sloping ST depression or >1 mm ST elevation in any of the leads, 
recurrent ventricular couplets or triplets, single run of non-sustained ventricular 
tachycardia (defined at >5 consecutive ventricular ectopics), sustained 
ventricular tachycardia or new atrial fibrillation. Side effects of dobutamine, 
symptoms with no or minor ECG changes, any other arrhythmias, persistent 
hypotension (reduction in the systolic blood pressure by >20 mm Hg on two 
consecutive recordings) with or without bradycardia or hypertension (systolic 
blood pressure >220 mm Hg) were considered complications of the procedure. 
The test was "feasible" if a pre-specified end-point was reached or the 
maximum dose of dobutamine was reached without reaching an end-point. The 
test was "incomplete" if a test was terminated due to a complication or 
deterioration of image quality. Intravenous atropine was not administered if 
there was a history of glaucoma or urinary retention. If needed, dobutamine 
effects were reversed by a short acting IV beta-blocker, esmolol at a standard 
dose.
Standard images (103) (3 cycles edited to exclude ectopic beats and without 
undue translational motion) in grey-scale with superimposed cTD data were 
acquired at rest and in the final 60 seconds of each stage with breath held in
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expiration under continuous 12-lead EGG and intermittent non-invasive blood 
pressure monitoring. The sector angle and depth were adjusted to achieve 
highest possible frame rates. Imaging was continued 9 minutes into recovery or 
till the ECG-changes at peak stress returned to normal. The loops were digitally 
stored. The 2-D grey scale images were analysed in a quad-screen format and 
the cTD images were analysed using customised software (Echopac TVI, GE 
Vingmed). The mitral inflow and the LVOT were interrogated with pulse-wave 
Doppler at each stage.
Using a 16-segment model of the LV, (118) segmental wall motion was 
classified as "normal", "hypokinetic", "akinetic", or "dyskinetic" based on a 
subjective visual evaluation of endocardial motion and degree of wall thickening. 
Wall motion score (WMS) was assigned to each segment as recommended (1 = 
normal, 2=hypokinesia, 3=akinesia and 4=dyskinesia).(103) Segments with 
'mild' or 'questionable' hypokinesia and those appropriately "hyperdynamic" at 
peak stress was graded normal. Segmental response to dobutamine was 
classified as "normal", "viable", "biphasic", "ischaemic" or "scar".(103) WMSI 
(sum of the wall motion scores of the interrogated segments divided by the 
number of segments interrogated) was calculated at rest, low dose dobutamine 
and peak stress.
The E and A velocities, EOT and IVRT were measured at rest, low dose of 
dobutamine and peak stress. If there was fusion of the E and A velocities at 
peak stress, these were measured at the latest stage (i.e. the highest heart rate) 
at which separate peak velocities could be appreciated. The EOT and IVRT 
were corrected for the heart rate using Bazett's formula {EDTc or IVRTc (msecs) 
= EOT or IVRT (msec)/VR-R interval (sees)} to allow comparison of these 
variables at different heart rates.
In the cTDI mode, the myocardial velocity curves were reconstituted by placing 
a 5 mm sample cursor at mitral annulus and the midpoint of each of the non- 
apical segments of the six walls in the 3 apical views. No tracking algorithm or 
angle correction was used. The systolic myocardial (Sm) and mitral annular (Sa) 
velocity during ejection, early diastolic (Em, Ea) velocity and late diastolic (Am, 
Aa) velocity were measured at rest, 10 mcg/kg/min of dobutamine and peak
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stress. If the diastolic velocities at peak stress were fused, these were 
measured at the highest heart rate at which separate velocities could be 
appreciated. The 6 peri-annular velocities were averaged. (57;58;212) E/Ea was 
calculated from early diastolic transmitral velocity and the averaged mitral 
annular velocity.
Reproducibilitv
A single observer, blinded to the clinical and echocardiographic characteristics 
of the patients, measured the systolic, early diastolic and late diastolic 
myocardial velocities and the time to peak velocity at the mitral annulus and the 
12 non-apical segments twice in 10 randomly selected patients at rest and peak 
stress. Differences in the paired measurements were calculated and reported 
as mean±SD. Confidence limits (95%) of differences were computed and 
expressed as absolute values and percentages of the average values of paired 
velocity measurements.
Patient classification
Patients were allocated into one of three groups dependent on symptoms and
left ventricular ejection fraction (LVEF).
Group 1: LVEF <45% and symptoms of heart failure: 'heart failure-LVSD' (HF-
LVSD) group. One patient, with LVEF <45% and no symptoms of heart failure
(asymptomatic LVSD), was considered in Group 1.
Group 2: LVEF >45% and symptoms of heart failure: "heart failure with normal
ejection fraction" (HFNEF) group.
Group 3: LVEF >45% and no symptoms of heart failure: 'No heart failure' (NoHF)
group.
Statistical analysis
All analyses were performed using commercially available software (SigmaStat 
v 3.5, Systat Software, Inc. San Jose). The continuous variables were described 
as means and standard deviations and the categorical variables as percentages. 
The data was tested for normal distribution using the Kolmogorov-Smirnov 
Normality test. The means between the study groups were compared by 
Student's unpaired t test assuming unequal variance and Mann-Whitney Rank 
Sum test as appropriate. The data at rest and peak stress within each group
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were compared by Student's paired t test and Wilcoxon Signed Rank test as 
appropriate. Multiple groups were compared using ANOVA with post-hoc 
Bonferoni analysis or ANOVA on Ranks. Proportions were compared using the 
Chi-square test. A two-tailed p value <0.05 was considered significant.
RESULTS
Five hundred and forty eight non-consecutive but unselected subjects were 
screened. (Figure 1) Twenty-four (4.4%) patients, who were admitted in hospital 
at referral died before consenting, 14 (2.6%) (median age 86 years) were 
deemed unfit to consent, 58 (10.6%) had contraindication to DSE (the 
commonest being significant valvular lesions) and 16 (2.9%) were not suitable 
for DSE. Of the 436 (79.6%) subjects eligible for the study, 89 (20.4%) (median 
age 82 years) refused consent. Three hundred and forty-seven subjects (63.3%) 
were thus recruited. The attending cardiologists did not refer 73 (21.0%) 
patients due to inadequate echocardiographic windows. Of the 274 subjects 
referred for DSE and the test was done in 207 (75.5 %) subjects. Of these 
patients, 183 patients (feasibility of 88.4%) reached a test end-point.
Feasibility
Sixty-seven referred subjects were excluded from the test. (Figure 1) Patients 
with persistent or permanent atrial fibrillation developed rapid ventricular 
response upon withdrawal of beta-blockers. Though the THR was expected to 
be reached quickly in these patients, it was anticipated that the stress images 
would be uninterpretable. Twelve patients requested test termination within the 
first two levels of dobutamine infusion due to subjective symptoms. Patients 
with resting SBP^180 mmHg despite replacement of the beta-blockers with 
other anti-hypertensives were excluded after two attempts. Eight patients with 
persistent severe heart failure were deemed too unwell for the test. Two 
patients had pacemakers implanted, 1 for CRT and 1 for complete heart block, 
between referral and the test. Two patients were awaiting implantable 
cardioverter defibrillator implantation. One patient was diagnosed with 
bronchogenic carcinoma.
Of the patients who underwent DSE, the test was "completed" in 183 patients 
(feasibility of 88.4%) (THR reached in 27, new RWMA 149, angina with ST-
68
segment depression 5 and was inconclusive in 2). The test was prematurely 
terminated in 24 patients: image deteriorated during the test in 9 (4.3%), 7(3.3%) 
developed NSVT without evidence of ischaemia, hypotension in 6(2.9%) and 
hypertension in 2(1%). The 9 patients whose images deteriorated very early in 
the test have been included "DSE not done" group for further analysis.
Baseline characteristics
The clinical characteristics of the study population are described in Table 1. The 
recruited patients were younger, predominantly male and with less valvular 
heart disease than those not recruited. Subjects aged >75 years were less 
frequently recruited (38.6% of those recruited versus 57.7% of the non-recruited, 
p=0.000). The subjects who "completed" DSE were younger, had lower mean 
BMI and a lower prevalence of COPD. Elderly patients completed DSE less 
frequently (33.5% amongst those who did versus 44.9% amongst those who did 
not, p=0.031). Only 28.8% had normal BMI. Chronic and paroxysmal AF was 
present in 19% and 8% respectively in subjects who underwent DSE compared 
to 25% (p=0.26) and 6% (p=0.47) respectively in subjects who did not. There 
were no differences in prevalence of risk factors and medication use between 
the two groups. The prevalence of heart failure symptoms and abnormal LV 
systolic and diastolic parameters was similar in the groups that did and did not 
undergo DSE. (Figure 2)
Response to stress
The response to stress of the 200 patients is shown in table 2. The mean peak 
dose of dobutamine needed to reach an end-point was similar in patients with 
LVSD and those without and in those who did and did not reach THR (29.9±9.2 
ugm/kg/min versus 32.1±7.8 ugm/kg/min respectively, p=0.064), a pre-specified 
end-point (31.3±8.5 ugm/kg/min versus 30±7.6 ugm/kg/min respectively, 
p=0.681) or developed RWMA (31.2±8.4 ugm/kg/min versus 31.3±8.5 
ugm/kg/min respectively, p=0.921). The THR was reached in 83 (41.5%) 
subjects, 22(26.5%) of who were in persistent AF during DSE. The mean peak 
dose of dobutamine in these patients was 31.2±8.5 ugm/kg/min.
Sixteen (8%) patients, all of whom were in sinus rhythm, needed atropine. 
Seven (40%) reached THR (concomitant RWMA in 3, NSVT in 1) and 9 patients
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(new RWMA in 7, non-diagnostic test in 2) did not. Atropine did not affect the 
maximum heart rate (124±15 with versus 124±13 without, p=0.933) or % of the 
THR achieved (95.9±7.8% with and 96.3±10.6% without, p=0.903). The 
proportion of patients achieving THR (44% versus 41%, p=0.849) or a 
diagnostic test (88% versus 92%, p=0.55) with and without atropine was also 
similar. The resting heart rates were higher in the patients who reached THR 
compared to those who did not (79±15 v 74±12, p=0.012). Atrial fibrillation at 
rest was more prevalent in patients who reached THR (27.8% v 13.7%, 
p=0.021). Amongst patients in sinus rhythm, there was no difference in the 
resting heart rates of patients who did and did not reach THR (77±14 v 74±12, 
p=0.120). A diagnostic result was achieved most frequently (34.6%) at 30 
ugm/kg/min of dobutamine followed by 40 ugm/kg/min (32.7%).
Reasons for discontinuation of the test
The reasons for test termination are shown in table 3. Stress induced ischaemia 
was identified in 156 (78%) patients, manifesting as new RWMA in 146 and 
ischaemia on EGG with chest pain in 10.
Major Complications
Six patients (3%), all with new RWMA, had major complications (sustained VT 
and Ml). There were no deaths. Four patients (mean age 74±6 years, 3 male, 
mean LVEF 28±5%, with prior Ml, and with RWMA at peak stress, 2 in sinus 
rhythm and 2 in atrial fibrillation) endured haemodynamically stable self- 
terminating sustained ventricular tachycardia at peak stress. They were 
monitored overnight without any further therapy. . Two patients (75 years (LVEF 
19%) and 79 years (LVEF 33%), males, previous Ml, new RWMA) had transient 
anterior ST elevation with minor increase in troponin but no new Q-waves. They 
were both treated with intravenous heparin and nitrate.
Minor complications
Minor complications (hypotension, hypertension and all other new onset
arrhythmias) were seen in 70 (35%) patients leading to test termination in 15
(7.5%).
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Hypotension was seen in 17 (8.5%) patients (5 had prior Ml, 5 developed 
RWMA). These patients were younger (64±8 years v 69±10 years, p=0.04), had 
higher mean LVEF (56±19% v 46±17%, p=0.02), lower prevalence of LVSD 
(23.5% v 56.3%, p=0.010) and comparable systolic (147±25 mmHg v 140±22 
mmHg, p=0.200) and diastolic (86±10 mmHg v 81±13 mmHg, p=0.150) blood 
pressure compared to those that did not. LVOT gradient increased in 6 patients, 
4 of whom were bradycardic. Hypotension led to test termination in 6 patients 
(all with normal LVEF, 3 of whom had increased LVOT gradient and 
bradycardia). Compared to others with hypotension, these patients were 
younger (57±4 years v 68±8 years, p=0.03) and had higher resting diastolic 
pressure (95.5±3.1 mmHg v 80.6±8.9 mmHg, p=0.001). Three other patients (1 
with bradycardia) had hypotension with increased LVOT gradient (2 reached 
THR and 1 had RWMA). Hypotension was associated with chest pain and 
ischaemia on ECG in 2 patients (both with normal LV function but without new 
RWMA at 80% of THR) and NSVT in 2 patients (normal LV function) at 97% 
and 91% of the THR respectively. Three patients with hypotension needed fluid 
resuscitation and 3 with additional bradycardia responded to atropine alone.
Hypertension (> 220 mmHg) was seen in 14 (7%) patients (all known 
hypertensives) leading to test termination in 2 (1%). The test was terminated for 
ischaemia on ECG in 3, achieving THR in 1 and developing new RWMA in 8. 
Hypertension settled spontaneously after termination of protocol in all except 3 
patients who needed intravenous nitrates.
The commonest dysrrhythmias included ectopic ventricular and supraventricular 
activity. These did not lead to test termination. Induced ventricular 
dysrrhythmias (p=0.461) and AF (p=0.504) were as frequent amongst patients 
who received atropine as those that did not. The mean peak dose of 
dobutamine in patients who developed significant ventricular dysrrhythmias was 
similar to that in patients who did not (31.7±8.2 ugm/kg/min versus 31.1±8.5 
ugm/kg/min, p=0.773). Five patients (3 with LVSD, mean EF 33.2±10.3% and 2 
without LVSD or RWMA at THR) developed AF. Intravenous esmolol was used 
in 4 patients with AF and rapid ventricular rates that did not respond to 
discontinuation of dobutamine. Bradycardia was seen in 4 patients, all in 
association with increased LVOT gradient. All had normal LV systolic function.
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Non-sustained ventricular tachycardia was seen in 18 (9%). The mean peak 
dose of dobutamine (33.9±7.0 ugm/kg/min versus 30.9±8.5 ugm/kg/min, 
p=0.156), the mean ejection fraction (49±14% versus 46±18%, p=0.53) and the 
prevalence of LVSD (44% versus 54%, p=0.42) were similar in patients who did 
and did not develop NSVT. Atropine was administered to one patient. The test 
was terminated in 7(3.5%) patients (1 with AF and 2 with previous Ml one of 
whom had PCI to LAD, 2 with symptomatic hypotension and mean LVEF 
59±6%) before an end-point. Of the other 11 patients (1 with AF, 8 with LVSD: 
mean LVEF 37±13), new RWMA developed below THR in 7 and at THR in 3 
while 1 attained THR without any RWMA. One patient had atropine. The mean 
peak dose of dobutamine was similar in patients who did and did not reach end- 
points (35.5±5.2 ugm/kg/min versus 31.4±9 ugm/kg/min, p=0.244). NSVT was 
terminated in all patients on discontinuation of dobutamine.
Chest pain was induced in 36(18%) patients (22% had known angina, 42% had 
previous Ml and 28% had previous revascularisation). Two had STEMI with 
RWMA below the THR. ST depression led to test termination in 10 patients (5 
developed new RWMA, 2 were hypotensive and 3 hypertensive). Twenty-four 
patients had no ST changes (12 had RWMA below the THR, 10 at THR and 2 
reached THR without any RWMA). Chest pain was as frequent in patients who 
received atropine than those who did not (19% versus 18%, p=0.935). Chest 
pain accompanied the induced AF in 5 patients 2 of who did not show any 
RWMA. Thirty-one patients needed sublingual and 4 intravenous nitrate.
The test was non-diagnostic for inducible ischaemia in 17(8.5%) patients (pre- 
mature termination in 15 and test end-point not reached in at maximum dose in 
2). Echocardiographic data of 174 patients could be analysed completely (90 
patients with HF-LVSD, 41 with HFNEF and 43 with NoHF). All subsequent 
analysis pertains to this group of patients.
Reproducibilitv
Overall intraobserver variability of the annular and myocardial velocities at rest 
and stress was low (<10% at rest and <15% at stress) (tables 4). At rest, the 
highest variability of the systolic velocity was seen in the posterior mitral
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annulus, septal basal and middle segments. The highest variability of the early 
diastolic velocity was seen in lateral mitral annulus, lateral basal and posterior 
middle segments. The late diastolic velocity was most variable at the posterior 
mitral annulus, anteroseptal basal and anterior middle segments.
Regional wall motion assessment
2784 segments of the left ventricle were visually scored at baseline, low dose 
and peak dose of dobutamine totalling 8352 observations. (Figure 3) Fewer 
segments could be visually assessed in the HF-LVSD group compared to the 
other two groups at all levels of stress. Fewer segments were assessed at 
stress compared to rest in the NoHF group (p=0.041) but not in the HF-LVSD 
(p=0.686) or the HFNEF (p=0.098) groups. The three segments of the anterior 
wall were the most difficult to score and those of the septal wall the easiest.
Regional myocardial velocities were quantitatively analysed in 2088 segments 
(12-segment model) at baseline and each dose of dobutamine totalling 6264 
observations. Segments could be quantitatively evaluated more frequently than 
visually in all (p<0.01) except the HFNEF group. (Figure 3) Myocardial velocities 
could be measured more frequently in the NoHF group compared to the other 
two groups at low dose (p=0.000) and peak stress (p=0.000) but not at rest 
(p=0.096). The levels of stress did not affect quantitative assessment in the 
HFNEF (p=0.13) and NoHF group (p=0.79) but velocities were measured less 
frequently at peak stress (p=0.000) in the HF-LVSD group. Fewer basal 
segments (p=0.000), but not the mid-segments (p=0.093), could be measured 
at peak stress than at rest and low dose dobutamine in the HF-LVSD group but 
not in the other two. The middle segments could be interrogated less 
successfully than the basal segments at all levels of stress in all the three 
groups. The segments could be interrogated least frequently at all levels of 
stress compared to the others were the middle segment of the anterior wall due 
to inadequate visualisation and that of the anteroseptal wall due to poor 
alignment
Mitral annular velocities were measured at 1044 sites totalling 3132 
observations. It could be measured in 99%, 97.3% and 100% of the instances in 
the HF-LVSD, HFNEF and NoHF groups respectively (p=0.000). Fewer
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observations could be made at peak stress compared to rest and low dose 
(p=0.000) in the HF-LVSD group but not in the others.
The wall motion response to stress could be visually characterised in 94.1% 
segments, 93.4% in the HF-LVSD, 96.8% in the HFNEF groups and 93.2% in 
the NoHF (p=0.004) and least commonly in the anterior wall. The inability to 
assign a response to a segment was due to the failure to score that segment at 
peak stress (p=0.001) in the NoHF group and at all levels of stress in the HF- 
LVSD and HFNEF groups.
Comparison between visual and quantitative assessment 
Segmental wall motion could be estimated both visually and quantitatively on 
91.8%, 94.0% and 95.4% instances in the three groups respectively (p<0.001). 
Neither modality could assess a segment 0.9-1.9% instances; most frequently 
in the HF-LVSD group (ANOVA, p=0.01). (Figure 4A) Fewer assessments were 
made visually only than by TDI only in all, except the HFNEF group. A response 
characteristic to stress could be assigned to 91.0%, 92.7% and 92.6% 
segments both visually and quantitatively in the three groups respectively 
(p=0.39). Neither modality could assign a response characteristic to 1-2.9% of 
segments most frequently in the HF-LVSD group (ANOVA, p<0.05) (figure 4B). 
Larger number of segments was assigned a response characteristic on the 
basis of TDI observations only compared to visual assessment only in the 
normal group.
A segment could not be visually assessed on 333 (5.3%) instances, most 
frequently in the HF-LVSD group (p<0.001) (figure 5 Panel 1A). TDI could 
assess segments on 73% of these attempts. The proportion of observations that 
could not be made visually but could be made quantitatively was similar in the 
three groups (ANOVA, p=0.57). A segment could not be assessed by TDI on 
180 (2.9%) instances; least commonly in NoHF group (p<0.001). (figure 5 Panel 
1B) Of these, higher proportion of observations could be done visually in the 
HFNEF group (ANOVA, p<0.001). A segment that could not be assessed 
quantitatively is less likely to be assessed visually (p<0.001). A response 
characteristic could not be visually assigned to 119 (5.7%) segments. 62% of 
these segments could be assessed by TDI (figure 5 Panel 2A). This was least
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likely in the HFNEF group (p=0.03). A response could be assigned using TDI to 
similar proportion of segments in the three groups (p=0.12). A response could 
not be assigned using TDI to 97 (4.6%) segments; most commonly in the HF- 
LVSD group (p=0.01). (figure 5 Panel 2B) The proportion of these segments 
that could be visually assessed was the highest in the HFNEF group (p=0.003).
Diastolic assessment
E could be measured in all patients at rest and peak stress. The A wave and 
thus the E/A ratio could be measured in 77%, 78% and 93% patients at rest 
(p=0.054) and 69% 76% and 91% patients at stress (p=0.023) in the three 
groups respectively. The proportions were similar at rest and stress (p=ns, rest 
v stress). The failure to measure E/A was exclusively due to AF at rest or 
induced by stress. Of the 136 patients who were in sinus rhythm under stress, 
fusion of the E and A waves was seen in 38(28%) patients all of whom reached 
heart rates higher than 110 bpm. The EOT could be measured in all patients at 
rest and peak stress. IVRT could not be measured in 1 patient in each of the 
heart failure groups.
The averaged Ea could be calculated in all and 98.8% patients with and without 
LVSD at rest and in 97.8% and 98.8% patients at stress. Aa could be calculated 
in all patients in sinus rhythm in both groups (75.6% and 72.2% patients with 
LVSD and 85.7% and 83.3% patients without at rest and stress respectively).
Ea could be measured more sites at rest than at peak stress (96.9% v 90.4%, 
p=0.000 in patients with LVSD and 98.8% v 97.0%, p=0.047 in patients without). 
Amongst the patients in sinus rhythm, Aa could be measured more frequently at 
rest than at peak stress (96.8% v 92.6%, p=0.007) in patients with LVSD but not 
in patients without (100% v 99.8%, p=0.310). Ea and Aa could be measured at 
fewer sites in patients with LVSD compared to those without (Ea: at rest, 
p=0.031; at peak stress, p=0.000; Aa: at rest and peak stress, p=0.000). In 
patients with and without LVSD, Em and Am could be measured in fewer mid 
segments compared to the basal segments at rest and at peak stress (p<0.001 
for all). Em and Am could be measured in fewer segments (both basal and mid) 
at peak stress compared to rest in all patients (p<0.001 for all). Ea/Aa ratio 
could be calculated for fewer annular sites in patients with than those without
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LVSD at rest and at peak stress (p=0.000). Ea/Aa ratios could be calculated at 
fewer annular sites at peak stress compared to rest in patients with LVSD 
(p=0.034) but not in patients without (p=0.310). The average annular E/Ea could 
be measured both at rest and peak stress in 168 patients; 85, 40 and 43 in the 
three groups respectively.
DISCUSSION
To the best of our knowledge this is the only report on the feasibility of DSE with 
cTDI in the assessment of an unselected population of patients with suspected 
heart failure in an ambulatory setting. The study included a heterogeneous 
population of subjects who were mostly elderly with multiple cardiac and non- 
cardiac co-morbidities.
An unselected population of patients with suspected heart failure that can be 
expected in a heart failure clinic were screened. DSE was offered to all 
recruited subjects. Previous studies (159;281-298;300) that have reported 
feasibility of DSE are retrospective analysis of data obtained on patients who 
underwent DSE for established clinical indications, and selected in terms of 
their echocardiographic image quality, suitability to tolerate the procedure and 
the absence of contraindications. Thus the information on the applicability of 
DSE to a heterogeneous population expected in a heart failure clinic is limited. 
About a third of the screened population had to be excluded. Death of 4% of the 
screened patients before recruitment is unsurprising given the high mortality 
(about 20%) amongst newly diagnosed patients with heart failure during index 
admission. (25;26;301) About 10% had contraindication to DSE. Even though 
the contraindications to the DSE in this study were set conservatively, we are 
unaware of any estimate of prevalence of conditions that would preclude DSE in 
this population. The median age of the population screened for this study was 
78 years, a decade higher than that included in most feasibility reports. Except 
for studies in the elderly, (294-298) most feasibility reports include patients who 
are younger than what could be expected in a heart failure population. This 
study accurately represents the population that suffer with heart failure the 
prevalence of which increases rapidly with age (1;15;302) with 15% of people 
over 85 suffering from it. (302) Co-morbidities precluded 3% of the screened 
patients from DSE. About 16% (median age 82 years) did not consent for the
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study. Though the reasons for refusal were not recorded, it could be presumed 
to be due to discomfort of the test, inconvenience, travel and travel costs as 
sighted as reasons in some studies. 3% (median age 86 years) subjects were 
adjudged incompetent of consenting. Impediments to consenting for studies in 
the elderly include impairment of cognition, inability to communicate etc. (303)
After screening, 21% of the subjects were excluded due to poor acoustic 
windows. Some authors have suggested that an inadequate acoustic window 
precludes the performance of successful DSE in only -5% of patients.(288;304) 
This may be an underestimate when applied to an unselected population. (159) 
Our experience matches the estimate that 10-20% of non-selected patients 
have suboptimal endocardial border visualisation even with tissue harmonic 
imaging without contrast. (305) Deterioration of endocardial border definition 
during DSE precluded analysis of images in another 6%. This conforms to 
reports that 0-6% of patients selected for DSE had to be excluded for poor 
image quality. (282;289;298;306)
In the absence of established clinical indication for DSE, patients, especially the 
elderly, were intolerant to subjective symptoms e.g. musculoskeletal pain. Beta- 
blockers were withdrawn 48 hours before the test. This resulted in a higher 
incidence of exclusion due to high ventricular response in patients with 
persistent atrial fibrillation and loss of control over blood pressure.
Complications
The overall incidence of ventricular arrhythmias was higher than previously 
reported (Table 5). Resting regional wall motion abnormality, history of previous 
myocardial infarction and arrhythmias were common in these patients. Only 1 
patient received atropine and the mean peak dose of the dobutamine was 
similar to the rest of the patients. This is consistent with previous reported 
experience that induction of ventricular tachycardia during DSE is not related to 
the addition of atropine (182;307) and is more frequently seen in patients with 
prior history of ventricular arrhythmias or baseline wall motion abnormalities. 
(159) Its relation to the peak dose of dobutamine is also reported to be 
uncertain. (289) Stress induced RWMA was common in these patients 
suggesting that stress induced ischaemia is likely to have precipitated these
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arrhythmias. However ventricular arrhythmias during DSE have not been 
related to inducible RWMA. (289;307) About 44% of the patients with NSVT had 
normal LVEF and no inducible ischaemia. Three-fourth of these patients did not 
have previous Ml or resting RWMA. In these subjects, the arrhythmia may be 
attributed to dobutamine-induced pi-receptor stimulation or reduction in plasma 
potassium. (308)
Beta-blockers were stopped 48 hours before testing. This resulted in lower 
number of non-diagnostic tests (8.5%) compared to previous estimates (10%). 
(287;288) This however, resulted in uncontrolled ventricular rates in patients 
with AF leading to exclusion of some of these patients and increased incidence 
of ventricular arrhythmias especially amongst patients with inducible ischaemia. 
The increased incidence of ventricular arrhythmias, however, did not 
necessitate termination of tests before ischaemic end-points were reached thus 
maintaining the diagnostic yield of the test. Beta-blockers reduce ventricular 
arrhythmias by limiting ischaemia and decreasing the susceptibility of the 
myocardium to the beta-adrenergic effect of dobutamine. (289)
The incidence of hypotension during DSE varies between 5-38% depending on 
the definition used. (288;309-311) The incidence of hypotension in our study 
was considerably lower than that reported by others using comparable cut-offs. 
(309-311) Hypotension led to test termination in 3% patients compared to 0-7% 
in previous reports. Stress-induced hypotension has been associated with older 
age, (296;309;310) higher resting systolic blood pressure in some (309;310) but 
not all studies (296) and symptoms in the younger but not older patients. (296) 
The patients with symptomatic hypotension leading to test termination were 
younger compared to those in whom the test could continue and had higher 
resting diastolic but not systolic blood pressure.
Fewer patients complained of chest pain in our study than previously reported 
(table 5). Ml occurred in 1% patients. Ml is rare during DSE. The higher 
incidence in this study could be related to withdrawal of beta-blocker and the 
troponin based definition of infarction. However it can occur due to intense 
coronary spasm in normal coronary arteries. (284)
78
Reproducibilitv of data
Interobserver variability of echocardiographic measurement has been assessed 
using 'real-time' pulsed tissue Doppler in one study. The 95% confidence 
intervals for standard deviations expressed as a percentage of the mean, were 
10-16% for longitudinal velocities and 14-24% for radial velocities. (200) Good 
reproducibility has been reported for off-line measurements of peak systolic 
velocity even by inexperienced observers. (197) In keeping with the latter study, 
the intraobserver variability for mitral annular and regional myocardial systolic 
and diastolic velocities was low.
Feasibility of TDI
Myocardial velocity was obtainable in 95-99% of segments interrogated at all 
stages of the protocol. Myocardial velocities could be most frequently measured 
in the NoHF group reaching success rates of 99% at all levels of stress. Most, 
(188;214;260;312) but not all (299;313;314) studies have reported similar 
feasibility. The lower proportion of analysable segments (90%) in the MYDISE 
study (299) resulted from non-analysable waveforms from the mid-anterior 
septum interrogated in the parasternal long axis view and the four apical 
segments interrogated in apical view. The higher yield of interpretable velocity 
curves in our study resulted from interrogation of the anteroseptal segments in 
the apical long axis view allowing better ultrasound beam alignment and the 
exclusion of the apical segments.
Measurement of regional myocardial velocities was least successful in the HF- 
LVSD group especially at peak stress. A segment could not be assessed either 
visually or quantitatively most frequently in the HF-LVSD group. Interrogation of 
the walls of dilated, spherical, often scarred and dyssynchronous ventricles may 
have resulted in uninterpretable myocardial velocity traces. Despite this 
limitation, success rate for quantitative evaluation of segments was consistently 
higher compared to visual assessment in this group. Both visual and 
quantitative were equally successful in the HFNEF group.
The three segments of the anterior wall were the most difficult to score visually. 
Visualisation of anterior or lateral walls may be suboptimal during 
echocardiography and worsen during stress.(305) The middle segments could
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be quantitative interrogated less successfully than the basal segments at all 
levels of stress in all the three groups. The segments that could be interrogated 
least frequently at all levels of stress were the middle segment of the anterior 
wall due to inadequate visualisation and that of the anteroseptal wall due to 
poor alignment. This mirrors the experience of the MYDISE investigators.(299) 
The success rate of quantitative assessment was consistently higher than visual 
assessment. Depending on the level of stress and the population of patients 
examined, 92-98% of the segments examined could be visually assessed. This 
concurs with the reported proportion of segments that could be scored visually 
(83-97%) in various studies. (214;313;314)
TDI supplemented visual assessment of wall motion quite appropriately. 
Myocardial velocities could be measured in similar proportion of segments (70- 
77%) that could not be visually assessed in all three groups. But as the HF- 
LVSD group had higher absolute number of non-visualised segments, TDI 
seemed to benefit this group the most. Concurrence between the visual scoring 
and myocardial velocity was modest at rest, being the lowest in the HF-LVSD 
group. Published comparison between conventional visual assessment of 
regional wall motion and TDI analysis is lacking.
Diastolic measures
Feasibility of diastolic assessment of the LV during stress is limited by the 
difficulties in the measurement of the diastolic waves and velocities. Fusion of 
the diastolic waves occurs at peak heart rates. Najos-Valencia et al could not be 
designate Em and Am velocities in 1.5% of 756 segments tested at rest and 
21 % at peak stress because of fusion between the E and A waves at peak heart 
rates.(186) Fusion prevented assessment of diastolic function in 40% (257) and 
71% (188) cases in other studies. This problem was avoided by measuring the 
diastolic velocities at the highest heart rates where they could be separately 
measured. Analysis of diastolic velocities at sub-maximal stress seemed to be a 
reasonable approach for diagnosis of stress-induced diastolic dysfunction firstly 
because ischaemia induces diastolic dysfunction occurs earlier than systolic 
(315) and secondly, heart failure patients with exercise intolerance are unlikely 
to achieve maximal heart rates during day-to-day physical activity that make 
them breathless. Interpretation of the patterns of diastolic waves under stress is
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further complicated by the presence of resting changes in relative magnitudes 
of these velocities. The ratio of Ea and Aa may be permanently inverted in 
regions of the myocardium supplied by stenotic arteries.(79) Age, hypertension 
and/or LV hypertrophy may have similar effect. This may conceal the effect of 
stress induced ischaemia on these variables or at least make interpretation 
difficult. The high prevalence of these conditions in patients with suspected 
heart failure could adversely affect the evaluation of diastolic function under 
stress in these patients. The reproducibility of these measurements has been 
reported to be suboptimal and probably less than that obtainable with systolic 
velocity.(299;312) Intraobserver variability in this study was <10% at rest and 
<15% at peak stress.
LIMITATIONS
The subjects underwent DSE as part of a research project. A significant 
proportion of eligible patients that did not consent for a research procedure may 
have done so if it was clinically indicated. DSE was offered to an unselected 
population of patients attending the heart failure clinic a substantial proportion of 
whom would never be considered for DSE in a real-world situation. This led to a 
high exclusion contrary to clinical experience.
CONCLUSION
DSE is feasible in patients with suspected heart failure only when they are 
appropriately selected for the test. DSE is applicable to a small portion of 
patients attending the heart failure clinics. The safety of DSE in an unselected 
population may be a concern. Both systolic and diastolic assessment of these 
patients is feasible using cTDI both at rest and stress and may supplement 
visual interpretation. DSE may have important influence on management of 
these patients but that needs to further assessed.
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Age (years) (meaniSD)
Age (yrs) range (median)
Males (%)
BMI (mean±SD)
Risk factors for CAD
H/0 Smoking (%)
Diabetes (%)
Family history (%)
Hypertension (%)
Obesity (%)
History of
Angina (%)
Revascularisation (%)
Myocardial infarction (%)
Valvular disease (%)
COPD (%)
Drugs
Loop diuretics (%)
ACEI or ARB (%)
Beta-blockers (%)
Aspirin (%)
Wafarin (%)
Spironolactone (%)
Systolic BP (mmHg)
Diastolic BP (mmHg)
Sinus rhythm (%)
QRSd (ms)
RR interval (ms)
Heart rate (bpm)
Echocardiography
IVSd
IVSs
LVPWd
LVPWs
LVIDd (cm)
LVIDs (cm)
LVEDVol (ml)
LVESVol (ml)
EF (mean±SD)
Screened/ not 
recruited 
(n=201)
76±10
42-95 (78)
51.6
27.9±8.2
64.6
14.3
29.1
35.2
-
30.1
10.4
32.4
14.3
11.4
73.8
65.1
66.5
80.6
16.2
12.1
148±28
84±12
70.3
98±20
810±152
78±12
1.3±0.4
1.6±0.6
1.3±0.4
1.7±0.8
5.5±1.2
4.211.3
127±74
80±61
42±15
p value for comparison between the DSE done
**p<0.01, ***p<0.05
Screened/ 
recruited 
(n=347)
71±11*
29-92 (72)
61.4***
28.6±5.8
71.9
19.6
35.2
38.9
-
33.5
11.2
33.4
3.2*
14.9
74.9
66.1
69.8
84.6
19.1
13.8
142±29
86±14
73.5
97±21
812±159
76±15
1.3±0.4
1.610.5
1.310.4
1.710.5
5.6+1.2
4.4+1.4
135180
82158
45116
and not done
DSE done 
(n=200)
69110
42-92 (70)
62.5
27.015.3
77.0
18.5
32.5
32.3
16.4
33.2
11.5
31.0
0
10.1
75.2
68.6
69.1
86.6
18.9
12.6
140126
82116
72.8
101120
8181153
76111
1.310.4
1.610.3
1.310.4
1.710.1
5.611.2
4.411.4
134169
82152
45116
groups. *p<0.
DSE not 
done 
(n=147)
72H1**
29-90 (74)
59.9
29.916.2*
76.9
21.1
38.8
48.3
52.5*
36.3
10.9
36.7
0.7
18.5***
74.8
65.9
70.3
83.8
19.6
15.2
139127
83114
69.6
100H 9
809H49
79111
1.410.5
1.610.1
1.310.5
1.710.6
5.6+1.2
4.3H.4
136H02
81172
46+17
001,
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Table 4.2. Haemodynamic response to stress.
• OWI-N / in-7\ Normal EFLSVD(n=107) (n=g3)
DSE End-point reached at
40 |jg/kg/min+atropine n (%) 9 (9.3) 6 (6.5)
40 (jg/kg/min n (%) 34 (29.9) 31 (36.6)
30 [jg/kg/min n (%) 34 (34.6) 34 (33.3)
20 (jg/kg/min n (%) 29(25.2) 19(20.4)
10 (jg/kg/min n (%) 1 (0.9) 3 (3.2)
Peak dose of dobutamine 31.1±8.3 31.5±8.7
HR(rest) 77±15 75±13
HR (peak stress) 125±14 123±13
Target HR 129±8 128±9
% of THR reached 96.7±10.3 95.8±10.6 
%ofTHR reached
>100%n(%) 42(39.3) 41(44.1)
> 90 % n (%) 87 (82.2) 70 (83.9)
> 80 % n (%) 99 (92.5) 86 (92.5)
>70%n(%) 107(100.0) 93(100.0)
SBP(rest) 135±24 146±20
SBP (peak stress) 170±26 162+22
DBP(rest) 80±13 84±11
DBP (peak stress) 95±8 89±8
0.623
0.397
0.971
0.524
0.517
0.631
0.531
0.236
0.544
0.860
0.489
0.760
0.798
<0.001 
0.169 
0.016 
0.002
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Table 4.3. Reasons for termination and side-effects observed during DSE.
Reason for complication
termination
NSVTn(%) 7(3.5) 18(9.0)
PVCs n(%) - 64 (32)
PSVCsn(%) - 26(13)
Atrial fibrillation/flutter n(%) - 5 (2.5)
Bradycardia n(%) - 4 (2)
Chest pain without ST depression n(%) - 24 (12)
Dyspnoea n(%) - 3(1.5)
Nausea n(%) - 7(3.5)
Headache n(%) - 2(1)
Shivering n(%) - 1 (0.5)
Dizziness n(%) - 1 (0.5)
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Figure 1 Screened 
548
Ineligible 
112
Refused consent 
89
Eligible 
436
Inadequate
echocardlographic windows 
73 (21.0%)
Feasible 183(88.4%) 
THR without RWMA : 27 
NewRWMAatTHR : 56
(Incl 3 with sustained VT) 
New RWMA below THR : 93 
(lnc!2withSTEMI
1 with sustained VT 
5 with angina + ST depression) 
Angina + ECG change : 5 
Maximum dose : 2
Early termination 24(11.6%)
Deterioration of image : 9*
NSVT without ischaemia :7
Hypotension : 6
Hypertension : 2
General frailty 13 
Spinocerebellar 
degeneration 1 
Malignancy 2
Lost data in storage 
Poor endocardial definition 
Non-identical images 
Incomplete image set
Data Interpretable 
174
6 
6 
7 
5
HF-LVSD 
89
HF-NEF 
41
No HF/No LVSD 
43
No HF/LVSD 
1
'These patients excluded from the final analysis
Critical Aortic Stenosis 26
Mechanical valves 7
AF (uncontrolled VR) 5
Ml within 2 weeks 5
Non-sustained VT 3
Severe hypertension 3
Large pericardial effusion 3
Critical Mitral Stenosis 2
Primpulmonaryhypertension 2
Ascending aortic aneurysm 1
Hypertrophic cardiomyopathy 1
AF (fast heart rate) 20(7.3%) 
Awaiting ICD implant 2(0.7%) 
BiV Pacemakerimplanted 2(0.7%) 
Patientrequest(veryearly) 12(4.4%)
anxiety 3(1.1 %)
back pain 4(1.5%)
breathlessness 3(1.1 %)
hip spasm 2(0.7%) 
Resting Hypertension 11(4.0%) 
Resting Hypotension 9(3.3%) 
P ersistent N YH A 111 sympto m 8(2.9%) 
No Venous access 2(0.7%) 
Metastatic Malignancy 1(0.4%)
Figure 4.1. The journey of the screened patients through the study.
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Figure 4.2. Prevalence of HF symptoms, systolic and diastolic left ventricular 
impairment at rest in the recuited population.
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Figure 4.3. Proportion of segments that could be assessed visually (plain bars) and 
quantitatively (dotted bars) overall, _ at rest, _low dose _ and peak dose I of
dobutamine in the HF-LVSD, HFNEF and No-HF groups.
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Figure 4.4. A: % of instances where a wall motion of a segment could be assessed 
visually only, TDI only and neither. B: % of segments where a wall motion 
response could be assigned visually only, TDI only and neither.* p<0.01, "kp<Q. 05, 
A p=ns versus visual.
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Figure 4.5. Panel 1: A. Instances where TDI could and could not assess segments 
that could not be visually assessed. B. Instances where segments that could not be 
assessed by TDI, could and could not be visually assessed. Panel 2: A. Instances 
where segmental response to stress could and could not be assigned using TDI in 
segments that could not be visually assessed. B. Instances where segmental 
response to stress could and could not assigned visually in segments that could 
not be assessed by TDI.
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Chapter 5: Dobutamine Stress Echocardiography with colour tissue Doppler 
imaging in an unselected population of patients with suspected heart failure.
ABSTRACT
Background: Exercise commonly induces or exacerbates symptoms in subjects 
with suspected heart failure. Guidelines recommend resting echocardiography for 
assessment of cardiac function in these patients. This is likely to miss stress- 
induced left ventricular dysfunction that may be the aetiology of the symptoms in 
patients with normal resting ejection fraction.
Method and results: 209 of 274 patients with suspected heart failure underwent 
DSE with cTDI. DSE was fully analysable in 174 patients (90 with HF and left 
ventricular systolic dysfunction (HF-LVSD), 41 with HF and normal ejection fraction 
(HFNEF) and 43 with no HF (NoHF)) with 89% feasibility. Prognostically significant 
improvement in global, regional and long-axis function was seen in dysfunctional 
ventricles in all three groups. Stress impairment in Ea was seen in the HFNEF but 
not the other groups with associated increase in the E/Ea ratio. The transmitral 
Doppler failed to detect any difference in the diastolic function with stress. LV 
outflow tract gradient increased with stress.
Conclusion: DSE can only be applied to a selected population of patients that are 
referred to a heart failure clinic. It reveals findings that are not seen at rest but may 
have therapeutic and prognostic implications. The increase in the LVEDP with 
stress in patients with HFNEF may explain the exercise intolerance in this group of 
patients. The therapeutic and the prognostic implication of these findings need to 
be tested in outcome studies.
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INTRODUCTION
Resting echocardiography has conventionally been the mainstay of assessment of 
patients with suspected HF.(1) Confirmation of the diagnosis of HF has been 
straightforward in patients with LVSD. However, the diagnosis of HF has been 
difficult to confirm or exclude in an estimated 1-3% of the Western European 
population with symptoms suggestive of HF but normal LVEF at rest. (15) 
Considerable uncertainties in the diagnosis of HF, has been reported in this group 
of patients in primary and secondary. (20;34)
Multiple cardiovascular pathologies that may result in HF may or may not give rise 
to abnormal LV function at rest or affect conventionally measured LVEF. These 
pathologies are likely to be highly prevalent in patients with suspected HF. 
Although symptoms in patients with suspected HF are often absent at rest and 
almost universally induced or exacerbated by exercise, most studies, and indeed 
the current guidelines have focused on assessing cardiac function at rest.(1) This 
strategy may be inadequate in the assessment of patients with suspected HF. 
Resting echocardiography may be sufficient to confirm HF secondary to LVSD, 
but it often fails to suggest an aetiological diagnosis or provide prognostic 
information. On the other hand, the very diagnosis of HF is put to jeopardy in 
the presence of symptoms without abnormal LVEF on resting echocardiography. 
The genesis of symptoms in these patients may be related to transient but 
extensive changes in global or regional systolic or diastolic dysfunction induced 
by exercise. Resting echocardiography potentially leaves a proportion of these 
patients undiagnosed.
Thus evaluation of cardiac function under stress in patients with suspected HF 
could potentially delineate the role of exercise induced stress in the genesis of 
their symptoms. It would potentially identify ischaemia as aetiology of LVSD in 
patients with low LVEF and as the cause of breathless in those without. It would 
detect viability or the lack of it in dysfunctional segments of impaired ventricles. 
It would also unmask changes in LV global or regional systolic or diastolic 
function in response to stress in patient with normal LVEF.
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In the present study the effect of pharmacological stress on the prevalence and 
severity of the abnormalities of cardiac function that could cause or contribute to 
the symptoms of HF in an unselected population of subjects suspected of having 
heart failure was studied. Conventional DSE supplemented by cTDI was used in 
this assessment.
METHOD
Patient selection
All consecutive subjects with a suspected diagnosis of HF who underwent DSE
were included for the study. These patients were selected from a screened cohort
assessed in a community-based heart failure programme as described in Chapter
4. Written informed consent was obtained. Medical Ethics Committee of the Hull
and East Yorkshire NHS Trust approved the protocol.
Patients with LVEF <45% and HF were designated as HF-LVSD group, LVEF 
>45% and HF as HFNEF group and LVEF >45% and no HF as NoHF group. One 
patient, with asymptomatic LVSD was considered in HF-LVSD.
Clinical evaluation
All subjects underwent a routine clinical examination, 12-lead ECG, chest X-ray, 
pulmonary function test (hand held spirometry) and six-minute hall walk. 
Demography, medical and drug history and cardiovascular risk factors were 
recorded. Hypertension was defined as a previous blood pressure recording on two 
separate occasions of >140 mmHg systolic or >90 mmHg diastolic or the ongoing 
prescription of anti-hypertensive medication. Myocardial infarction was defined 
according to World Health Organisation criteria. Ischaemic heart disease was 
defined as a history of myocardial infarction, unstable angina or angiographic 
evidence of >50% stenosis of one or more coronary arteries with or without a past 
history of revascularisation. Patients underwent physical examination, a 12-lead 
ECG, chest X-ray and pulmonary function tests. Body mass index (BMI) >25 was
94
considered overweight and that >30 as obese. Airways disease was diagnosed if 
FEV1/FVC ratio was <75%.
A standard echocardiographic examination was undertaken. LV mass, chamber 
volumes and ejection fraction were measured. (118) Left ventricular hypertrophy 
(LVH) was defined as LV mass index >134 gm/m2 in men and >110 gm/m2 in 
women and LVSD as LV ejection fraction of <45%. LVSD was considered 
moderate-to-severe if resting WMSI was >1.6. Diastolic volume index >75 ml/m2 
and systolic volume index >30 ml/m2 were considered abnormal. (118) The E, A, 
EOT and IVRT were measured. LV diastolic dysfunction was defined as per age 
related normal values. (66) Impaired diastolic compliance was defined as E/A>1.7 
and EDT<138 msec. Pseudonormalisation of the E/A ratio was diagnosed in the 
presence of reversed Ea/Aa ratio. The peak systolic velocity was measured using 
the pulse wave Doppler sample volume at the LVOT.
Stress echocardiography
Subjects underwent DSE using standardised dobutamine-atropine protocol 48 
hours after stopping beta-blockers. The image acquisition is described in detail in 
Chapter 4.
Hibernation in >4 or >6 segments of myocardium was considered to be prognostic. 
(172;316) Contractile reserve (CR) was defined as the change in WMSI (AWMSI) 
i.e. the difference between the resting and low dose WMSI. Improvement in WMSI 
>0.2 and 0.4 were considered prognostic. (26;317) CR at low dose was also 
determined as the ratio of number of segments with improved wall motion scores at 
low dose to the number of segments scored at this dose expressed as a 
percentage. The proportion of patients with contractile reserve in at least 25% of 
ventricular myocardium was also determined. (318)
The IVRT and EOT were corrected for heart rate using the Bazett's formula to 
compare observations at rest and peak stress {EDTc=EDT(msec)/VR-R(sec)}. The 
LVOT maximum velocity £2.5 m/sec was considered raised.
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Resting averaged periannular Sa <2.8 cm/sec was considered prognostically 
abnormal. (319) The velocities were considered "abnormal" at rest if it was 
<mean+2SD of published normal value for that segment for that age. (212) At each 
wall ASa (the difference between mitral annular velocity at rest and at low dose of 
dobutamine) was calculated. An increase in the Sa >1 cm/sec from rest to low- 
dose dobutamine in walls with low resting velocities was considered to denote 
"significant viability". (268) A segment was identified being abnormal at peak stress 
if the Sm was £ 5.5 cm/sec. (255) A segment was labelled "normal" if the velocity 
was normal at rest and increased at peak stress, "ischaemic" if velocity decreased 
or failed to increase at higher dose and "scar" if the velocity was abnormal at rest 
and did not change with stress. The response was considered "biphasic" if a 
segment that was abnormal at rest improved at low dose and then worsened at 
high dose. These segments were designated viable and ischaemic.
Ea/Aa<1 was considered abnormal. The mitral inflow pattern was considered 
"pseudo-normalised" if the Ea/Aa ratio was <1 in the presence of a normal E/A ratio. 
E/Ea were calculated. E/Ea at rest, (191;204) and stress (183; 192) was used as an 
estimate of the LVEDP. As velocities measured by cTDI are 20% less than that 
measured by pulse-wave TDI, (320) the measured Ea was corrected to obtain the 
corresponding value in pulse-wave TDI. The E/Ea was then calculated at rest and 
stress using these new values. E/Ea<8 was considered normal, 8-15 was 
intermediate and >15 was high. (193)
Reproducibilitv
As described in Chapter 4.
Statistical analysis
As described in Chapter 4.
RESULT
274 subjects were referred for DSE. DSE was done in 207 (76%). Test end-points 
were reached in 183 (88.4%). (Figure 1) DSE data was completely analysable in 
174 (83.3%) subjects: HF-LVSD group (n=90), HFNEF group (n=41) and NoHF
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group (n=43). All subsequent analysis pertains to these patients. Table 1 describes 
the baseline characteristics of the population.
Resting Echocardiography (Table 2)
The mean LV mass was highest in the HF-LVSD group. WMSI was >1 in 41-49% 
patients without LVSD. The A velocity could not be measured in 24.4%, 21.9% 
and 7.0% patients in the three groups respectively due to AF during imaging 
(p=0.054). LV diastolic dysfunction was common (about 50%) in the three groups. 
6.7% patients of the HF-LVSD group had restrictive LV filling. Low Sa and Ea were 
most prevalent and reversed Ea/Aa was least prevalent in HF-LVSD group.
Systolic function (global) 
WMSI and Sa (figure 2 and 3)
WMSI was higher in the HF-LVSD group compared other groups at rest and all 
levels of stress with no differences between the HFNEF and NoHF groups. WMSI 
improved with low dose dobutamine in the HF-LVSD (2.27±0.49 v 2.01±0.54, 
p=0.001) and NoHF (1.15±0.24 v 1.03±0.11, p=0.005) groups but not in the 
HFNEF (1.15±0.25 v 1.01 ±0.04, p=0.39) group. The Sa in the HF-LVSD group was 
lower than in others both at rest and peak stress with no differences between the 
HFNEF and NoHF groups. The Sa increased with stress in all the three groups. 
The increase in the Sa from rest to peak stress was 2.15±1.60 cm/sec in the HF- 
LVSD group (p=0.018 v normals and p=0.009 v HFNEF), 2.85±1.37 cm/sec in 
HFNEF (p=0.731 v normals) and 2.95±1.75 cm/sec in the normal group (p=0.006, 
Single factor ANOVA).
The prevalence of abnormal WMSI and Sa and its change with stress are 
described in figure 3. Resting WMSI was >1 in 73.6% patients overall, 71.1% of 
whom improved with low dose dobutamine. Of the 82 (47%) ventricles with resting 
WMSI >1.6, 61(74.4%) improved with low dose dobutamine. WMSI decreased by 
>0.2 in 50.0%, 23.5% and 47.6% of the ventricles that were abnormal at rest in the 
HF-LVSD, HFNEF and NoHF groups (p=0.132). It decreased by >0.4 in 32.2%, 
17.6% and 28.6% in the three groups (p=0.132). Normal Sa at rest was least 
frequently seen in the HF-LVSD group (p<0.001). Sa improved in 80.4% of patients
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with reduced velocities at rest, overall. Of the 67.8%, 24.4% and 25.2% walls that 
had low Sa at rest in the HF-LVSD, HFNEF and normal groups, 60.9%, 65% and 
58.5% improved by >1 cm/sec with low-dose dobutamine respectively suggesting 
"significant viability" in these walls.
Systolic function (Regional) 
WMS and Sm (figure 3)
The segmental wall motion response to stress could be characterised in 94.1% 
segments. The rest are excluded from further analysis. Of the dysfunctional 
segments at rest, 41.6%, 54.4% and 94.7% in the HF-LVSD, HFNEF and NoHF 
groups respectively showed viability with low dose dobutamine and 35.8%, 54.4% 
and 93.4% subsequently became ischaemic at peak dose. The rest showed 
sustained improvement. Of the dysfunctional segments at rest, 28.4%, 19.6% and 
1.3% in the HF-LVSD, HFNEF and NoHF groups respectively were scars. Of the 
segments that were normal at rest, 32.9%, 4.7% and 8.3%segments were 
ischaemic in the three groups
Of the patients with WMSI>1 at rest, 57.8% patients in the HF-LVSD group had 
viability in >4 dysfunctional segments compared to 23.5% in the HFNEF group and 
33.3% in the normals (p=0.01). Viability was seen in > 6 dysfunctional segments in 
38.9%, 17.7% and 33.3% patients in the three groups respectively (p=0.239). Of 
the patients with WMSI>1, contractile reserve was seen in 82.2%, 64.7% and 
76.2% patients in the HF-LVSD, HFNEF and normal groups respectively (p=0.253) 
and contractile reserve of > 25% was seen in 42.2%, 17.7% and 14.3% patients 
(p=0.016).
The median number of segments that were normal, reversibly abnormal (i.e. had a 
viable, ischaemic or biphasic response) and irreversibly abnormal (i.e. scarred) 
was 1 (range 0-14), 8 (range 1-16) and 4 (range 0-15) in the HF-LVSD group 
compared to 14 (range 5-16), 0 (range 0-8) and 0 (range 0-5) in the HFNEF group 
and 13 (range 1-16), 1 (range 0-12) and 0 (range 0-1) in the NoHF respectively.
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Sm could not be measured on 181 (2.9%) occasions. The segments without 
response characteristic were excluded. Amongst the segments that were 
dysfunctional at rest, 83.3%, 85.2% and 84.2% in the three groups respectively 
were viable (p=0.892) and 17.9%, 14.8% and 8.9% segments (p=0.071) showed a 
biphasic response. An ischaemic response was seen in 33.7%, 27.9% and 30% of 
the segments that were normal at rest and 5.6%, 5.7% and 6.9% of the segments 
that were abnormal at rest in the three groups respectively.
Mitral Inflow (Figure 4)
E/A became abnormal with stress in 65%, 25% and 36% of the patients (p=0.045) 
who were normal at rest and remained abnormal in 81%, 67% and 73% patients 
(p=0.499) who were abnormal at rest in the HF-LVSD, HFNEF and NoHF groups 
respectively. E/A was pseudonormalised in 29.4%, 56.3% and 62.5% in the three 
groups (p=0.001) at rest and 21%, 71% and 56.4% patients at peak stress 
(p=0.000). The prevalence did not change with stress (p=0.269 in HF-LVSD, 0.225 
in HFNEF and 0.581 in NoHF).
EOT failed to shorten with stress in 34.4%, 43.9% and 30.2% patients in the HF- 
LVSD, HFNEF and NoHF groups respectively. The EDTc increased with stress in 
52.2%, 58.5% and 53.5% (p=0.795, HF-PLVF v normal, p=0.641) patients in the 
HF-LVSD, HF-PLVF and NoHF groups and decreased in the rest. Amongst 
patients with high EDTc at rest, it increased further with stress in 21.7% 28.6% and 
38.9% patients (p=0.486), decreased to above normal range in 13.0%, 14.3% and 
16.7% patients (p=0.948) in the HF-LVSD, HFNEF and No-HF group respectively. 
No one in the NoHF group had low EDTc at rest. Amongst patients with low EDTc 
at rest, it decreased further with stress only in the HF-LVSD group.
IVRT was normal at rest in 47.8%, 65.9%, 58.1% patients in the three groups 
(p=0.135). It failed to shorten with stress in 21.1%, 46.3% and 34.9% patients in 
the three groups (p=0.011, HFNEF v normal, p=0.285). IVRTc increased in 55.0%, 
67.5% and 58.1% patients (p=0.413, HFNEF v normal, p=0.513) in the three 
groups. IVRTc increased to >105 msec in 54.8%, 56.3% and 62.5% patients 
(p=0.878) with resting IVRTc<105 msec in the three groups. Amongst patients with
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IVRTc>105 msec at rest, it decreased to <105 msec in 28.8%, 28% and 14.8% 
patients (p=0.357).
The E/A ratio decreased in the HF-LVSD group but did not change with stress in 
the other two. The IVRTc did not change in the HF-LVSD group but got prolonged 
in the other two. EDTc however did not change with stress in any group.
Mitral annular diastolic velocity (Figure 4 and 5)
The Ea could be measured in all patients at rest. The average peri-annular Ea was 
lower than normal at rest in 24.4%, 4.9% and 2.3% in the three groups respectively 
(p=0.000). Amongst the patients with normal Ea at rest, it decreased with stress in 
20.6%, 69.2% and 42.9% in the HF-LVSD, HFNEF and NoHF group respectively 
(p=0.000, p=0.017 HF-PLVF v NoHF group) and increased in the rest. The Ea 
decreased by >20% in 11.1%, 31.7% and 20.9% patients in the three groups 
respectively (p=0.016, HFNEF v NoHF, p=0.261) while it increased by > 20% in 
61.1%, 9.76% and 30.23% in the three groups respectively (p=0.000, HFNEF v 
NoHF, p=0.02).
Ea/Aa could be measured in >70% patients at rest and peak stress. Ea/Aa was <1 
in 71.4%, 84.4% and 85% patients in the three groups (p=0.171) at rest and 84.1%, 
90.6% 89.7% under stress (p=0.576) (p for rest v stress: 0.086 for HF-LVSD, 0.450 
for HFNEF and 0.526 for NoHF). Of the patients with Ea/Aa>1 at rest, it decreased 
to <1 in 66.7%, 60% and 83.3% (p=0.324) patients in the three groups with stress. 
Ea/Aa increased to >1 with stress in 8.9%, 3.7% and 8.8% (p=0.681) of the 
patients with Ea/Aa<1 at rest, in the three groups.
•
The mean Ea velocity in the HF-LVSD group was lower than HFNEF group that 
was similar to the normal group at rest. At peak stress, Ea in the HFNEF group 
was lower compared to the normal group but was similar to the HF-LVSD group. In 
the HF-LVSD group, Ea and Aa increased with stress and their ratio remain 
unchanged. In the HFNEF group, Ea decreased, Aa increased but their ratio does 
not change. In the normal group, Aa increases but there are no changes in the Ea 
or Ea/Aa. It decreased with stress in the former but not in the later group.
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Left atrial pressure
E/Ea could be measured in 98.9%, 97.6% and 100% patients at rest and 95.6%, 
100% and 100% patients at stress in three groups. 5.4%, 52.2% and 25% of the 
patients that had normal resting E/Ea in the HF-LVSD, HFNEF and NoHF groups, 
had high E/Ea at peak stress. (Figure 4) Among the patients with high E/Ea ratio at 
rest, it remained high at peak stress in 43.3%, 92.2% and 87.6% patients in the 
HF-LVSD, HFNEF and NoHF groups. E/Ea decreased to normal in 46.7%, 7.8% 
and 12.4% patients in the three groups.
At rest, E/Ea HF-LVSD>HFNEF=NoHF (HF-LVSD v HFNEF and NoHF, p=0.000) 
and HFNEF v NoHF, p=0.391) (figure 5). At peak stress, the E/Ea in the HF-LVSD 
group was similar to the other groups (p=0.128 v HFNEF, p=0.206 v NoHF group) 
with HFNEF>NoHF (p=0.002). With stress, E/Ea decreased in HF-LVSD (0.000), 
increased in HFNEF (p=0.002) and remained unchanged in NoHF group (p=0.598)
In the HF-LVSD group, most patients had E/Ea >15 at rest and 8-15 at stress. Most 
HFNEF patients had E/Ea 8-15 at rest and >15 at stress. Most NoHF had E/Ea 8- 
15 at rest and stress. In the HF-LVSD group the prevalence of E/Ea 8-15 increased 
and that of >15 decreased with stress. In the HFNEF group prevalence of E/Ea 
>15 increased with stress. (Figure 6A). More than 70% of the patients in the HF- 
LVSD and HFNEF groups with resting E/Ea<8, worsened with stress compared to 
43% in the NoHF group. All HFNEF and 89% of NoHF patients with resting E/Ea 8- 
15 either remained so or worsened and 39% of HF-LVSD and 11% of NoHF 
patients improved with stress. Of the patients with resting E/Ea ratio >15, 44% 
improved in the HF-LVSD group compared to 8% and 12.5% in the HFNEF and 
NoHF groups (figure 6B).
LVOT gradient
The velocity could not be measured in 1 patient in the HF-LVSD group and 2 in the 
HFNEF group at peak stress. The maximum velocity (Vmax) was £1.5 m/sec in 
2.3%, £2.0 m/sec in 0.6% and > 2.5 m/sec in 0% patients at rest and 36.3%, 14.0% 
and 5.8% patients at peak stress. None, 20.5% and 4.7% of patients in HF-LVSD,
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HFNEF and NoHF had Vmax >2.5 m/sec at peak stress (p<0.001). Vmax 
increased with stress in 87.6%, 97.4% and 100% patients (p=0.016) and increase 
was >20% in 66.3%, 84.6% and 88.4% (p=0.007) in the three groups. The average 
velocity in the HF-LVSD group was lower than both the other groups at rest and at 
peak stress (p<0.05, ANOVA) with no difference between the HFNEF and NOHF 
groups. It increased with stress in all the three groups (p<0.001 for all three 
groups).
DISCUSSION
Evaluation of subjects with suspected heart failure using TDI supplemented DSE 
has identified new or worsening regional, global and long axis systolic and diastolic 
dysfunction. Prognostic volumes of dysfunctional but viable myocardium was found 
not only in those with reduced LVEF but also in those without. The improvement of 
overall LV function, as measured by WMSI, with LDDSE matched these changes. 
The prevalence of hibernating myocardium in patients with HF and LVSD was 
similar to that previously reported. (321;322) These findings may have prognostic 
significance. In medically treated patients with post-infarction LVSD, the extent of 
hibernating myocardium, determined either by the degree of improvement of WMSI 
or by the proportion dysfunctional segments that improve with LDDSE, predicts 
survival. (323) The extent of myocardial hibernation and/or ischaemia determines 
the improvement in LVEF in patients with ischaemic and non-ischaemic 
cardiomyopathy treated with carvedilol (324-326) and bucindolol. (327) In a meta- 
analysis where half of the patients had their viability tested using DSE, 
revascularisation offered a higher prognostic benefit compared to medical therapy 
for patients with chronic CAD and LVSD with viable myocardium while absence of 
viability was associated with no significant difference in outcomes, irrespective of 
treatment strategy. (115) The extent of hibernating myocardium predicts survival, 
improvement in LVEF and functional status after revascularization in chronic 
ischaemic LVSD. (173;176;316-318) Contractile reserve however, did not predict 
outcome in one study. (318) Ischaemia was detected in 35%, 6% and 10% of 
dysfunctional segments in the three groups. Myocardial ischaemia detected by 
DSE was predictive of cardiac death in ischaemic cardiomyopathy treated 
medically after adjustment for LVEF in some (175;323;328) but not all studies.
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(318;329) The prevalence of coronary disease is between 5-67% in patients with 
HFNEF. Studies with higher prevalence of CAD reported higher annual mortality 
rate in contrast to those that excluded patients with coronary disease. 84 Despite 
this high prevalence of CAD, there is paucity of data on the extent of hibernation in 
patients with normal LVEF presenting with symptoms suggestive of heart failure.
The trans-mitral variables of LV diastolic function that either became abnormal or 
continued to remain abnormal with stress were common in all the three groups. 
This is consistent with some (77;80;186) but not all studies. (75;76) The 
interpretation of these changes during DSE is constrained by the influence of 
multiple factors on these variables during various stages of the test. These 
variables are influenced not only by the relaxation properties of the myocardium in 
diastole but also by the pre- and after-load of the ventricle, age and sex of the 
subjects, presence or absence of LV hypertrophy, heart rate, intraventricular 
conduction abnormalities, PR interval etc. During dobutamine stress testing, many 
of these factors are altered depending on the stage of the test making rest-stress 
comparisons difficult. Lowering of after-load due to the vasodilatory effects of low 
dose dobutamine may "truly" improve an abnormal resting diastolic filling pattern. 
Increase in the left atrial pressure due to stress-induced ischaemia may 
pseudonormalise the resting delayed relaxation pattern. These may underestimate 
the prevalence of diastolic abnormality at peak stress. Trans-mitral velocity that 
measures global LV diastolic function may not be altered if only small areas of 
regional dysfunction are induced with stress. Fusion of the E and A waves and 
shortening of the diastolic timings at higher heart rates are additional problems.
Sa and Sm are well-established indices of longitudinal LV global and regional 
systolic function. (213;330;331) Resting Sa <2.8 cm/s predicted survival in patients 
with LVSD. (319) Basal Sm at peak stress of <6 cm/s predicted cardiac death and 
non-fatal infarctions in patients with known or suspected coronary artery disease, 
60% of whom had resting RWMA. (332) Investigators have reported the ability of 
Sm to identify dysfunctional segments with fair degree of accuracy. Sm (cTDI) of 
the non-apical segments of ^ 5.5 cm/sec at peak stress identified visually abnormal 
segments 96% sensitivity, 81% specificity and 86% accuracy irrespective whether
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the segment was basal or mid-wall. (255) Sm (pTDI) <12cm/s distinguished 
ischaemic from non-ischaemic segment with sensitivity and specificity of 86% and 
96% for the basal regions, and 81% and 89% for the mid segments. A percentage 
increase in Sm of <90% from rest to peak identified ischaemic segments from 
normal segments with a sensitivity and specificity of 83% and 87%, respectively. 
(188) TDI is able to detect improvements in the velocity of contraction earlier than 
that possible visually, (254) making it a sensitive tool for detection of viability in 
hypocontractile segments with low dose DSE. (333;334) Rambaldi et al 
demonstrated that improvement of systolic velocity, measured by pTDI, of 1±0-5 
cm/s predicted myocardial viability confirmed with F18-fluorodeoxyglucose-SPECT, 
with a sensitivity of 87% and a specificity of 52%. (268)
Ea, an index of diastolic relaxation at rest (202;335;336) and during sinus 
tachycardia (183) is relatively load independent (193;202;204;209) making it more 
suitable for assessment of such function during DSE. However, this has rarely 
been assessed during DSE. (185; 188) The response of Ea to stress is influenced 
by a number of physiological processes often with opposing effects. Sa and Ea are 
positively and non-linearly correlated across a wide range of LVEFs at rest. (61;62) 
This is due to the inter-dependence of the systole and diastole. During systole, the 
longitudinal shortening and "twisting" motion of the myocardial fibres compresses 
the elastic cardiac elements generating potential energy that is stored within the 
coiled fibres of the myocardium. This creates early diastolic restorative forces that 
produce diastolic recoil that contributes to the Ea velocity. It is thus conceivable 
that inotropic stimulation during dobutamine stress would result in a parallel 
increase in both the Sa and Ea. The lusitropic effect of dobutamine is also likely to 
increase in the Ea velocity. On the other hand, dobutamine stress induced 
ischaemia, hypertension and tachycardia may impair diastolic relaxation and 
reduce Ea. Stress-induced ischaemia impairs both regional (184;185;188) and 
global left ventricular diastolic relaxation (77;80) and this occurs earlier than the 
impairment of systolic contraction. (187) Even transient, reversible episodes of 
ischaemia can impair LV relaxation and elevate LV filling pressures (74) Ischaemia 
induced by dobutamine stress (188) and coronary occlusion (81) causes regional 
impairment of myocardial relaxation of ischaemic segments even when systolic
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contraction is preserved. (79) Stress-induced tachycardia worsens ischaemic 
diastolic relaxation by increasing myocardial oxygen demand and decreasing 
coronary perfusion time. It shortens the diastole allowing less time for relaxation. 
This is further amplified in hypertrophied and fibrosed myocardium that is unable to 
generate a higher rate of diastolic relaxation causing the diastolic pressures to 
increase. (85; 189) Stress-induced elevation of systolic blood pressure, slows LV 
relaxation due to increased afterload with a resultant increase in the LA pressure. 
(82) In hypertensives, a rapid increase in SBP at rest 94 or following exercise (183) 
results in deterioration of LV diastolic function without worsening systolic function. 
Similar changes in response to stress have been demonstrated in patients with 
HFNEF. (84) Sa and Ea increased with stress in HF-LVSD group. This is likely to 
have resulted from the inotropic and lusitropic effect of dobutamine. As Ea was 
measured at submaximal stress to avoid the problem of fusion, significant 
hypertension and tachycardia are unlikely to have affected it. The degree of 
ischaemia at these stages was also likely to be low but probably severe enough to 
impair diastolic but not systolic function. The effect of dobutamine induced 
augmented systole may have overridden the negative effect of low-grade 
ischaemia on Ea resulting in net increase of Ea. On the other hand, Sa increased 
and Ea decreased with stress in the HFNEF patients. The difference in the 
ultrastructural and functional properties of the myocardium between these groups 
(337-344) may have affected this diverse response. The low-grade hypertension 
and tachycardia at submaximal stress, when Ea was measured, may have been 
enough to reduce Ea in the presence of an abnormally relaxing myocardial 
substrate. The effect of ischaemia on diastolic function may also have been 
intensified in the presence of such a substrate.
In the HFNEF group, most patients with high resting E/Ea ratio remained so at 
stress while it worsened in 70% of patients who were normal at rest. The E/Ea 
increased with stress in a substantially more patients in the HFNEF group than in 
the NoHF group. This is consistent with invasive findings of impaired diastolic 
relaxation and a rise in the left atrial pressure during exercise in patients with 
HFNEF. (183)
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In the NoHF group, the E, Ea, Aa increased with stress with no change in the E/Ea 
or Ea/Aa ratios. This response was similar to that of normal subjects. (194)
LIMITATIONS
Pharmacological rather than exercise stress was used in this study. Exercise being 
the most physiological stressor would have been preferable. Supine bicycle 
ergometry was not available. Treadmill exercise, the available form of exercise 
stress in our setting, has several limitations. Only 40% of patients tested for CAD, 
can perform a truly diagnostic exercise test. (101; 102) This proportion is likely to be 
even lower in the elderly patients, with musculoskeletal or neuromotor problems, 
general frailty and breathlessness, that were studied. The heart cannot be 
continuously imaged. Thus the time of onset of ischaemia and changes in the 
cardiac function at each level of exercise cannot be precisely identified. Myocardial 
viability, a prognostically important component of left ventricular evaluation in 
patients with heart failure, cannot be assessed. Ischaemia induced wall motion 
abnormalities may resolve if imaging is not completed quickly after the completion 
of exercise. Even under "study" conditions, about a third of new RWMA that 
develop at peak exercise may resolve by the time images were acquired after 
exercise. About 29% patients may be missed if imaging is performed only after 
exercise. (105) In 31% of patients with positive exercise echocardiography, the 
new RWMA at peak exercise resolved at post-exercise imaging obtained within 80 
seconds of exercise termination. (106) It was envisaged that imaging was unlikely 
to be completed in a significant proportion of the subjects studied within 60-90 
minutes of completing exercise. However, as both exercise and dobutamine have a 
similar accuracy for the detection of coronary disease; (107-109) it was felt that 
DSE would not be inferior to exercise for studying the patients with suspected heart 
failure.
The procedural limitations affecting DSE and cTDI influenced the study. The 
absence of universally accepted gold standard definition of LV diastolic dysfunction 
and the influence of heart rate and loading conditions on the diastolic mitral inflow 
velocities made interpretation if these changes difficult. These variables had to be 
assessed at sub-maximal stress to avoid fusion of the diastolic velocities. This was
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considered reasonable, as these breathless patients are unlikely to achieve age- 
predicted maximal heart rates during daily living. Moreover, sub-maximal stress is 
likely to be adequate to unmask LV diastolic dysfunction as the later is induced by 
ischaemia earlier than systolic dysfunction. The E/Ea measured using cTDI is 
higher than previously reported with pTDI. (20;345) The conversion used (21) may 
be somewhat arbitrary. Without measured NT-proBNP the diagnosis of heart 
failure in patients with normal ejection fraction was clinical.
The study groups were not compared to "true" healthy controls. The mean age of 
the HFNEF and the NoHF groups was similar. A proportion of patients with HFNEF 
who were very elderly may not have been recruited, as seen in other research 
studies, driving down the mean age in this group. The prevalence of diabetes, 
hypertension, COPD and LV hypertrophy all of which may affect diastolic function 
was also similar. This resulted in similar prevalence of resting LV diastolic 
dysfunction in these groups as reflected in the measured echocardiographic 
variables.
The therapeutic and prognostic implications of the findings in this heterogeneous 
group of patients were not tested. However, studies on better-defined populations 
suggest that the implications are likely to be significant.
CONCLUSION
TDI supplemented DSE is feasible only in a very selected group of patients that are 
referred to a heart failure clinic. It reveals information on cardiac function that is not 
identifiable at rest but have diagnostic, therapeutic and prognostic implications. 
DSE may be especially useful in evaluating patients with symptoms suggestive of 
heart failure but normal ejection fractions. The increase in the LVEDP with stress in 
patients with HFNEF may explain the exercise intolerance in these patients. The 
therapeutic and prognostic implication of the data in a heterogeneous group of 
subjects with suspected heart failure needs to be tested in larger outcome studies.
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Table 5.1 Baseline characteristics of the study population
Age (years) (meaniSD)
Age (yrs) range (median)
Males (%)
BMI (mean+SD)
NYHA (I/II/III/IV) (%)
Risk factors for CAD
H/O Smoking (%)
Diabetes (%)
Family history (%)
Hypertension (%)
History of
Angina (%)
Revascularisation (%)
Myocardial infarction (%)
Valvular disease (%)
COPD (%)
Drugs
Loop diuretics (%)
ACEIorARB(%)
Beta-blockers (%)
Aspirin (%)
Wafarin (%)
Spironolactone (%)
Systolic BP (mmHg)
Diastolic BP (mmHg)
6-min walk test (m)
Sinus rhythm (%)
Heart Rate
HF-LVSD 
(n=90)
68±9
43-88(69)
80.0
27.4513.6
1/31/58/0
64.4
18.9
35.5
64.4
61.1
28.9
47.8
8.9
26.7
74.4
67.8
68.8
86.7
8.1
23.3
134±24
80±13
217±139
74.4
76±15
HFNEF 
(n=41)
70±11
42-86(74)
46.3
26.64±4.8
0/27/14/0
63.4
19.5
31.7
63.4
63.4
9.7
29.3
7.3
24.4
75.6
68.3
70.7
87.8
9.7
4.9
148±22
85±11
174±109
78.1
76±14
NoHF 
(n=43)
68±11
46-89(69)
51.2
26.6513.3
43/0/0/0
62.8
13.9
32.5
46.5
23.3
0.0
7.0
9.3
30.2
26.5
44.2
37.2
34.9
0.0
•
0.0
145+18
83±11
363196
90.7
75±13
HFNEF v 
NoHF (p)
0.37
-
0.05
0.99
0.00
1.00
0.79
1.00
0.30
0.00
0.03
0.03
0.95
0.87
0.00
0.08
0.01
0.00
0.11
0.34
0.50
0.47
0.00
0.65
0.69
ANOVA 
(P)
0.51
-
0.00
0.38
0.00
0.98
0.74
0.89
0.12
0.00
0.00
0.00
0.94
0.83
0.00
0.02
0.00
0.00
0.13
0.00
0.00
0.04
0.00
0.09
0.76
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Table 5,2: Resting echocardiographic characteristics
IVSd
IVSs
LVPWd
LVPWs
LVIDd (cm)
LVIDs (cm)
LV mass (gm)
LV mass index
(gm/m2)
LVH n(%)
LVEDVol (ml)
LVESVol (ml)
LVEDVIsmp
LVESVIsmp
LVEDVol high n (%)
LVESVol high n (%)
EF (mean±SD)
WMSI >1 n (%)
WMSi>1.6n(%)
E/A <0.5 (%)
E/A>1.7(%)
EOT long n(%)*
EOT short n(%)*
IVRT long n(%)
Mod-sev MR n(%)
Mod-sev TR n(%)
Mild AS n (%)
Raised PAP n (%)
LVDD %
HF-LVSD 
(n=90)
1.3±0.3
1.5±0.4
1.4±0.5
1.8±0.5
6.4±0.9
5.2±1.0
411 ±178
218±81
54 (60.0)
135±55
92±44
74±31
50±26
38 (42.2)
70 (77.8)
33+9
90 (100)
77 (85.6)
22.1
26.5
14(15.7)
20 (22.2)
48 (53.3)
34 (37.8)
17(18.9)
3 (3.3)
21 (23.3)
55.6
HFNEF 
(n=41)
1 .4±0.4
1.7±0.5
1.3±0.3
1.7±0.3
4.711.1
3.1±1.0
248+114
139±65
22 (53.7)
71 ±26
24+12
39+14
1417
1 (2.4)
2 (4.9)
66±9
17(41.4)
0
9.4
3.1
14 (34.2)
4(9.8)
14(34.2)
7 (17.0)
4(9.8)
2 (4.9)
2 (4.9)
43.9
NoHF 
(n=43)
1.310.4
1.610.4
1 ,2±0.4
1.710.5
5.0±0.9
3.5±0.8
249±95
139±54
23 (53.5)
83±33
34±17*
46±17
19±9**
3(7)
6(13.9)
60±10*
21(48.8)
0
0
2.5
13(30.2)
1(2*3)
18(41.9)
3 (7.0)
2(4.7)
2 (5.6)
2 (5.6)
53.5
HFNEF v 
NoHF (p)
0.31
0.30
0.61
0.81
0.16
0.16
0.95
0.97
-
0.06
0.00
0.06
0.01
-
-
0.00
0.50
-
-
-
-
-
0.18
0.33
0.80
0.82
0.38
ANOVA 
(P)
0.55
0.05
0.38
0.64
0.00
0.00
0.00
0.00
0.69
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.03
0.01
0.10
0.00
0.05
0.76
0.00
0.45
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Low Sa %
Low Ea %
High Aa %
Ea/Aa<1 %
Normal E/Ea %
87.8
24.4
2.2
48.9
7.8
31.7
4.9
7.3
65.8
9.8
34.9
2.3
9.3
79.1
16.3
0.70
0.56
0.70
0.35
0.38
0.00
0.00
0.17
0.00
0.32
LVIDd, LV internal diameter in diastole. LVIDs, LV internal diameter in systole. LVEDvol, LV end- 
diastolic volume. LVESvol, LV end-systolic volume. EF, ejection fraction. MR, mitral regurgitation; 
TR, tricuspid regurgitation; AS, aortic stenosis; PAP, pulmonary artery pressure. LVDD, LV diastolic 
dysfunction; EOT, E-wave decelarartion time; IVRT, isovolumic relaxation time; *age dependent cut­ 
off values.
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Feasible 183(88.4%) 
THR without RWMA : 27 
New RWMA at THR : 56
(Incl 3 with sustained VT) 
New RWMA belowTHR :93 
(lnc!2withSTEMI
1 with sustained VT 
5 with angina + ST depression) 
Angina + ECG change : 5 
Maximum dose : 2
Earlytermination 24(11.6%)
Deterioration of image : 9*
NSVT without ischaemia : 7
Hypotension : 6
Hypertension : 2
Lost data in storage 6
Poor endocardial definition 6
Non-identical Images 7
Incomplete image set 5
Data Interpretable 
174
LVSD
89
No
LVSD 
41
No
LVSD 
43
LVSD
1
AF (fast heart rate) 20(7.3%) 
AwaitinglCDimplant 2(0.7%) 
BiV Pacemaker implanted 2(0.7%) 
Patientrequest(veryearly) 12(4.4%)
anxiety 3(1.1%)
back pain 4(1.5%)
breathlessness 3(1.1 %)
hip spasm 2(0.7%) 
Resting Hypertension 11 (4.0%) 
Resting Hypotension 9(3.3%) 
Persistent NYHA III symptom 8(2.9%) 
No Venous access 2(0.7%) 
Metastat ic Ma lig nancy 1(0.4%)
* These patients excluded from the final analysis
Figure 5.1. The patient journey.
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Figure 5.2. Median, interquartile range, 95% confidence and outlying results for 
wall motion score index and mitral annular systolic velocity in the three groups at 
rest, low dose dobutamine and peak stress.^ p<0.001, ANOVA vs the other 
groups.
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WMSI
Figure 5.3. Pie-chart showing the response of the ventricles to stress in the three 
groups. WMSI and Sa are reported as % of the total number of patients studied. 
Segmental WMS and Sm are reported as % of the total number of segments 
studied. The small % of segments not accounted for include the ones that either 
could not be assessed at rest and/or stress or a response to stress could not be 
determined.
HN-N, normal at rest with normal response to stress (normal). D N-l, normal at 
rest and worsened with stress (ischaemic)D A-l, abnormal at rest and worsened 
with stress (ischaemicjP A-B, abnormal at rest with biphasic response to stress 
(viable and ischaemic)EIO A-SI, abnormal at rest with sustained improvement with 
stress (viable and non-ischaemic)S A-S, abnormal at rest with no change with 
stress (scar).
113
Ea Ea/Aa E/Ea
1DDB
rail
1DK
H
^s
s^
^sVSXV
^$$
^
^
^
1 "=1
HF4.VBI HFKF HIT
SM-D DN4 HL-D n u
•urn
o%
=1=
-s
1
S
s
1
^
1DDK
HF-LVn HFBEF BlHF HF-LVMI HF^F Mmtf
ESi-H DH-N
E/A EDTc
SSL-H HL-N HL-L
IVRTc
HIM
— ro»
1
*
4
\t
n 
i
IL-NQL-L
Figure 5.4. Changes (first letter denoting the resting and second, the stressed state) 
in the prevalence of the diastolic variable as a % of the total number of patients. H, 
high; N, normal; L, low; D, decreased; I, increased; A, abnormal
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Figure 5.6. A. Changes in the prevalence of E/Ea ratios amongst patients with 
resting E/Ea <8, 8-15 and >15 in the three groups. B. Patients with E/Ea <8, 8-15 
and >15 at peak stress as a % of patients with resting E/Ea <8, 8-15 and >15.
Chapter 6: Impaired Diastolic Reserve in Patients with Heart Failure and Normal 
Ejection Fraction. Circ Heart Fail 2009 Oct 30. [Epub ahead of print]
ABSTRACT
Background: The genesis of symptoms in patients with heart failure (HF) and 
normal ejection fraction (HFNEF) is unclear. Most investigations of HFNEF have 
focused on cardiac function at rest though most of these patients are breathless 
only on exercise. Stress induced impairment in systolic or diastolic function could 
result in these symptoms.
Method and results: Forty-one patients with HFNEF and 29 controls underwent 
DSE with cTDI. Regional wall motion score and wall motion score index (WMSI) 
and regional myocardial systolic velocity (Sm) were measured at and peak stress. 
Sa, Ea and Aa were averaged over the 6 peri-annular sites. Sa, but not the Ea, Aa 
or Ea/Aa ratio, was lower and the E/Ea ratio was higher in the HFNEF than 
controls at rest. Global, regional and long axis systolic function did not worsen with 
stress in the HFNEF group. The Ea decreased and the E/Ea increased with stress 
in the HFNEF but not in controls. The 6-minute walk distance was shorter and 
negatively correlated to the E/Ea ratio at rest and stress only in the HFNEF group. 
Conclusion: Impaired diastolic reserve resulted in stress-induced increase in the 
left ventricular end-diastolic pressure (LVEDP) in patients with HFNEF giving rise 
to exercise intolerance.
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INTRODUCTION
The clinical syndrome of heart failure may arise in the absence of any substantial 
abnormality of conventionally measured LVEF. Epidemiological studies suggest 
that up to half of subjects with heart failure have a normal LVEF.(13;29;51-53;346) 
The genesis of the symptoms of HF in the absence of reduced global LV systolic 
function is uncertain and may reflect a great deal of heterogeneity. Misdiagnosis 
may account for a proportion of cases.(55) Transient LVSD may occur due to 
ischaemia or arrhythmia (56) although serial echocardiographic studies have 
suggested that this is rare. (63) Many patients do have subtle forms of LVSD e.g. 
selective impairment of long-axis systolic and diastolic dysfunction at rest that do 
not manifest as a major impairment of global LVEF. (57;58)
Most investigations of HFNEF have focused on cardiac function at rest, yet most 
patients are breathless only on exertion. The pathophysiological basis of the 
exercise induced symptoms and signs in these patients with HFNEF has not been 
well characterised.
DSE is a standardised method of assessing the heart under stress. Using cTDI 
with DSE, global, regional and longitudinal systolic and diastolic function can be 
measured. (193;204) These techniques were used to test the hypothesis that 
stress induced diastolic impairment occurs and might contribute to exercise 
induced breathlessness in patients with HFNEF.
METHOD 
Patient Selection
Patients with a suspected HFNEF were identified from a community-based heart 
failure programme. The diagnosis of HF was based on clinical evaluation by a 
cardiologist on the basis of the patients' previous and current history and physical 
examination in concordance with the ESC definition of HF.(1) Most patients had 
previous hospital admissions with acute breathlessness, clinical and/or radiological 
evidence of pulmonary congestion and clinical improvement with diuresis. The 
patients with pacemakers, severe valvular disease, prosthetic heart valves, 
inadequate echocardiographic window and contraindication to DSE were excluded.
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From a cohort of 200 consecutive patients with suspected heart failure who were 
referred between January 2002 and June 2003, 41 subjects (HFNEF group) were 
identified who matched the study criteria. Twenty-nine other subjects without a 
history of diabetes, hypertension, angina, myocardial infarction, with normal EGG, 
echocardiogram, and whose breathlessness was thought to be due to other 
problems (13 with obesity, 8 with obstructive airways disease, 1 with restrictive 
airways disease, 5 with obesity and obstructive airways disease and 2 with 
undetermined cause) acted as controls (control group). All subjects gave written 
informed consent. The Medical Ethics Committee of the Hull and East Yorkshire 
NHS Trust approved the protocol.
Study protocol
Following clinical evaluation, resting echocardiography the patients underwent a 
DSE supplemented with cTDI using a standard dobutamine atropine protocol. The 
procedure is detailed earlier.
Statistical analysis 
As described earlier.
RESULT
Patients with HFNEF (table 1) had a higher prevalence of hypertension, diabetes 
and previous myocardial infarction and greater use of ACEI or ARB and beta- 
blockers. The mean BMI and the prevalence of obesity were similar in each group. 
The mean FEV1/FVC ratio was higher in the HFNEF group but a similar proportion 
in each group had a ratio <75%. The blood pressure and LVEF were higher on 
average in patients with HFNEF.
Reproducibilitv
The intra-observer variability for all velocities was <10% at rest (Sa: 2.4-8.1%; 
Ea:3.4-8.3%; Aa: 3.3-8.1% and Sm:3.2-9.8%) and 13% at stress (Sa: 2.1-9.3%; 
Ea:2.9-12.7%; Aa: 2.7-6.3% and Sm:4.1-12.4%). The reproducibility of the annular 
measurements was better then that of the myocardial segments.
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Response to stress
No major adverse event occurred during DSE (table 1). The final dose of 
dobutamine was higher in the controls. The blood pressures increased with stress 
in both groups. Intraobserver variability of the measured myocardial velocities 
remained low at rest (<10%) and peak stress (<15%).
The WMSI was similar in both groups at rest and at stress and did not worsen with 
stress in either group (figure 1). Fifty one percent and 59% patients at rest 
(p=0.540) and 68% and 69% patients at peak stress (p=0.952) had WMSI of 1 in 
the HFNEF and control groups respectively (p=0.115 rest v stress in HFNEF and 
p=0.412 rest v stress in controls). The increases in WMSI did not exceed 20% in 
any subject. 96.5% segments in the HFNEF group and 91.6% in controls could be 
assigned a response to stress (p<0.001). Except for a higher prevalence of scars in 
the HFNEF group, the segmental response to stress was similar in the two groups 
(table 1).
Six patients in the HFNEF group and none in the control group had low Sa at rest. 
The Sa (figure 1) was lower in the HFNEF group than the controls at rest and peak 
stress but increased with stress in both groups. Sa increased from rest to stress in 
all subjects with increase of >20% seen in 37/41 (90.2%) and 26/29 (89.7%) in 
HFNEF and controls respectively. The Sa was higher in the controls in all the walls 
at rest and most walls at peak stress. With stress, it increased in all walls in both 
groups (table 2).
The mean Sm for each non-apical segment of the HFNEF group was similar to that 
of the controls at rest and peak stress except those for the inferior basal and 
anteroseptal basal segments that were higher in the controls at peak stress. It 
increased for all the segments of both groups in response to stress (table 2). 
Amongst the segments that could be assessed quantitatively at rest (97.2% in the 
HFNEF and 98.9% in controls) Sm was low in 18.4% and 9.9% segments in the 
HFNEF and controls respectively (p=0.001). Amongst the segments that could be
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assessed quantitatively at rest and stress, the Sm decreased with stress in 27.6% 
segments in the HFNEF group compared to 28.7% in controls (p=0.727).
The averaged LVOT gradient of the HFNEF group was similar to controls both at 
rest and peak stress and increased with stress in both groups (table 2). The 
highest LVOT gradient recorded were 13.5 and 8.4 mmHg at rest and 52.1 and 
46.2 mmHg at peak stress in the HFNEF and controls respectively. The highest 
increases in the LVOT gradient with stress were 47.7 and 39.7 mmHg in the two 
groups respectively.
Conventional measures of LV diastolic function (table 2) were similar in both 
groups at rest and stress. With stress, the E/A ratio remained unchanged and the 
IVRT and EOT shortened in both groups. The heart rate corrected IVRT increased 
in the HFNEF group but not in controls and EOT did not change in either group. 
Diastolic LV dysfunction at rest was seen in 39% of subjects (14 with slow 
isovolumic relaxation and 2 with restrictive filling pattern) with HFNEF and 52% of 
the controls (15 with slow isovolumic relaxation) respectively (p=0.292).
The changes in the prevalence of the diastolic variables are shown in figure 2. E/A 
decreased with stress by >20% in 26% and 33% patients in HFNEF and controls 
respectively (p=0.53). Amongst the subjects with normal EOT at rest, it increased 
or failed to decrease in 50% in the HFNEF and 42% in controls (p=0.606). 
Amongst the patients with normal IVRT at rest, it failed to decrease in 58% and 
43% in the two groups (p=0.37).
At rest, E/Ea ratio in the HFNEF group was higher than the controls (figure 3). At 
peak stress, the Ea and Ea/Aa were lower and the E/Ea ratio higher in the HFNEF 
group compared to controls. The Ea and Ea/Aa ratio decreased and the Am and 
E/Ea ratio increased in the HFNEF group with stress. In the controls, all the 
variables remained unchanged with stress except Aa that increased.
The Ea decreased by at least 20% in 47.5% and 17.3% (p=0.009) and increased in 
the same amount in 7.5% and 24.1% (p=0.05) in the HFNEF and controls
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respectively. E/Ea ratio increased by > 20% in 72.5% and 31.0% (p=0.001) 
subjects in the two groups respectively. Amongst those whose Ea decreased with 
stress the E/Ea increased in 97.1% patients in the HFNEF group and 58.3% in the 
controls (p=0.001).
The distance walked in 6 minutes was shorter in the HFNEF group compared to 
controls. On univariate analysis, (table 3) E/Ea (p<0.001), Ea (p=0.008), E 
(p<0.001), A (p=0.028) at peak stress; E/Ea (p<0.001), EOT (p=0.045), E 
(p=0.042), A (p=0.014) at rest and age (p=0.003) correlated with the 6 minute walk 
distance.
There was a negative correlation between the distance walked and the E/Ea ratio 
at rest and stress (figure 4) in the HFNEF group.
DICUSSION
This study excludes stress-induced LVSD as a common cause of symptoms in 
patients with HFNEF. Obesity and obstructive airways disease are also unlikely to 
account for these symptoms. Impaired diastolic relaxation provoked by stress 
associated with increased LV end-diastolic pressure (LVEDP) is likely to reduce 
exercise tolerance in these patients.
The symptoms in patients with HFNEF have been attributed to obesity, respiratory 
disease and myocardial ischaemia. (55) This study does not support these 
hypotheses. High BMI and abnormal spirometry were equally prevalent in the 
HFNEF and control groups. Search for myocardial ischaemia, transient but 
extensive enough to impair global LV systolic function has rarely been undertaken 
in these patients. In most studies history of CAD, electrocardiograph^ evidence of 
myocardial infarction or ischaemia and coronary angiography has been used to as 
evidence of ischaemia. (55;89) Ischaemia was systematically evaluated in only 
1(n=20) (88) of the 11 studies (n=763) reviewed by Choudhury et al and was 
found to be absent. (89) Preserved LV systolic function during episodes of 
pulmonary oedema has been reported in hypertensives. (63) Studies have 
suggested exclusive diastolic impairment in patients with HFNEF. (90;91) In our
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HFNEF patients global, regional and long axis systolic function did not worsen with 
stress suggesting that ischaemia-induced systolic dysfunction is an unlikely cause 
of heart failure. The lack of evidence of LVSD in patients with HFNEF may be due 
to the remoteness of its estimation relative to the episode of heart failure. (52) 
Though the LV function was not assessed in relation to an episode of heart failure, 
it is unlikely that these symptoms were due to LVSD, in the absence of stress- 
induced systolic abnormalities.
Impaired LV long-axis systolic function at rest has been reported in HFNEF. 
(57;58;60) Consistent with these studies, the resting Sa was lower in the patients 
compared to controls. Baicu et al (91) argued that the impaired resting long axis 
systolic function reported in these studies (57;58;60) resulted from the inclusion of 
a substantial number of the patients LVEF <0.50 into the HFNEF group. None of 
our HFNEF patients had LVEF <0.50. Contrary to a previous report (59) the Sm of 
most segments in the two groups were similar at rest. The Sa and Sm increased 
during stress in the HFNEF group as in controls suggesting improvement rather 
than a deterioration of the long axis function with stress.
Effect of stress on diastolic function
The changes in the indices of diastolic function in the controls were consistent with 
the effects of exercise on these indices in normal middle-aged subjects. (194) The 
effect of stress on LV diastolic indices has rarely been studied in patients with 
HFNEF. Kitzman et al demonstrated a increase in LV filling pressure with exercise 
in 7 patients with heart failure and preserved systolic function. (183) Similar 
changes have been reported in normotensive patients with normal LVEF without 
inducible myocardial ischaemia and exaggerated SBP response to exercise (83) 
and in about a third of patients with conventional indications for cardiac 
catheterisation. (184) Though these studies did not assess the effect of stress on 
the diastolic indices specifically in patients with HFNEF, our conclusion that stress 
impairs LV diastolic relaxation resulting in an increase in the LVEDP in patients 
with HFNEF is consistent with these findings. The causal relation between exercise 
intolerance and stress induced diastolic impairment seen in our study has also
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been demonstrated in patients with exercise intolerance and normal LV systolic 
function. (184;239)
Mechanisms of stress induced diastolic dysfunction
The diastolic dysfunction induced by dobutamine stress may have resulted from 
ischaemia, increased systolic blood pressure and induced tachycardia. Impaired 
ventricular relaxation may be a manifestation of early ischaemia. Myocardial 
ischaemia impairs ventricular relaxation earlier than systolic contraction. (187) In 
patients with coronary artery disease ischaemia induced by pacing, (78) 
dipyridamole, (77) dobutamine (76;80) and exercise (75) results in a transmitral 
flow pattern consistent with delayed relaxation. Even transient, reversible episodes 
of ischaemia can impair LV relaxation and elevate LV filling pressures. (74) 
Regional impairment of myocardial relaxation of ischaemic segments has been 
seen at rest even when systolic contraction is preserved (79) and after 
dobutamine stress (188) and coronary occlusion. (81)
Stress-induced tachycardia may have worsened ischaemic diastolic relaxation by 
increasing myocardial oxygen demand and decreasing coronary perfusion time. 
Shortening the diastole allows less time for relaxation. This is further amplified in 
hypertrophied and fibrosed myocardium that is unable to generate a higher rate of 
diastolic relaxation causing the diastolic pressures to increase. (85; 189)
Stress-induced elevation of systolic blood pressure, may have contributed. 
Elevated SBP slows LV relaxation due to increased afterload with a resultant 
increase in the LA pressure. (82) In hypertensives, a rapid increase in SBP at rest 
(63) or following exercise (83) results in deterioration of LV diastolic function 
without worsening systolic function. Similar changes in response to stress have 
been demonstrated in patients with HFNEF.(84)
LIMITATION
Pharmacological stress used in this study may differ qualitatively from exercise. 
This choice permitted us to investigate patients who were elderly with poor 
exercise capacity and mobility. The problem of inadequate image quality due to the
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increased rate and depth of breathing after exercise stress was eliminated. The 
lack of diagnostic gold-standard for diastolic heart failure made diagnosis difficult. 
The diastolic blood flow and annular velocities were measured at sub-maximal 
heart rates to avoid the problem of fusion of these velocities at peak stress. This 
strategy was reasonable considering that these breathless patients were unlikely to 
generate maximal heart rates during daily living. The E/Ea ratio measured was 
higher than previously reported. (193;204) This is because myocardial velocities 
measured by cTDI in this study are lower than that measured by pulsed TDI. (196) 
The left atrial diameter measured in the parasternal long axis view may not have 
reflected the true increase in LA size that often occurs in the apico-basal direction 
in patients with HFNEF. The study group was heterogeneous comprising of 
patients with IHD, myocardial infarction, hypertension and diabetes, all of which 
may have influenced LV relaxation. Some of the subjects in the control group had 
obesity and COPD both of which may have affected the LV diastolic function. This 
may have underestimated the difference in the diastolic parameters between the 
groups. The study involved small number of patients and the findings need to be 
confirmed on a larger population.
CONCLUSION
Stress does not commonly induce systolic dysfunction in patients with HFNEF. It is 
unlikely that exercise intolerance is due to global regional or long axis systolic 
dysfunction or other non-cardiac causes. Abnormalities in diastolic function are 
often induced or exacerbated by stress in these patients, whether or not the final 
diagnosis is thought to be diastolic heart failure. Stress-induced impairment of early 
diastolic relaxation with consequent rise in the LVEDP is the likely cause of 
exercise intolerance. This study suggests that cputine stress echocardiography 
may be useful in fully evaluating these patients. However, utility of the test is 
uncertain till it is shown to predict symptoms, morbidity, mortality and effects of 
treatment.
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Table 6.1. Clinical characteristics of the HFNEF and controls.
Age (yrs)
Male n (%)
BMI
Overweight/Obesity n (%)
Current smoker n (%)
Hypertension n (%)
Diabetes n (%)
Previous Ml n (%)
Drug history
Loop diuretics (%)
ACEIorARB(%)
Beta-blockers (%)
Aspirin (%)
Spironolactone (%)
NYHA I Ml I n (%)
Heart rate (bpm)
SBP (mm Hg)
DBF (mm Hg)
FVC (I)
FEV! (l/min)
FEWFVC (%)
FEWFVC <75% n (%)
QRS duration (ms)
6 min walk test (m)
Resting Echocardiography
LA (cm)
LV mass (gm)
LV mass index (gm/m2)
LVH n (%)
EDVsmp (ml)
ESVsmp (ml)
EDVIsmp (ml/m2)
ESVIsmp (ml/m2)
HFNEF (n=41)
70±11
19(46)
26.6±4.2
25(61)
24 (58)
26 (63)
8(19)
12(29)
31 (76)
28 (68)
29 (71)
36 (89)
2(5)
40 (98)
76±14
148±22
85±12
2.7±1.3
2.1+1.0
80±7
16 (39)
95±21
174±109
3.84±0.80
248±115
139±65
25(61)
70.6±26.0
24.5±12.4
39.2±13.8
13.6±6.9
Controls (n=29) p
66±11
17(59)
26.53±3.4
21(72)
16(55)
0(0)
0(0)
0(0)
22 (76)
3(10)
2(7)
24 (83)
0(0)
25 (86)
76±13
135±12
78±8
2.2±0.9
1.6±0.79
71±16
13(45)
94+21
373±100
3.66±0.69
234±92
129±50
13(45)
76.8±23.1
30.0±13.2
41.8±10.8
16.3±6.4
0.14
0.31
0.92
0.32
0.78
<0.001
0.01
<0.001
0.98
O.001
<0.001
0.55
0.23
0.69
0.89
0.01
0.01
0.67
0.09
0.003
0.63
0.90
O.001
0.36
0.59
0.47
0.19
0.31
0.08
0.41
0.11
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EF (%) 66±9 62±8 0.02
Stress Response
Final dobutamine dose
THR
HR reached
% of THR reached, (%)
THR reached n (%)
SBP (mm Hg)
DBP (mm Hg)
Test Termination
THR n (%)
THR+RWMA n (%)
RWMA n (%)
Hypertension n (%)
Hypotension n (%)
NSVT n (%)
Ischaemia n (%)
Pain/Breathlessness n (%)
Segmental Response
Normal (%)
Ischaemic (%)
Scar (%)
29±9
127±9
124±13
98±10
24(59)
176±21
98±11
10(24)
12(29)
6(15)
1(2)
4(10)
5(12)
2(5)
1(2)
82.2
10.2
4.1
34±8
131 ±9
124±13
95±10
14(48)
170±12
97±5
9(31)
4(14)
5(17)
1(3)
5(17)
1(3)
3(10)
1(3)
86.2
7.3
0
0.02
0.14
0.76
0.17
0.39
0.23
0.81
0.54
0.13
0.77
0.80
0.36
0.20
0.38
0.80
0.07
0.10
0.00
CAD, Coronary artery disease; IHD, ischaemic heart disease; NYHA, New York Hear 
Association; ACEI, angiotensin converting enzyme inhibitor; ARE, angiotensin receptor 
blocker; HR, heart rate; THR, target heart rate; FVC, forced vital capacity; FE\A|, forced 
expiratory volume in 1 second, LA, left atrial diameter; EDVsmp, left ventricular end- 
diastolic volume by Simpson's; ESVsmp, left ventricular end-systolic volume by Simpson's; 
EDVIsmp, left ventricular end-diastolic volume index by Simpson's; ESVIsmp, left 
ventricular end-systolic volume index by Simpson's; EF, ejection fraction.
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Table 6.2. The echocardiographic variables at rest and stress in the HFNEF and control 
groups.
REST
HFNEF 
(n=41)
Controls 
(n=29)
P PEAK STRESS
HFNEF 
(n=41)
Controls 
(n=29)
P
Mitral annular systolic velocities (mean±SD)
LMA (cm/s)
SMA (cm/s)
AMA (cm/s)
IMA (cm/s)
PMA (cm/s)
ASMA (cm/s)
Myocardial Segmental
LB (cm/s)
SB (cm/s)
AB (cm/s)
IB (cm/s)
PB (cm/s)
ASB (cm/s)
LM (cm/s)
SM (cm/s)
AM (cm/s)
IM (cm/s)
PM (cm/s)
ASM (cm/s)
LVOT Vmax (cm/s)
LVOT Pmax (mmHg)
5.4±1.7
4.6H .3
5.311.6
5.011.4
5.2±1.5
4.411.4
Velocities
4.112.1
4.6H.3
4.U1.8
5.1H.6
4.511.8
3.911.5
3.0±2.2
3.511.2
2.412.1
3.7H.3
3.2±2.0
3.111.7
109±28
5.0±2.7
6.8H.5
5.2H.1
6.111.5
5.811.3
6.4H.3
5.6H.O
(mean±SD)
5.0H.9
4.9H.2
4.0H.9
5.411.2
5.211.8
4.5±0.9
3.5±2.0
3.311.0
2.711.5
3.811.3
3.811.6
3.211.0
113120
5.211.8
0.00
0.02
0.04
0.01
0.00
0.00
0.06
0.39
0.83
0.30
0.16
0.06
0.27
0.40
0.54
0.78
0.25
0.89
0.51
0.73
8.111.9*
7.4±2.5*
7.9±2.5*
8.112.6*
8.311.8*
7.5±2.3*
6.512.5*
7.6±2.5*
6.6±2.9*
7.7±2.8*
7.2±2.6*
6.8±2.2*
5.2±2.6*
6.2±2.5*
4.7±2.6*
6.2±2.5*
5.9+2.4*
6.3±2.2*
186±73*
15.4112.8*
9.6±1.6*
9.112.1*
8.7±2.6*
8.9±2.0*
9.5±2.0*
8.6H.8*
7.512.1*
8.512.1*
6.7±2.6*
9.112.0*
7.8±2.3*
7.9±2.0*
5.6±2.0*
6.7±2.4*
4.4±2.5**
7.112.6*
6.0±2.8*
6.712.1*
172±52*
14.0±8.9*
0.004
0.01
0.20
0.21
0.01
0.03
0.09
0.13
0.96
0.02
0.31
0.03
0.50
0.45
0.60
0.12
0.93
0.44
0.87
0.62
Diastolic variables median (IQR)
E(cm/s) 68(54-95) 65(53-75) ns
A (cm/s) 77(71-92) 81(68-96) ns
E/A 0.83(0.61-0.94) 0.77(0.6-0.9) ns
IVRTms 102(91-112) 107(82-115) ns
EDTms 235(184-286) 244(194-306) ns
IVRTcms 109(91-134) 114(96-133) ns
EDTcms 267(198-309) 268(226-328) ns
77(65-91)*** 
97(88-114)* 
0.73(0.62-0.84) 
92(69-111)*** 
189(140-265)*** 
127(98-153)* 
257(203-362)
70(54-93)*** ns
97(80-108) ns
0.73(0.56-0.89) ns
82(71-92)* ns
183(153-214)** ns
120(109-135) ns
252(214-298) ns
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L, lateral; S, septal; A, anterior; I, inferior; P, posterior; AS, anteroseptal; MA, mitral 
annulus; B, basal segment; M, middle segment; E, early mitral inflow velocity; A, late mitral 
inflow velocity; IVRT, isovolumic relaxation time; EOT, E wave decelaration time; IVRTc, 
isovolumic relaxation time corrected for heart rate; EDTc, E wave decelaration time 
corrected for heart rate. Rest versus stress: *p<0.0001, **p<0.01, ***p<0.05
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Table 6.3.Correlation of 6 minute walk distance to the clinical and echocardiographic 
parameters
HFNEF
Rest
Age (yrs) -0.4569*** 
BMI 0.0551 
SAP -0.1505 
DAP -0.2159 
LA 0.0649 
LV mass 
index -0.0300 
EDVIsmp 0.2906 
ESVIsmp 0.2877 
EF -0.2318 
FEV1 0.0751
Stress
FEV/FVC -0.2882
WMSI
LVOT
Pmax
E
A
E/A
EOT
IVRT
IVRTc
DTc
Sa
Ea
Aa
Ea/Aa
E/Ea
-0.2585
-0.1980
-0.3249*
-0.4299***
-0.0580
0.3151*
0.0464
-0.0537
0.2004
0.2455
0.2578
0.0895
0.1758
-0.6260****
-0.2578
0.1409
-0.5276****
-0.3950**
-0.1868
0.2452
0.0962
0.1069
0.2761
0.2811
0.4164***
0.3359
0.1617
-0.7621****
Cont
Rest
-0.3020 
0.0285 
0.2296 
0.2308 
-0.0220
0.1246 
-0.1073 
-0.1620 
0.0521 
0.2818
0.0450
-0.2266
0.0076
0.4898***
0.2316
0.3279
-0.2597
0.1045
0.2116
-0.1882
0.2848
0.4212
-0.0421
0.4751***
0.0826
Stress
-0.1425
-0.1096
0.3457
0.3108
0.0824
-0.0311
-0.2735
-0.2490
0.0099
0.2784
0.1934
0.0882
0.0660
0.1904
ALL
-0.3895**** 
0.0200 
-0.0624 
-0.1417 
-0.0648
-0.0553 
0.1821 
0.2281 
-0.2928** 
0.0158
-0.1302
-0.3143***
-0.0734
-0.1644
-0.1745
-0.0126
0.1270
0.0689
0.0223
0.1178
0.4493****
0.3048
0.1911
0.1547
-0.4780****
-0.2902**
-0.0068
-0.2093
-0.1212
-0.1584
0.0542
-0.0858
-0.0839
0.0772
0.4106****
0.5652****
0.2630*
0.3978****
-0.6649****
*p<0.05, **p<0.02, ***p<0.01, ****p<0.001
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Figure 6.1. Median, interquartile range, 95% confidence and outlying results for 
WMSI, Sa of the HFNEF and controls at rest and peak stress. ^rp<0.001 and 
Ap=ns comparing HFNEF v controls at rest and peak stress.*p<0.001 and Ap=ns 
comparing rest v peak stress in the HFNEF and controls.
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Chapter 7: The Effect of Pharmacological Stress on Intraventricular Dyssynchrony 
in Left Ventricular Systolic Dysfunction. Eur J Heart Fail. 2008 Apr; 10(4):412-20.
ABSTRACT
Background: Cardiac resynchronisation therapy (CRT) improves symptoms and 
exercise capacity in many patients with heart failure (HF) who have left ventricular 
systolic dysfunction (LVSD) and markers of dyssynchrony. LV dyssynchrony is 
conventionally measured at rest but the symptoms of heart failure occur 
predominantly on exercise. Induction or exacerbation of dyssynchrony during 
stress might identify additional patients who could benefit from CRT. 
Methods and Results: Seventy-seven patients (47 with QRSd<120 ms and 30 with 
QRSd>120 ms) with heart failure due to left ventricular systolic dysfunction and 22 
normal subjects underwent DSE using colour tissue-Doppler imaging. Left 
intraventricular dyssynchrony was measured as the standard deviation of the time 
to peak velocity from the onset of the QRS (Ts-SD) and the difference between the 
maximum and minimum time to peak velocity (Tscor-diff) in the 12 non-apical 
segments at rest and during peak stress. Timings were corrected for heart rate. 
The mean values of these indices increased with stress in both groups of patients 
but not in control subjects (p<0.001). The prevalence of conventionally-defined 
dyssynchrony also increased with stress.
Conclusion: In patients with heart failure, the severity and the prevalence of 
intraventricular dyssynchrony increase with stress. Whether stress-induced 
dyssynchrony will identify patients who might benefit from CRT awaits further 
research.
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INTRODUCTION
Left ventricular mechanical dyssynchrony is present in 30-50% of patients with 
heart failure and LV systolic dysfunction (LVSD) at rest, depending on the 
population studied and the definition of dyssynchrony applied. (93-96) The optimal 
method for assessing dyssynchrony is unclear. Prolonged QRS duration (QRSd), 
widely perceived as a marker of cardiac dyssynchrony, was a universal entry 
criterion for the randomised controlled trials demonstrating clinical and 
echocardiographic benefits of cardiac resynchronization therapy (CRT). (347;348) 
However, QRSd is a crude indicator of mechanical dyssynchrony (93;95) and 
QRSd prior to implantation and its reduction with CRT are poor predictors of 
therapeutic response. (349) Some non-randomised observations have suggested 
that direct measurement of mechanical systolic dyssynchrony before implantation 
may improve prediction of response to CRT either alone or in addition to QRSd but 
conclusive evidence is lacking. (271;350-354) These studies have considered 
dyssynchrony as a relatively stable phenomenon that neither changes during 
cardiovascular stress nor during prolonged follow-up. (348) The failure of current 
approaches to consistently identify therapeutic response, especially the long-term 
response, may reflect a failure to appreciate the potential for dyssynchrony to be a 
dynamic problem. The possibility that the prevalence and severity of LV 
dyssynchrony change when the ventricle is subjected to stress was investigated.
METHOD 
Patient selection
Inclusion criteria were NYHA class II-IV symptoms despite the use of diuretics and, 
unless not tolerated or contraindicated, treatment with ACE inhibitors or 
angiotensin receptor antagonists and beta-blockers for at least 3 months, LV 
ejection fraction (LVEF) <40% and sinus rhythm. Exclusion criteria were an acute 
coronary syndrome in the previous 6 months, significant valvular abnormality or a 
technically inadequate echocardiogram. The study population was divided into two 
groups: WQRS group (QRSd >120 ms) and NQRS group (QRSd < 120 ms). The 
aetiology of heart failure was considered to be ischaemic if there was evidence of 
previous myocardial infarction or angiographic evidence of >50% stenosis in major 
coronary arteries. Subjects, referred for the investigation of cardiac function, with a
136
low probability of ischaemic heart disease, without a history of myocardial infarction, 
diabetes, hypertension, with normal resting EGG and echocardiography and no 
inducible ischaemia on DSE (DSE), acted as controls.
Following a clinical examination and ECG every subject underwent standard 
transthoracic echocardiography followed by DSE. All subjects gave written 
informed consent and the Medical Ethics Committee of the Hull and East Yorkshire 
NHS Trust approved the protocol.
Echocardiographv
A standard set of images was recorded digitally at rest using GE Vingmed System 
V scanner (Horten, Norway) equipped with a 2.5 to 5-MHz phased-array 
transducer and analysed off-line. LV volumes and LVEF were assessed using the 
biplane modified Simpson's rule.
Stress echocardioqraphv
Protocol
As described in Chapter 4.
In the cTDI mode, a sample cursor was placed at the midpoint of each of the 12 
non-apical segments of the lateral, septal, anterior, inferior, posterior and 
anteroseptal walls in the 3 apical views and myocardial velocity curves were 
reconstituted. The onset of the QRS to the peak of the T wave was taken as 
systole. The time to peak systolic velocity (Ts) was measured from the onset of the 
QRS complex to the peak of the myocardial systolic velocity during ejection in each 
of the 12 segments at rest and at peak stress. (271;354) Ts was corrected for 
heart rate (Tscor) using the Bazett's formula (Tscor=Ts/VR-R) to allow comparison 
between the Ts of any segment at rest and at peak stress. (191) Any segment that 
developed the highest positive velocity after systole with low flat velocity profile 
during ejection phase was excluded from the analysis.
Intraventricular dyssynchrony was measured as the standard deviation of the Ts 
and Tscor of all 12 segments (Ts-SD and Tscor-SD) (94;271;272;354) and the
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maximum difference in the Ts (Tsdiff) and Tscor (Tscordiff) between any two of the 
12 segments. (272) A segment was labelled as "delayed" if the Ts or Tscor was > 
the mean+2SD of controls in that state (i.e. rest or stress). The prevalence of 
systolic dyssynchrony was defined as % of patients with Ts-SD, Tscor-SD, Tsdiff or 
Tscordiff of > the mean+2SD of controls in that state. All timings were calculated as 
the average of 2 to 3 consecutive cardiac cycles. All images were analysed by a 
single investigator (SC) blinded to the clinical characteristics of the patient.
Statistical analysis 
As described before.
Intraobserver variability in the Ts measured at the 12 non-apical segments was 
calculated in a sample of 10 randomly selected patients at rest and at peak stress 
totalling 240 pairs of measurements. It was reported as meaniSD. Confidence 
limits (95%) of differences were computed and expressed as absolute values and 
percentages of the average values of paired velocity measurements.
RESULTS
Between January 2002 and March 2003, 77 patients with heart failure (mean age 
68±9 years, 60 (78%) males) were enrolled (47 (61%) in NQRS group and 30 (39%) 
in WQRS group) (Table 1). Patients were in New York Heart Association class II 
(n=42), III (n=26) and IV (n=9). The QRSd, LV volumes and WMSI at rest were 
higher in the WQRS group. Twenty-two controls (mean age 67±12 years, 14 (64%) 
males) were also enrolled. Controls and patients had similar characteristics apart 
from measures of LV dysfunction. All controls and 31 (40%) patients reached the 
target heart rate (THR), 33 (43%) reached >90%, 8 (10%) reached >80% and 5 
(7%) reached >70% of the THR. There were no major adverse events or limiting 
side effects during the study. Of those with heart failure, 32/77 (41.5%) complained 
of chest discomfort with or without minor ST-segment depression. The heart rate, 
systolic and diastolic blood pressure and the rate-pressure product were higher at 
peak stress than at rest in all three groups (Table 2).
Seamental Time to Peak Velocity (Ts) at rest and during stress
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At rest, Ts could be measured in 261/264 (98.9%) segments in the control group 
compared to 896/924 (97.0%) segments in patients with heart failure (p=0.23). At 
peak stress, Ts could be measured in 260/264 (98.4%) segments in the control 
group and 906/924 (98.1%) in patients with heart failure (p=0.84). The overall 
intraobserver variability (Table 3) was low (range 1.2-5.9% at rest and 1.0-9.6% at 
peak stress). The variability was highest in the basal segment of the anteroseptal 
wall at rest and in the basal segment of the septum at peak stress.
In patients with heart failure, the Ts was delayed in most myocardial segments at 
rest and in all myocardial segments at peak stress compared to controls (Figure 1). 
Ts was shortened in most segments during stress except postero-basal, lateral-mid 
and postero-mid segments where Ts was similar to or delayed compared to resting 
values. Comparing patients with NQRS and WQRS, the mean Ts of each segment 
was similar at rest but at peak stress, the postero-basal, lateral-mid and postero- 
mid segments in the WQRS group were delayed compared to the NQRS (Figure 1).
Correction for heart rate (Tscor) had little effect on the overall pattern (Figure 1). 
The Tscor shortened in all segments with dobutamine stress in controls. It failed to 
shorten in any segment and increased in the mid-segments of the lateral and 
posterior walls in patients with and without wide QRS. At rest, Tscor was delayed 
in 6/264 (2.3%) segments in the control group compared to 73/564 (12.9%) in the 
NQRS (p<0.001) and 81/360 (22.5%) in the WQRS (p<0.001) (p<0.001 comparing 
patient QRS groups). At peak stress, delays were identified in 10/264 (3.8%) 
segments in the control group compared to 215/564 (39.4%) in the NQRS (p<0.001) 
and 163/360 (45.28%) in the WQRS (p<0.001) (p=0.08 comparing patient QRS 
groups). In response to stress, the Tscor lengthened in 44/264 (16.7%) segments 
in the control group compared to 262/564 (46.5%) in the NQRS (p<0.001) and 
172/360 (47.8%) in the WQRS (p<0.001) (p=0.69 comparing patient QRS groups).
Standard Deviation of the Time to Peak Systolic Velocity (Ts-SD) 
Ts-SD uncorrected for heart rate was markedly greater in patients compared to 
control subjects but changed little with stress (Figure 2). However, marked 
differences with stress were observed after correction for heart rate. In the controls,
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Ts-SD and Tscor-SD were 20.3±8.8 and 23.9±11.4 at rest and 22.3±6.7 and 
28.4±7.3 at peak stress. At rest, a Tscor-SD > 46.7 ms (mean+2SD of controls) 
was seen in one control subject and 46 (60%) patients with heart failure (p<0.001), 
21(45%) in NQRS (p=0.004 v controls) and 25(83%) in WQRS (p<0.001 v controls) 
groups (p=0.003 for the difference between NQRS and WQRS groups). At peak 
stress, a Tscor-SD of > 43.0 ms (mean+2SD of controls) was seen in none of the 
controls but 65 (83%) (p<0.0001) patients with heart failure, 36(77%) in NQRS 
(p<0.001 v controls) and 29(97%) in WQRS (p<0.001 v controls) groups (p=0.061 
for the difference between patient QRS groups) (Figure 3).
Maximum Difference Between Segmental Peak Velocities (Ts-diff) 
Ts-diff uncorrected for heart rate was markedly greater in patients compared to 
control subjects and increased with stress especially in patients with WQRS 
(Figure 2). After correction for heart rate, the effects of stress were even more 
marked in patients but not in control subjects. In the controls, Ts-diff and Tscor-diff 
were 62.7±24.4 and 73.6±30.5 at rest and 70.9±22.4 and 88.3±21.8 at peak stress. 
At rest, no (0%) control subject but 47 (61%) patients (p<0.001) had Tscor-diff 
>134.5 ms (mean+2SD of controls). Twenty-three (49%) patients in NQRS group 
(p<0.001 v controls) and 24(80%) in WQRS group (p<0.001 v controls) (p= 0.024 
for the difference between patient QRS groups) had Tscor-diff > 134.5 ms. At peak 
stress, 38 (81%) patients in NQRS group (p<0.001 v controls), 30 (100%) patients 
in the WQRS group (p<0.001 v controls and p= 0.038 comparing patient QRS 
groups) and none of the control subjects had Tscor-diff > 131.8 ms (mean+2SD of 
controls) (Figure 3).
Depending on the TD variable, 95-100% of controls were normal at rest and all 
remained that way at peak stress compared to 8-13% in the NQRS group and 
none in the WQRS group (Figure 4). In 43% of NQRS patients, the TD variables 
were normal at rest and became abnormal at peak stress compared to 20% in the 
WQRS group and none of the controls. 80% of the WQRS patients were 
dyssynchronous at rest and continued to be abnormal at stress compared to 38- 
40% in the NQRS and none of the controls. Depending on the variable, 6-8% of 
patients in the NQRS group and none of the WQRS group improved with stress.
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DISCUSSION
Cardiac dyssynchrony has rarely been studied during stress. This study 
corroborates the reported high prevalence of intraventricular dyssynchrony at rest 
in patients with LVSD irrespective of QRS duration.(93-96) However, during 
pharmacological stress both the prevalence and severity of dyssynchrony increase. 
Since the prevalence of dyssynchrony at rest is lower in patients with QRSd <120 
ms the increase is most evident in this population. The prevalence of stress- 
induced dyssynchrony in these patients approached that observed in patients with 
QRSd >120 ms during pharmacological stress. Indeed, most patients with LVSD 
had dyssynchrony during stress regardless of QRS duration. Stress rarely 
improved dyssynchrony in this study.
Compared to control subjects, the time to peak systolic velocity was greater in 
most myocardial segments at rest and in all segments at peak stress in patients 
with LVSD regardless of QRS duration. Stress shortened the time to peak systolic 
velocity in all segments in healthy subjects and in most segments of patients with 
LSVD. Indeed, when corrected for heart rate, stress shortened the time to peak 
velocity in control subjects but not in patients with LSVD regardless of QRS 
duration. Additional delays in some segments were observed in the latter. The 
lateral and posterior wall segments were particularly prone to delay both at rest 
and during stress in patients regardless of QRSd, as previously reported in patients 
at rest. (272;355) The greater vulnerability of the LV free-wall to dyssynchrony 
presumably reflects an exaggeration of the usual pattern of ventricular activation in 
the presence of a dilated ventricle, greater myocardial mass, slowed intra- 
myocardial conduction and areas of fibrosis and scar. (356)
Studies, investigating the effects of pacing-induced tachycardia, exercise or 
pharmacological stress on ventricular dyssynchrony, have yielded conflicting 
results.(97-100;357) Indices of dyssynchrony did not change in subjects without 
heart disease in these studies whether the stressor was exercise or dobutamine. 
Pacing induced tachycardia augmented LV mechanical dyssynchrony in one study 
of patients with non-ischaemic LVSD. In 65 patients with heart failure studied by
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Lafitte et al (97) , only 22 of whom had QRS <120 ms, the mean values of the 
dyssynchrony indices did not change with exercise stress. Dyssynchrony increased 
in 37% and diminished in 20%. The changes may partly have reflected 
measurement error given the technical difficulties of exercise echocardiography. 
Valzania et al (99) reported a lack of increase in dyssynchrony indices, derived 
from timings not corrected for heart rate, with dobutamine-stress in patients with 
QRSd > 130 ms undergoing CRT. This is consistent with our findings. Neither 
Hummel et al (98) nor Da Costa et al (100) reported the effects of stress on 
dyssynchrony in heart failure patients with wide QRS. Differences in the proportion 
of patients with QRSd <120 ms, the proportion with dyssynchrony at rest, the 
magnitude of change in heart rate, the stressor and the criteria by which 
dyssynchrony is judged to be present may account for some of the differences 
observed. Importantly, CRT appears to maintain its synchronising effect during 
exercise stress. (195)
Pharmacological stress permitted us to investigate patients who were elderly with 
poor exercise capacity and mobility and those with severe heart failure; patients 
that are difficult or impossible to study using exercise stress. (97) Higher heart 
rates may be reached during exercise than with peak dose dobutamine but the 
rapid decline in heart rate after exercise and delays in acquisition are common 
(262) as are the difficulties in obtaining adequate images due to the increased rate 
and depth of breathing.
Patients with LVSD are prone to subendocardial ischaemia whether or not they 
have epicardial coronary disease (324;358) and treatments that decrease 
ischaemia may improve dyssynchrony. (324;359) Stress induced dyssynchrony 
could reflect induction of ischaemia and this could not be discounted as a 
contributing factor. However, in the absence of substantial deterioration of WMSI 
and mitral annular velocity at peak stress, it is unlikely that clinically overt 
ischaemia played a significant role in inducing dyssynchrony in our patients. The 
chronotropic effect of dobutamine may at least partly be responsible. Pacing 
induced tachycardia augments LV mechanical dyssynchrony in patients with non- 
ischaemic LVSD. (357)
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LIMITATION
The mechanism of stress-induced dyssynchrony or its ability to predict the 
response to CRT was not studied. The absence of recent coronary angiograms or 
segmental strain data precludes exclusion of ischaemia as a mechanism. In the 
absence of data on the sequence of electrical activation through the LV at rest and 
stress, we are unable to say whether the stress induced worsening of 
dyssynchrony is due to alteration in the electrical activity as a result of changes in 
the conduction properties or impaired mechanical coupling. The dyssynchrony was 
assessed at heart rates that are unlikely to be reached in elderly patients with 
relatively sedentary life styles and optimally treated with beta-blockers. It is 
uncertain what effects would be produced by a lesser degree of stress. The 
relationship of post-systolic motion induced by stress to dyssynchrony was not 
studied. Segments that developed extreme delay in attaining their highest positive 
velocity were excluded from analysis (36/924, 3.9 %). These would have 
contributed even further to the severity of dyssynchrony on stress.
CLINICAL IMPLICATION
It is far from clear how patients should be selected for CRT. QRS duration 
thresholds and echo dyssynchrony criteria were chosen rather arbitrarily as entry 
criteria for clinical trials based on pathophysiological concepts and observed 
associations in small series of patients. Widened QRS is a marker of more severe 
left ventricular dilatation and dysfunction (12) and may be a marker of 
dyssynchrony mainly because it indicates a sicker ventricle. There is remarkably 
little evidence that echo dyssynchrony is associated with a worse prognosis and 
indeed some evidence that inter-ventricular dyssynchrony is associated with better 
outcome. (348) If QRS duration and dyssynchrony are being used as markers of 
risk rather than of dyssynchrony then NT-proBNP is better than either. (360;361) 
Now that it is known that CRT works for some patients, it is important to find out 
whether current guidelines are appropriate or too restrictive.
Observational studies suggest that CRT may be effective in patients with narrower 
QRS (362;363) whether or not they have mechanical dyssynchrony at rest. Recent
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reports have failed to identify a strong-link between echo dyssynchrony at rest and 
outcome of CRT. (364) One of the many potential explanations for the lack of this 
relationship may be that dyssynchrony is dynamic and changes with stress. If 
stress-dyssynchrony is an appropriate target for therapy stress-echocardiography 
might be considered necessary in order to select patients for CRT. However, if 
stress dyssynchrony is as common as this study suggests, then a strategy of CRT 
implantation in all patients who have persistent major LVSD could be considered a 
more pragmatic approach. These concepts need to be tested in randomised 
controlled trials. This data also suggests that measuring dyssynchrony only at rest 
underestimates its prevalence and fixed setting of the biventricular pacemakers 
may not be physiological in the presence of such dynamicity.
CONCLUSION
Dobutamine-stress induces and exacerbates dyssynchrony in patients with LVSD. 
LV dyssynchrony, unmasked by stress in patients with narrow QRS, could be a 
target for therapy. If so, then most patients with LVSD, regardless of QRS duration 
or evidence of dyssynchrony at rest might benefit from CRT. This hypothesis 
remains to be tested.
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TABLE 7.1. Comparison of Baseline Clinical Characteristics of the Controls and 
Study Groups.
Control N QRS W QRS p value* p value
Age (years) 
Males n (%) 
BMI
QRSd (ms) 
Aetiology
IHD n(%)
DCM n(%)
Hypertension n(%) 
Ml n (%)
Prior revascularisation n (%) 
Diabetes n (%) 
Hypertension n (%) 
Drugs
Diuretics n (%)
ACEI n (%)
ARB n (%)
Beta-blockers n (%)
Spironolactone n (%)
Digoxin n (%) 
Echocardiography
LVIDd (cm)
LVIDs (cm)
LVEDvol (ml)
LVESvol (ml)
EF (%)
WMSI
Sm 
DSE End-point reached at
(n=22)
69 ±12
14 (64)
26. 5 ±5.0
93 ±21
0
0
0
0
0
0
0
0
0
0
0
0
0
4.5±1.0
2.9±1.0
71 ±27
25±14
65±9
1.0±0
5.7±1.6
(n=47)
68 + 9
37 (79)
26.4 ±3.5
98 ±12
36 (77)
9(19)
2(4)
20 (43)
14 (30)
8(17)
13(28)
47(100)
42 (89)
5(11)
42 (89)
8(17)
2(4)
6.3±0.91
5.2+1.0
129±53
89±44
33±9
2.3±0.4
3.3±1.4
(n=30)
69 ±9
23 (77)
26.1 ±4.0
146 ±20
20 (67)
7(23)
3(10)
1 1 (37)
1 1 (37)
9(30)
1 1 (33)
30(100)
25 (83)
5(17)
24 (80)
4(13)
2(7)
6.6±1.0
5.7±0.9
161±56
114±43
29±8
2.6±0.3
2.9±0.9
0.89
0.83
0.72
O.001
0.34
0.66
0.32
0.61
0.53
0.18
0.41
1.00
0.44
0.44
0.25
0.66
0.64
0.08
0.09
0.02
0.02
0.12
0.00
0.14
ANOVA
0.86
0.39
0.78
0.023
-
-
-
-
-
-
-
-
-
-
-
-
O.001
<0.001
O.001
O.001
<0.001
<0.001
O.001
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40 (jg/kg/min+atropine n (%) 2(9) 7(15) 1(3) 0.11 0.26 
40 ug/kg/min n (%) 16(73) 16(34) 8(27) 0.50 0.00 
30 ug/kg/min n (%) 4(18) 17(36) 10(33) 0.80 0.31 
20 ug/kg/min n (%) 0(0) 6(13) 11(37) 0.01 0.00 
10 ug/kg/min n(%) 0(0) 1(2) 0(0) 0.42 0.57 
IHD, ischaemic heart disease; DCM, dilated cardiomyopathy; BMI, body mass 
index; QRSd, QRS duration; Ml, myocardial infarction; ACEI, angiotensin- 
converting enzyme inhibitor; ARB, angiotensin receptor blocker; LVIDd, left 
ventricular internal diameter in diastole; LVIDs, left ventricular internal diameter in 
systole; LVEDvol, left ventricular end-diastolic volume; LVESvol, left ventricular 
end-systolic volume; EF, ejection fraction; WMSI, wall motion score index; Sm, 
mitral annular myocardial velocity; DSE, DSE. Values are mean±2SD unless stated 
otherwise. * p value for comparison of NQRS versus WQRS
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Table 7.3. Intraobserver variability in the Ts measured in the 12 non-apical 
segments at rest and peak stress in a random sample of 10 patients.
REST
Diff in Ts
Segment (Mean±SD)
LB
LM
SB
SM
AB
AM
IB
IM
PB
PM
ASB
ASM
13
10
7
7
8
7
7.
6
8.
8
9.
4
.3±19.5
J±10.3
.6±8.
.3±8.
.0±6.
.4±6.
9±12
.8±5.
2±13
.8±7.
3±18
.3±3.
3
2
8
6
.6
6
.8
5
.3
7
95%
Cl
±12.1
±6.4
±5.1
±5.1
±4.2
±4.1
±7.8
±3.5
±8.6
±4.6
±12.0
±2.4
STRESS
Diff in Ts
% (Mean±SD)
5.1
3.0
2.4
2.3
1.9
1.5
3.3
1.5
3.3
1.9
5.9
1.2
2
7
8.
3
7
5
8.
7
8
6
8
5
.5±2.
.2±6.
8+19
.4±3.
.5±7.
.0±4.
2
7
.1
2
6
8
6±10.9
.4±7.
.3±8.
.1±6.
.0+6.
.2±5.
6
9
6
8
6
95%
f^ 1 O/ Ul 70
±1.
±4.
±11
±2.
±4.
±3.
±6.
±4.
+5.
±4.
±4.
+3.
3
2
.8
0
7
0
7
7
5
1
2
5
1.0
3.1
9.6
1.6
3.7
2.4
5.1
3.4
4.0
3.1
3.2
2.6
B, basal; M, middle; L, lateral; S, septal; A, anterior, I, inferior; P, posterior; AS, 
anteroseptal
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Figure 7.1. Segmental time to peak velocity (mean±SE), uncorrected and corrected 
for heart rate, at rest and stress across the groups. Unmarked values, p<0.05 
NQRS and WQRS v controls; p=ns, BlORS and WQRS v controls; p<0.05
#QRS v WQRS.
• Controls + NQR» WQRS. B=basal, M=mid, L=lateral, S=septal, l=inferior, 
A=anterior, P=posterior, AS=anteroseptal.
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* Tscor-SD
Control HQ«S WQRS
Figure 7.3. Percentage of patients with Tscor-SD and Tscordiff of > mean+2SD of 
controls at rest and stress within and across the groups.^ p=0.000 and U p=0.004 
compared to controls.
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Figure 7.4. Percentage of patients in whom the dyssynchrony indices either 
improved or worsened under stress grouped according to whether they were 
normal or abnormal at rest. "A" p<0.05,A p= ns. N-N, normal at rest and stress; N-A, 
normal at rest and abnormal at stress; A-N, abnormal at rest and normal at stress; 
A-A, abnormal at rest and stress.
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Chapter 8: Summary
To the best of our knowledge this is the only report on the feasibility of DSE with 
cTDI in the assessment of an unselected population of patients with suspected 
heart failure in an ambulatory setting. All previous reports on feasibility of DSE are 
based on retrospective analysis of data obtained on patients who underwent the 
test for established clinical indications, and selected in terms of their 
echocardiographic image quality, suitability to tolerate the procedure and the 
absence of contraindications. Thus the applicability of this technique in a truly 
unselected population of patients who attend a heart failure clinic with multiple 
cardiovascular and non-cardiovascular co-morbidities was hitherto unknown. The 
screened subjects were elderly (median age of those not recruited 78 years and 
those recruited 72 years) and reflected the population expected in a heart failure 
clinic. About 20% of the patients screened were ineligible for DSE. High mortality at 
index admission amongst patients admitted with heart failure, inability to consent, 
contraindications to DSE and non-cardiac co-morbidities that would constrain 
acquisition of images resulted in ineligibility. About 20% of the eligible patients 
refused to consent. The discomfort of the test described, inconvenience of 
attending for the test that may not be clinically relevant, general reluctance to join a 
research study, travel and travel costs may all have dissuaded the elderly subjects 
from consenting. Obtaining consent for clinically indicated DSE may be less of a 
problem. Of those recruited, 21% were excluded due to poor acoustic windows 
detected during resting echocardiography and a further 6% had uninterpretable 
studies due to deterioration in image quality during DSE. This conforms to 
published data. About a quarter of the referred patients could not undergo the test. 
Withdrawal of beta-blockers resulted in a higher incidence of exclusion due to loss 
of control over heart failure symptoms, ventricular response in patients with 
persistent atrial fibrillation and blood pressure. This finding is clinically relevant as a 
substantial proportion of patients with suspected heart failure are likely to suffer 
with the latter conditions. Intolerance to subjective symptoms may not lead to early 
termination of clinically indicated test. The test was feasible in 88% of the patients 
who underwent DSE. This compares favourably with published data suggesting 
that DSE is highly feasible in patients appropriately selected for the test.
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The major complication rate (3%) was higher than previously reported. This was 
expected in absence of rigorous selection for the procedure and discontinuation of 
beta-blockers before the test. Safety of DSE would not be an issue if patients are 
appropriately selected. Minor complication rates leading to termination of the test 
conform to published data.
Similar to previous reports, 92-98% of the segments could be visually scored 
depending on the group of subjects and the level of stress. The feasibility of 
longitudinal systolic and diastolic and regional systolic quantitative analysis of the 
left ventricle was higher than some of the previous reports due to methodological 
differences. The apical segments were excluded from analysis. The anteroseptal 
and posterior walls were analysed in the apical rather than the parasternal view. 
Intraobserver variability was low. Segments could be evaluated quantitatively more 
frequently than visually at all levels of stress. 5% of the attempts at visual 
assessment of a segment were unsuccessful, most frequently in the HF-LVSD 
group. TDI could assess segments on 73% of these attempts. The levels of stress 
did not affect regional quantitative assessment in the HFNEF and NoHF group. 
Visual and quantitative analysis was least successful in subjects with LVSD 
especially at peak stress. Despite this limitation, success rate for quantitative 
evaluation of segments was consistently higher compared to visual assessment in 
this group. Both visual and quantitative analysis were equally successful in the 
other subjects. The three segments of the anterior wall were the most difficult to 
score visually. Quantitative analysis was least successfully at all levels of stress at 
the middle segment of the anterior wall due to inadequate visualisation and the 
basal and middle segments of the anteroseptal wall due to misalignment. About 
three fourths of the segments that could not be assessed visually could be 
analysed quantitatively. Mitral annular velocities were measured in 99%, 97% and 
100% of the instances in the HF-LVSD, HFNEF and NoHF groups respectively. 
Fewer observations could be made at peak stress compared to rest and low dose 
in the HF-LVSD group but not in the others.
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The feasibility of the analysis of the diastolic waveforms (conventional and TDI) 
was higher than previously reported. This resulted from the analysis of these 
waveforms at the highest heart rates where they could be separately measured. 
This prevented the problems associated with fusion. Analysis of diastolic velocities 
at sub-maximal stress seemed reasonable for diagnosis of stress-induced diastolic 
dysfunction firstly because ischaemia induces diastolic dysfunction occurs earlier 
than systolic and secondly because heart failure patients with exercise intolerance 
are unlikely to achieve maximal heart rates during day-to-day physical activity that 
make them breathless. Resting variables e.g. age, hypertension, LV hypertrophy, 
ischaemia etc. may alter resting diastolic functions in a way that may conceal the 
effect of stress induced ischaemia on these variables or at least make 
interpretation difficult. The high prevalence of these conditions in patients with 
suspected heart failure could adversely affect the evaluation of diastolic function 
under stress in these patients. The reproducibility of these measurements was 
acceptable.
Depending on the cut-offs used, 32-50% patients of the HF-LVSD, 17-23% in the 
HNEF and 29-48% in NoHF groups had prognostically significant volumes of 
myocardium in ventricles with systolic dysfunction. The systolic annular velocity at 
each wall increased by >1 cm/sec in 61%, 65% ad 59% of the walls with low resting 
velocities in the three groups respectively suggesting viability in these walls. On 
visual assessment, 13%, 82%, 75% of the segments responded normally to stress, 
42%, 10%, 18% were ischaemic and 30%, 4%, 0.3% were scars in the three 
groups respectively. On quantitative assessment, 29%, 56%, 55% of the segments 
responded normally to stress, 26%, 26%, 27% were ischaemic and 4%, 0.6%, 1% 
were scars.
E/A became abnormal with stress in 65%, 25% and 36% of the patients who were 
normal at rest and remained abnormal in 81%, 67% and 73% patients who were 
abnormal at rest in the HF-LVSD, HFNEF and NoHF groups respectively. EOT 
failed to shorten in 34%, 44% and 30% and EDTc increased with stress in 52%, 
59% and 54% patients in the HF-LVSD, HF-PLVF and NoHF groups respectively.
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IVRT failed to shorten in 21%, 46% and 35% and IVRTc increased with stress in 
55%, 67% and 58% patients in the three groups respectively.
Amongst the patients with normal Ea at rest, it decreased with stress in 21%, 69% 
and 43% in the HF-LVSD, HFNEF and NoHF group respectively. It decreased by 
>20% in 11%, 32% and 21% and increased by > 20% in 61%, 10% and 30% in the 
three groups. The mean Ea in the HF-LVSD group was lower than HFNEF group 
that was similar to the normal group at rest. At peak stress, Ea in the HFNEF group 
was lower compared to the normal group but was similar to the HF-LVSD group. In 
the HF-LVSD group, Ea and Aa increased with stress and their ratio remain 
unchanged. In the HFNEF group, Ea decreased, Aa increased but their ratio does 
not change. In the normal group, Aa increases but there are no changes in the Ea 
or Ea/Aa.
Among the patients who had normal resting E/Ea, 5%, 52% and 25% had high 
E/Ea at peak stress in the HF-LVSD, HFNEF and NoHF groups. Among the 
patients with high E/Ea ratio at rest, it remained high at peak stress in 43%, 92% 
and 88% patients in the three groups. At rest, E/Ea HF-LVSD>HFNEF=NoHF. With 
stress, E/Ea decreased in HF-LVSD, increased in HFNEF and remained 
unchanged in NoHF group.
The genesis of the symptoms of HF in the absence of reduced global LV systolic 
function was explored in this study. The changes in the LV global systolic and 
diastolic, and regional systolic function in response to stress were assessed. 
Pharmacological stress did not induce LV global (as assessed by WMSI), regional 
(as assessed by WMS and Sm) and long axis (as assessed by averaged peri- 
annular Sa) systolic dysfunction excluding this as a common cause of symptoms in 
patients with HFNEF. Obesity and obstructive airways disease also did not account 
for these symptoms. Stress impaired diastolic relaxation as evidenced by a 
reduction in the Ea as compared to controls. It also increased E/Ea ratio (an 
echocardiographic surrogate for left atrial and LV end-diastolic pressure). The E/Ea 
ratio at rest and stress correlated negatively with the 6-minute walk distance in the
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HFNEF but not in the control group. On multiple regression analysis, the Ea and E 
at peak stress were found be predictive of the 6-minute walk distance.
This study was undertaken to assess the effect of pharmacological stress on 
intraventricular dyssynchrony in patients with heart failure with and without wide 
QRS duration (defined as 120 msec). Ts could be measured in 97% and 99% of 
segments being assessed at rest and 98% and 98% at peak stress in the HF- 
LVSD group and controls respectively. Ts was delayed in most myocardial 
segments at rest and in all myocardial segments at peak stress in the patients. The 
Tscor shortened in all segments with stress in controls. It failed to shorten in any 
segment and increased in the mid-segments of the lateral and posterior walls in 
patients with and without wide QRS.
The study confirmed the previously reported high prevalence of intraventricular 
dyssynchrony at rest in patients with LVSD irrespective of QRS duration. 
Depending on the parameter used, the prevalence of dyssynchrony increased from 
45-49% at rest to 77-81% at peak stress in the NQRS and 80-83% at rest to 97- 
100% at peak stress in the WQRS patients. The prevalence of dyssynchrony in 
patients with QRSd <120 ms approached that observed in patients with QRSd 
>120 ms during pharmacological stress. Indeed, most patients with LVSD had 
dyssynchrony during stress regardless of QRS duration. Stress rarely improved 
dyssynchrony in this study. The severity of dyssynchrony increased during 
pharmacological stress irrespective of the QRS duration.
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Chapter 9: Conclusions
DSE is feasible in patients with suspected heart failure only when they are 
appropriately selected for the test. About 46% of patients attending the heart failure 
clinic with suspected heart failure are likely to be excluded from undergoing DSE 
due to several reasons. Inadequate imaging windows and contraindications to DSE 
are the commonest causes for exclusion. The proportion of eligible patients who 
refused to or could not consent for the procedure or requested early test 
termination due to subjective symptoms are likely to be lower in a real-world 
situation where more patients are likely to undergo a clinically indicated DSE. The 
safety of DSE in an unselected group of patients may be a concern. This is unlikely 
to be an issue in selected patients. In a selected group of patients with suspected 
heart failure, both global and regional systolic and diastolic assessment is feasible 
during DSE. cTDI both at rest and stress may supplement visual interpretation of 
wall motion.
DSE identified prognostic volumes of hibernating and ischaemic myocardium in 
patients with suspected heart failure who had LVSD. It also unmasked stress 
induced diastolic impairment in patients with normal ejection fraction. The 
therapeutic and prognostic implications of this data were not tested in this thesis 
and needs to be tested larger outcome studies.
It is unlikely that exercise intolerance in patients with HFNEF is due to global, 
regional or long axis systolic dysfunction at rest or other non-cardiac causes. 
Stress does not commonly induce systolic dysfunction in these patients. 
Abnormalities in diastolic function are often induced or exacerbated by stress in 
these patients. Stress-induced impairment of early diastolic relaxation with 
consequent rise in the LVEDP is the likely cause of exercise intolerance. This 
study suggests that routine stress echocardiography may be useful in fully 
evaluating these patients. However, utility of the test is uncertain till it is shown to 
predict symptoms, morbidity, mortality and effects of treatment.
158
Chattopadhyay
High prevalence of resting dyssynchrony was detected in patients with LVSD 
irrespective of the QRS duration. Dobutamine-stress induced and exacerbated 
dyssynchrony in these patients. It unmasked dyssynchrony especially in patients 
with LVSD and narrow QRS complexes. The prevalence and severity of 
dyssynchrony detected in patients with LVSD and narrow QRS duration under 
stress approaches that of patients with LVSD and wide QRS duration. LV 
dyssynchrony, unmasked by stress in patients with narrow QRS, could be a target 
for therapy. This hypothesis remains to be tested.
Thus, DSE identified left ventricular dysfunction not apparent at rest that could be 
therapeutic targets e.g. the hibernating and/or ischemic myocardium and 
dyssynchrony. It could be a useful diagnostic tool in evaluating patients with 
HFNEF both to detect stress-induced ischemia masquerading as breathlessness 
and/or impairment of diastolic relaxation. It may allow selection of patients for 
cardiac ^synchronisation therapy. The diagnostic, therapeutic and prognostic 
implication of these findings will only be evident when tested in larger outcome 
studies.
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APPENDIX A 
Additional figures
Figure 1. The 16-segment model of the left ventricle, as recommended by the 
American Society of Echocardiography for interpretation of regional wall motion. 
The lateral and septal (left: apical 4-chamber view), the anterior and inferior 
(middle: apical 2-chamber view) and antero-septal and posterior (right: apical 3- 
chamber view) walls of the left ventricle are divided into 3 segments each (basal, 
middle and apical). The apical segments of the anteroseptal and posterior walls are 
excluded from analysis.
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Figure 2. Typical myocardial and annular velocity pattern seen with cTDI. S^ 
systolic velocity during isovolumetric contraction corresponding to the QRS 
complex; S2 : systolic velocity during ejection phase seen after the QRS complex; E: 
early diastolic velocity seen after the T-wave; A: late diastolic velocity seen after 
the P-wave. PSM: post systolic velocity.
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Figure 3: Apico-basal gradient in velocity from annulus to apex in the same wall. 
The systolic myocardial velocity increases and the diastolic velocities decrease 
from the annulus to the apex in a typical normal left ventricular wall. Annulus: 
yellow; basal segment: light green; middle segment: red; apical segment: deep 
green
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Figure 4. Stress-induced impairment in early diastolic myocardial relaxation as 
measured at the septal annulus in a patient with HFNEF.
cTDI at the septal annulus shows reversal of Ea/Aa ratio at rest (upper panel). The 
Sasep and Aasep increased but the Easep halved at sub-maximal stress (lower panel) 
suggesting stress-induced abnormal myocardial relaxation without significant 
systolic impairment.
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Figure 5. Appearance of LV Dyssynchrony with Stress in a patient HF with LVSD. 
At rest (upper panel), the Smiat (green) and Smsep (yellow) reach their peak nearly 
simultaneously i.e. there is almost no difference in the time from the onset of the 
QRS complex to the peak Sm in these two opposing segments. At peak stress 
(lower panel), the Smiat reaches the peak later than Smsep i.e. the difference 
between the times from the onset of the QRS complex to the peak systolic 
velocities in the two segments increase. Post-systolic velocity (open-arrow) 
becomes evident in the septal segment.
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Figure 6. Uninterpretable cTDI curves at the anterior and inferior annuli in a patient 
with ventricular trigemminy. The auto-calibration of the EGG amplitude during 
acquisition resulted in very small sinus complexes. The three beats that were 
automatically captured were the 3 larger amplitude ectopic beats. In the process, 
the interim smaller sinus beats were also acquired leading to several 
Uninterpretable waveforms.
199
Chattopadhyay
Velocity (TVI) .ran??: -16.48- +16.48 crn/s 
Tracsno: 1 8 S [Trace op«7| |C*MM| hlmodc |Sjye image] |H&A| [Export] [Delete all]
Figure 7. Uninterpretable cTDI curves at the lateral wall in a patient whose EGG 
electrode disconnected during acquisition.
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